10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2016

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from              to            

Commission File Number 001-34583

Team Health Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware	36-4276525
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

265 Brookview Centre Way

Suite 400

Knoxville, Tennessee 37919

(865) 693-1000

(Address, zip code, and telephone number, including area code, of registrant’s principal executive office)

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 and 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of July 28, 2016, there were outstanding 74,157,535 shares of common stock of Team Health Holdings, Inc., with a par value of $0.01.

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-Q that are not historical facts and that reflect the current view of Team Health Holdings, Inc. (the Company) about future events and financial performance are hereby identified as “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some of these statements can be identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “could,” “should,” “may,” “plan,” “project,” “predict” and similar expressions. The Company cautions readers of this Form 10-Q that such “forward looking statements,” including without limitation, those relating to the Company’s future business prospects, revenue, working capital, professional liability expense, liquidity, capital needs, interest costs and income, wherever they occur in this Form 10-Q or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward looking statements.” Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

• the current U.S. and global economic conditions;

• the current U.S. and state healthcare reform legislative initiatives;

• our exposure to financial risk under the BPCI program and other value based payment programs;

• our ability to find suitable acquisition candidates or successfully integrate completed acquisitions, including our acquisition of IPC Healthcare, Inc. (IPC);

• our ability to realize the expected benefits of the acquisition of IPC.;

• the risk that the IPC acquisition disrupts current plans and operations and disrupts our relationship with payors, physicians and other healthcare professionals;

• our ability to realize the value of intangible assets, including goodwill, recognized in connection with our acquisitions;

• the effect and interpretation of current or future government regulation of the healthcare industry, and our ability to comply with these regulations;

• our exposure to billing investigations and audits by private payors and federal and state authorities, as well as auditing contractors for governmental programs;

• our exposure to professional liability lawsuits;

• the adequacy of our insurance reserves;

• our reliance on reimbursements by third-party payors, as well as payments by individuals;

• the impact of recent or potential federal and state legislation that restricts our ability to balance bill patients, or prescribes how potential out of network charges are calculated and reimbursed;

• change in rates or methods of government payments for our services;

• the general level of emergency department patient volumes at our clients’ facilities;

• our exposure to the financial risks associated with fee for service contracts;

• our ability to timely or accurately bill for services;

• our ability to timely enroll healthcare professionals in the Medicare program;

• a reclassification of independent contractor physicians by tax authorities;

• the concentration of a significant number of our programs in certain states, particularly Florida, Ohio, and Tennessee;

• any loss of or failure to renew contracts within the Military Health System Program, which are subject to a competitive bidding process;

• our exposure to litigation;

• fluctuations in our quarterly operating results, which could affect our ability to raise new capital for our business;

• effect on our revenues if we experience a net loss of contracts;

• our ability to accurately assess the costs we will incur under new contracts;

• our ability to implement our business strategy and manage our growth effectively;

• our future capital needs and ability to raise capital when needed;

• our ability to successfully recruit and retain qualified healthcare professionals;

• enforceability of our non-competition and non-solicitation contractual arrangements with some affiliated physicians and professional corporations;

• the high level of competition in our industry;

• our dependence on numerous complex information systems and our ability to maintain these systems or implement new systems or any disruptions in our information systems;

2

• our ability to protect our proprietary technology and services;

• our loss of key personnel and/or ability to attract and retain highly qualified personnel;

• our ability to comply with privacy regulations regarding the use and disclosure of patient information;

• our ability to comply with federal or state anti-kickback laws;

• our ability to comply with federal and state physician self-referral laws and regulations or issuance of additional legislative restrictions;

• changes in existing laws or regulations, adverse judicial or administrative interpretations of these laws and regulations or enactment of new legislation;

• changes in accounting standards, rules and interpretations or inaccurate estimates or assumptions in the application of accounting policies and the impact on our financial statements;

• our exposure to a loss of contracts with our physicians or termination of relationships with our affiliated professional corporations in order to comply with antitrust laws;

• our substantial indebtedness and ability to incur substantially more debt;

• our ability to generate sufficient cash to service our debt; and

• restrictive covenants in our debt agreements, which may restrict our ability to pursue our business strategies and our ability to comply with them.

For a more detailed discussion of these factors, see the information under the caption “Risk Factors” herein and in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” herein and in the Company’s most recent Annual Report on Form 10-K filed on February 22, 2016.

The Company’s forward-looking statements speak only as of the date of this report or as of the date they are made. The Company disclaims any intent or obligation to update any “forward looking statement” made in this Form 10-Q to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

3

TEAM HEALTH HOLDINGS, INC.

QUARTERLY REPORT FOR THE SIX MONTHS

ENDED JUNE 30, 2016

TABLE OF CONTENTS

		Page
Part I. Financial Information
Item 1.	Financial Statements (Unaudited)	5
	Consolidated Balance Sheets—December 31, 2015 and June 30, 2016	5
	Consolidated Statements of Comprehensive Earnings—Three Months Ended June 30, 2015 and 2016	6
	Consolidated Statements of Comprehensive Earnings—Six Months Ended June 30, 2015 and 2016	7
	Consolidated Statements of Cash Flows—Six Months Ended June 30, 2015 and 2016	8
	Notes to Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	45
Item 4.	Controls and Procedures	46
Part II. Other Information
Item 1.	Legal Proceedings	47
Item 1A.	Risk Factors	47
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	47
Item 3.	Defaults Upon Senior Securities	47
Item 4.	Mine Safety Disclosures	47
Item 5.	Other Information	47
Item 6.	Exhibits	48
Signatures		49

4

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

TEAM HEALTH HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

	December 31, 2015			June 30, 2016
	(Unaudited) (In thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	28,563		$	16,281
Short-term investments	1,985			1,581
Accounts receivable, less allowance for uncollectibles of $500,645 and $655,050 in 2015 and 2016, respectively	730,459			787,169
Prepaid expenses and other current assets	73,807			66,492
Receivables under insured programs	36,004			40,801
Income tax receivable	28,791			13,526
Total current assets	899,609			925,850
Insurance subsidiaries' and other investments	111,940			111,390
Property and equipment, net	87,907			86,727
Other intangibles, net	335,637			325,284
Goodwill	2,427,802			2,447,856
Deferred income taxes	50,250			40,369
Receivables under insured programs	90,747			98,912
Other	56,950			65,364
	$	4,060,842		$	4,101,752
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	66,358		$	57,000
Accrued compensation and physician payable	337,455			316,404
Other accrued liabilities	257,651			299,509
Current maturities of long-term debt	68,900			61,870
Total current liabilities	730,364			734,783
Long-term debt, less current maturities	2,337,363			2,311,598
Other non-current liabilities	346,427			357,302
Shareholders’ equity:
Common stock, ($0.01 par value; 100,000 shares authorized, 73,092 and 74,156 shares issued and outstanding at December 31, 2015 and June 30, 2016, respectively)	731			742
Additional paid-in capital	836,458			865,896
Accumulated deficit	(196,144		)	(176,691		)
Accumulated other comprehensive earnings	1,503			2,414
Team Health Holdings, Inc. shareholders’ equity	642,548			692,361
Noncontrolling interests	4,140			5,708
Total shareholders' equity including noncontrolling interests	646,688			698,069
	$	4,060,842		$	4,101,752

See accompanying notes to consolidated financial statements.

5

TEAM HEALTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS

	Three Months Ended June 30,
	2015			2016
	(Unaudited) (In thousands, except per share data)
Net revenues before provision for uncollectibles	$	1,466,984		$	1,815,904
Provision for uncollectibles	589,029			693,328
Net revenues	877,955			1,122,576
Cost of services rendered (exclusive of depreciation and amortization shown separately below)
Professional service expenses	687,540			891,141
Professional liability costs	27,279			33,455
General and administrative expenses (includes contingent purchase and other acquisition compensation expense of $7,856 and $9,762 in 2015 and 2016, respectively)	78,586			95,548
Other (income) expenses, net	961			(879		)
Depreciation	5,560			8,066
Amortization	21,175			24,142
Interest expense, net	4,571			30,437
Transaction, integration, and reorganization costs	2,215			6,106
Loss on refinancing of debt	—			1,069
Earnings before income taxes	50,068			33,491
Provision for income taxes	21,186			14,577
Net earnings	28,882			18,914
Net (loss) earnings attributable to noncontrolling interests	(53		)	129
Net earnings attributable to Team Health Holdings, Inc.	$	28,935		$	18,785
Net earnings per share of Team Health Holdings, Inc.
Basic	$	0.40		$	0.25
Diluted	$	0.39		$	0.25
Weighted average shares outstanding
Basic	71,956			73,958
Diluted	73,602			75,234
Other comprehensive (loss) earnings, net of tax:
Net change in fair value of investments, net of tax of $(340) and $338 for 2015 and 2016, respectively	(573		)	628
Comprehensive earnings	28,309			19,542
Comprehensive (loss) earnings attributable to noncontrolling interests	(53		)	129
Comprehensive earnings attributable to Team Health Holdings, Inc.	$	28,362		$	19,413

See accompanying notes to consolidated financial statements.

6

TEAM HEALTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS

	Six Months Ended June 30,
	2015			2016
	(Unaudited) (In thousands, except per share data)
Net revenues before provision for uncollectibles	$	2,865,273		$	3,655,435
Provision for uncollectibles	1,146,834			1,397,218
Net revenues	1,718,439			2,258,217
Cost of services rendered (exclusive of depreciation and amortization shown separately below)
Professional service expenses	1,351,005			1,793,724
Professional liability costs	53,897			80,439
General and administrative expenses (includes contingent purchase and other acquisition compensation expense of $15,760 and $18,851 in 2015 and 2016, respectively)	152,148			199,602
Other (income) expenses, net	(2,321		)	(1,611		)
Depreciation	11,134			16,103
Amortization	41,452			47,653
Interest expense, net	8,560			61,730
Transaction, integration, and reorganization costs	3,301			27,501
Loss on refinancing of debt	—			1,069
Earnings before income taxes	99,263			32,007
Provision for income taxes	42,341			12,363
Net earnings	56,922			19,644
Net (loss) earnings attributable to noncontrolling interests	(67		)	191
Net earnings attributable to Team Health Holdings, Inc.	$	56,989		$	19,453
Net earnings per share of Team Health Holdings, Inc.
Basic	$	0.80		$	0.26
Diluted	$	0.78		$	0.26
Weighted average shares outstanding
Basic	71,666			73,650
Diluted	73,137			75,129
Other comprehensive earnings (loss), net of tax:
Net change in fair value of investments, net of tax of $(337) and $492 for 2015 and 2016, respectively	(600		)	911
Comprehensive earnings	56,322			20,555
Comprehensive (loss) earnings attributable to noncontrolling interests	(67		)	191
Comprehensive earnings attributable to Team Health Holdings, Inc.	$	56,389		$	20,364

See accompanying notes to consolidated financial statements.

7

TEAM HEALTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended June 30,
	2015			2016
	(Unaudited) (In thousands)
Operating Activities
Net earnings	$	56,922		$	19,644
Adjustments to reconcile net earnings:
Depreciation	11,134			16,103
Amortization	41,452			47,653
Amortization of deferred financing costs	727			4,394
Equity based compensation expense	9,213			14,374
Provision for uncollectibles	1,146,834			1,397,218
Deferred income taxes	(14,578		)	2,794
Non-cash loss on refinancing of debt	—			905
(Gain) loss on sale of investments and other assets	(400		)	94
Equity in joint venture income	(1,714		)	(2,990		)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,244,045		)	(1,459,597		)
Prepaids and other assets	(9,753		)	715
Income tax accounts	3,967			11,319
Accounts payable	5,555			(8,950		)
Accrued compensation and physician payable	(10,710		)	(14,972		)
Contingent purchase liabilities	6,872			16,237
Other accrued liabilities	(2,178		)	(4,586		)
Professional liability reserves	18,870			14,067
Net cash provided by operating activities	18,168			54,422
Investing Activities
Purchases of property and equipment	(17,364		)	(15,333		)
Net proceeds from disposition of assets held for sale and property and equipment	269			50
Cash paid for acquisitions, net of cash acquired	(84,792		)	(29,930		)
Payments for the purchase of investments	—			(458		)
Proceeds from the sale of investments	6,560			1,169
Purchases of investments at insurance subsidiaries	(44,935		)	(46,539		)
Proceeds from investments at insurance subsidiaries	51,187			48,184
Net cash used in investing activities	(89,075		)	(42,857		)
Financing Activities
Payments on long-term debt	(7,500		)	(21,568		)
Proceeds from note payable	—			288
Payments on revolving credit facility	(631,000		)	(463,200		)
Proceeds from revolving credit facility	701,500			448,700
Payments of financing costs	—			(1,587		)
Payments related to contingent purchase obligations	—			(6,888		)
Contributions from noncontrolling interests	1,377			1,377
Proceeds from the issuance of common stock under stock purchase plans	3,445			4,952
Proceeds from exercise of stock options	20,519			15,756
Tax benefit from exercise of stock options	13,775			1,075
Payments related to settlement of equity based awards	—			(2,752		)
Net cash provided by (used in) financing activities	102,116			(23,847		)
Net increase (decrease) in cash and cash equivalents	31,209			(12,282		)
Cash and cash equivalents, beginning of period	20,094			28,563
Cash and cash equivalents, end of period	$	51,303		$	16,281
Supplemental cash flow information:
Interest paid	$	9,380		$	61,562
Taxes paid, net of refunds	$	37,160		$	(2,368	)

See accompanying notes to consolidated financial statements.

8

TEAM HEALTH HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Organization and Basis of Presentation

The accompanying unaudited consolidated financial statements include the accounts of Team Health Holdings, Inc. (the Company) its subsidiaries and its affiliates, including its affiliated medical groups, and have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial reporting, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements.

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring items) necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The consolidated balance sheet of the Company at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and disclosures required by U.S. GAAP for complete financial statements. These financial statements and the notes thereto should be read in conjunction with the December 31, 2015 audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for fiscal year 2015 filed with the Securities and Exchange Commission (the SEC).

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements and notes. Actual results could differ from those estimates. Certain amounts for the prior year have been reclassified to conform to the current year’s presentation.

Note 2. Recently Adopted and Recently Issued Accounting Guidance

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which establishes a comprehensive revenue recognition standard for virtually all industries under U.S. GAAP. The standard is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein, with early adoption permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which will change how companies account for and present lease arrangements. The guidance requires companies to recognize leased assets and liabilities for both capital and operating leases. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods therein, and early adoption is permitted. Companies are required to adopt the guidance on a modified retrospective method. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting,” which requires companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled (i.e., additional paid-in-capital pools will be eliminated). In addition, the new guidance changes the limit that companies are allowed to withhold for employees without triggering liability classification and allows companies to make a policy election to either recognize forfeitures as they occur or estimate them. The new guidance is  effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods, and early adoption is permitted. The required transition methods for each aspect of the new guidance varies between prospective, retrospective and modified retrospective. The Company has not yet determined which method of adoption it will select and is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

9

The Company has implemented all new accounting pronouncements that are in effect and that could materially impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued, but are not yet effective, that might have a material impact on the consolidated financial statements of the Company unless otherwise noted in prior updates or above.

Note 3. Acquisitions and Contingent Purchase Obligations

Acquisitions

During the six months ended June 30, 2016, the Company completed three acquisitions of emergency medicine businesses with operations in Rhode Island, Connecticut, California and Ohio for a total of $29.9 million, which expanded the Company's emergency medicine presence in those respective markets. The results of operations of the acquired businesses have been included in the Company’s consolidated financial statements beginning on the acquisition date. Pro forma results of operations have not been presented because the effect of these acquisitions is not material to the Company’s consolidated results of operations individually or in the aggregate.

The purchase price for these acquisitions was allocated, based on management’s estimates, in accordance with ASC Topic 805, “Business Combinations” (ASC 805). The Company’s purchase price allocation for business combinations completed during recent periods is preliminary and may be subject to revision as additional information about the fair value of acquired working capital becomes available. Additional information, which existed as of the acquisition date but at that time was unknown to the Company, may become known to the Company during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. The purchase price for these acquisitions completed during the six months ended June 30, 2016 was allocated as shown in the table below (in thousands):

	June 30, 2016
Accounts receivable	$	1,286
Prepaid expenses and other assets	3
Other intangibles (consisting of physician and hospital agreements)	15,600
Goodwill (of which $3.8 million is tax deductible)	16,601
Accounts payable	(41		)
Accrued compensation and physician payable	(291		)
Other accrued liabilities	(241		)
Net deferred income taxes	(2,987		)
Total purchase price	$	29,930

IPC Healthcare, Inc. (IPC) Acquisition

On November 23, 2015, the Company completed the acquisition of IPC in a cash transaction. At closing, the Company paid approximately $1.60 billion in cash to the former owners of IPC in exchange for all of the outstanding equity interests of IPC.

The accounting for the acquisition of IPC will be completed within the timeframe prescribed by the provisions of ASC 805. The Company continues to obtain information relative to the fair values of assets acquired and liabilities assumed. Acquired assets and assumed liabilities include, but are not limited to, accounts receivable, other intangible assets, current and noncurrent taxes payable, deferred taxes, contingent purchase liabilities, and other accrued liabilities. The valuations are based on appraisal reports or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed.

During 2016, factors became known that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of the IPC transaction. The estimated fair values of assets acquired and liabilities assumed, specifically accounts receivable, current and noncurrent taxes payable, deferred taxes, contingent purchase liability and other intangible assets, may be subject to change as additional information is received. The purchase price allocation adjustments for this acquisition are summarized as follows (in thousands):

10

	As of			Adjustments to			As of
	December 31, 2015			Purchase Price Allocation			June 30, 2016
Short term investments	$	1,985		$	—		$	1,985
Accounts receivable	127,265			(6,955		)	120,310
Prepaid expenses and other assets	6,347			(316		)	6,031
Receivables under insured programs	36,255			—			36,255
Property and equipment	10,541			216			10,757
Income tax receivable	12,528			—			12,528
Net deferred income taxes	64,301			(3,608		)	60,693
Other intangibles (consisting of marketing-related and technology-based intangibles and physician and hospital agreements)	4,975			21,700			26,675
Goodwill (of which the tax deductible amount was $368,283)	1,574,757			3,212			1,577,969
Accounts payable	(15,627		)	(33		)	(15,660		)
Accrued compensation and physician payable	(43,856		)	—			(43,856		)
Other accrued liabilities	(63,809		)	(13,260		)	(77,069		)
Contingent purchase liability	(30,639		)	(2,768		)	(33,407		)
Assumed notes payable	(148,249		)	—			(148,249		)
Other non-current liabilities	(61,894		)	1,812			(60,082		)
Total consideration paid, net of acquired cash and cash equivalents of $28,059	$	1,474,880		$	—		$	1,474,880

Subsequent Acquisition

In July 2016, the Company completed the acquisition of the operations of an anesthesiology business located in Florida. This acquisition will add approximately 18,000 patient visits annually to the Company's existing anesthesia operations. The Company is still in the process of completing the purchase price allocation for this acquisition.

Contingent Purchase Obligations

In accordance with ASC 805, the Company records its contingent consideration as a component of the opening balance sheet unless there is a continuing employment provision. Contingent consideration with a continuing employment provision is recognized ratably over the defined performance period as compensation expense which is included as a component of general and administrative expense (and parenthetically disclosed with other acquisition-related compensation expense) in the results of the Company’s operations. The payment of contingent purchase obligations is included as a component of financing, unless there is a continuing employment provision, in which case it is included as a component of operating cash flows.

As of June 30, 2016, the Company estimates it may have to pay $101.1 million in future contingent payments for acquisitions made prior to June 30, 2016, based upon the current projected performance of the acquired operations of which $69.2 million is recorded as a liability in other liabilities and other non-current liabilities on the Company’s consolidated balance sheet. The remaining estimated liability of $31.9 million will be recorded as contingent purchase compensation expense over the remaining performance periods. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over the respective performance periods. These payments will be made should the acquired operations achieve the financial targets or certain contract terms as agreed to in the respective acquisition agreements, including the requirements for continuing employment. When measured on a recurring basis, this liability is considered Level 3 in the fair value hierarchy due to the use of unobservable inputs to measure fair value.

The contingent purchase and other acquisition compensation expense recognized for the six months ended June 30,2015 and 2016 was $15.8 million and $18.9 million, respectively.

11

The changes to the Company’s accumulated contingent purchase liability for the six months ended June 30, 2016 are as follows (in thousands):

Contingent purchase liability at December 31, 2015	$	57,080
Payments	(9,501		)
Contingent purchase and other acquisition compensation expense recognized	18,851
Adjustments to contingent purchase liability recognized at acquisition date	2,781
Contingent purchase liability at June 30, 2016	$	69,211

Estimated unrecognized contingent purchase compensation expense as of June 30, 2016 is as follows (in thousands):

For the remainder of the year ended December 31, 2016	$	16,409
For the year ended December 31, 2017	9,681
For the year ended December 31, 2018	3,635
For the year ended December 31, 2019	1,515
For the year ended December 31, 2020	625
	$	31,865

Note 4. Fair Value Measurements

The Company applies the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (ASC Topic 820), in determining the fair value of its financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements.

ASC Topic 820 prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2	Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;
Level 3	Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The following table provides information on those assets and liabilities the Company currently measures at fair value on a recurring basis as of December 31, 2015 and June 30, 2016 (in thousands):

	Carrying Amount in Consolidated Balance Sheet December 31, 2015		Fair Value December 31, 2015		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	18,238	$	18,238	$	18,238	$	—	$	—
Municipal bonds	87,121		87,121		—		87,121		—
Mutual funds	64		64		—		64		—
Private investments	2,818		2,818		—		—		2,818
Corporate bonds	3,699		3,699		—		3,699		—
Total investments of insurance subsidiaries	$	111,940	$	111,940	$	18,238	$	90,884	$	2,818
Supplemental employee retirement plan investments:
Mutual funds	$	45,868	$	45,868	$	—	$	45,868	$	—

12

	Carrying Amount in Consolidated Balance Sheet June 30, 2016		Fair Value June 30, 2016		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	14,654	$	14,654	$	14,654	$	—	$	—
Municipal bonds	86,389		86,389		—		86,389		—
Mutual funds	54		54		—		54		—
Private investments	2,185		2,185		—		—		2,185
Corporate bonds	8,108		8,108		—		8,108		—
Total investments of insurance subsidiaries	$	111,390	$	111,390	$	14,654	$	94,551	$	2,185
Supplemental employee retirement plan investments:
Mutual funds	$	52,237	$	52,237	$	—	$	52,237	$	—

The Company’s insurance subsidiaries' and other investments are valued using market prices on active markets (Level 1) and less active markets (Level 2), in addition to using alternative information when market data is not available (Level 3). Level 1 investment valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets. Level 2 investment valuations are obtained from readily available pricing sources for comparable investments or identical investments in less active markets. The fair values of the Company’s supplemental employee retirement investments are based on quoted prices. Level 3 investment valuations require significant management judgment and are based on transaction price, company performance, and market conditions. For the six months ended June 30, 2016 there were no transfers between Levels 1, 2 or 3. See Note 5 for more information regarding the Company’s investments.

The Company classified its municipal bonds, mutual funds, and corporate bonds within Level 2 because these securities were valued based on quoted prices in markets that are less active, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency.

The Company classified its private investments within Level 3 because active market pricing is not readily available and, as such, the Company uses net asset values as an estimate of fair value as a practical expedient. The valuation of non-public private equity investments requires significant management judgment due to the absence of observable quoted market prices, inherent lack of liquidity, and the long-term nature of such assets. These investments are valued initially based upon transaction price. In determining valuation adjustments resulting from the investment review process, emphasis is placed on current company performance and market conditions.

In addition to the preceding disclosures prescribed by the provisions of FASB ASC Topic 820, ASC Topic 825 “Financial Instruments” requires the disclosure of the estimated fair value of financial instruments. The Company’s short term financial instruments include cash and cash equivalents, short term investments, accounts receivable, and accounts payable. The carrying value of the short term financial instruments approximates the fair value due to their short term nature. These financial instruments have no stated maturities or the financial instruments have short term maturities that approximate market.

The fair value of the Company's debt is estimated using quoted market prices when available. When quoted market prices are not available, fair value is estimated based on current market interest rates for debt with similar maturities (Level 2). At June 30, 2016, the estimated fair value of the Company’s outstanding debt was $2.47 billion compared to a carrying value of $2.42 billion.

Note 5. Investments

Investments are primarily comprised of securities held by the Company and its captive insurance subsidiaries in connection with its participant directed supplemental employee retirement plan. Investments held by the Company and its captive insurance subsidiaries are classified as available-for-sale securities. The unrealized gains or losses of investments held by the Company and its captive insurance subsidiaries are included in accumulated other comprehensive earnings as a separate component of shareholders’ equity, unless the decline in value is deemed to be other-than-temporary and the Company does not have the intent and ability to hold such securities until their full cost can be recovered, in which case such securities are written down to fair value and the loss is charged to current period earnings.

13

The investments held by the Company in connection with its participant directed supplemental employee retirement plan are classified as trading securities; therefore, changes in fair value associated with these investments are recognized as a component of earnings.

At December 31, 2015 and June 30, 2016, amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by investment type were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Money market funds	$	18,238	$	—	$	—		$	18,238
Municipal bonds	84,983		2,411		(273		)	87,121
Mutual funds	64		—		—			64
Private investments	2,712		106		—			2,818
Corporate bonds	3,718		6		(25		)	3,699
	$	109,715	$	2,523	$	(298	)	$	111,940
June 30, 2016
Money market funds	$	14,654	$	—	$	—		$	14,654
Municipal bonds	83,100		3,432		(143		)	86,389
Mutual funds	54		—		—			54
Private Investments	1,982		203		—			2,185
Corporate bonds	7,974		134		—			8,108
	$	107,764	$	3,769	$	(143	)	$	111,390

At December 31, 2015 and June 30, 2016, the amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by contractual maturities were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Due in less than one year	$	24,099	$	35	$	(54	)	$	24,080
Due after one year through five years	57,537		1,647		(79		)	59,105
Due after five years through ten years	23,389		674		(56		)	24,007
Due after ten years	1,914		61		(109		)	1,866
Total	$	106,939	$	2,417	$	(298	)	$	109,058
June 30, 2016
Due in less than one year	$	24,816	$	122	$	(17	)	$	24,921
Due after one year through five years	58,911		2,235		(25		)	61,121
Due after five years through ten years	20,001		1,204		—			21,205
Due after ten years	2,000		5		(101		)	1,904
Total	$	105,728	$	3,566	$	(143	)	$	109,151

14

A summary of the Company’s temporarily impaired available-for-sale investment securities as of December 31, 2015 and June 30, 2016 follows (in thousands):

	Impaired Less Than 12 Months						Impaired Over 12 Months					Total
	Fair Value		Unrealized Losses				Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
December 31, 2015
Municipal bonds	$	13,189	$	(103	)		$	2,575	$	(170	)	$	15,764	$	(273	)
Corporate bonds	3,120		(25		)		—		—			3,120		(25		)
Total investment	$	16,309	$	(128	)		$	2,575	$	(170	)	$	18,884	$	(298	)
June 30, 2016
Municipal bonds	$	2,405	$	(30	)		$	2,782	$	(113	)	$	5,187	$	(143	)
Corporate bonds	1,048		—			(a)	—		—			1,048		—
Total investment	$	3,453	$	(30	)		$	2,782	$	(113	)	$	6,235	$	(143	)

(a) Unrealized loss is less than $1,000.

The unrealized losses resulted from changes in market interest rates, not from changes in the probability of contractual cash flows. Because the Company has the ability and intent to hold the investments until a recovery of carrying value and full collection of the amounts due according to the contractual terms of the investments is expected, the Company does not consider these investments to be other-than-temporarily impaired at June 30, 2016.

During the six months ended June 30, 2016, the Company recorded a gain of approximately $0.4 million on the sale of specifically identified investments.

As of December 31, 2015 and June 30, 2016, the investments related to the participant directed supplemental employee retirement plan totaled $45.9 million and $52.2 million, respectively, and are included in other assets in the accompanying consolidated balance sheets. The net trading gains on those investments for the six months ended June 30, 2015 and June 30, 2016 that were still held by the Company as of June 30, 2015 and June 30, 2016 are as follows (in thousands):

	2015		2016
Net gains (losses) recognized during the six months ended June 30, 2015 and 2016, respectively on trading securities	$	1,066	$	(530	)
Less: Net gains (losses) recognized during the period on trading securities sold during the six months ended June 30, 2015 and 2016, respectively	20		(207		)
Unrealized gains (losses) recognized on trading securities still held at June 30, 2015 and 2016, respectively	$	1,046	$	(323	)

Note 6. Net Revenues

Net revenues consists of fee for service revenue, contract revenue and other revenue. The Company’s net revenues are principally derived from the provision of healthcare staffing services to patients within healthcare facilities and is recorded in the period the services are rendered. Under the fee for service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payors. Fee for service revenue reflects gross fee for service charges less contractual allowances and policy discounts, where applicable. Contractual adjustments represent the Company’s estimate of discounts and other adjustments to be recognized from gross fee for service charges under contractual payment arrangements, primarily with commercial, managed care and governmental payment plans such as Medicare and Medicaid when the Company’s providers participate in such plans. Contractual adjustments are not reflected in self-pay fee for service revenue. Contract revenue represents revenue generated under contracts in which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates, monthly contractual rates, or certain operational or financial metrics. Revenue in such cases is recognized as the hours are worked by the Company’s affiliated staff and contractors or as metrics are realized. Other revenue consists primarily of revenue from management and billing services provided to outside parties. Revenue is recognized for such services pursuant to the terms of the contracts with customers. The Company also records a provision for uncollectible accounts based primarily on historical collection experience to record accounts receivables at the estimated amounts expected to be collected.

15

Net revenues consisted of the following (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2015					2016					2015					2016
Medicare	$	178,168		20.3	%	$	339,092		30.2	%	$	346,927		20.2	%	$	687,863		30.5	%
Medicaid	157,601			18.0		202,918			18.1		310,136			18.0		399,810			17.7
Commercial and managed care	448,043			51.0		526,954			46.9		860,000			50.0		1,060,089			46.9
Self-pay	464,089			52.9		505,687			45.0		908,342			52.9		1,014,549			44.9
Other	19,921			2.3		23,147			2.1		40,202			2.3		46,961			2.1
Unbilled	5,523			0.6		(6,695		)	(0.6	)	13,609			0.8		2,583			0.1
Net fee for service revenue before provision for uncollectibles	1,273,345			145.0		1,591,103			141.7		2,479,216			144.3		3,211,855			142.3
Contract revenue before provision for uncollectibles	183,727			20.9		206,117			18.4		367,367			21.4		406,945			18.0
Other	9,912			1.2		18,684			1.7		18,690			1.0		36,635			1.6
Net revenues before provision for uncollectibles	1,466,984			167.1		1,815,904			161.8		2,865,273			166.7		3,655,435			161.9
Provision for uncollectibles	(589,029		)	(67.1	)	(693,328		)	(61.8	)	(1,146,834		)	(66.7	)	(1,397,218		)	(61.9	)
Net revenues	$	877,955		100.0	%	$	1,122,576		100.0	%	$	1,718,439		100.0	%	$	2,258,217		100.0	%

The Company employs several methodologies for determining its allowance for uncollectibles depending on the nature of the net revenues before provision for uncollectibles recognized. The Company initially determines gross revenue for its fee for service patient visits based upon established fee schedule prices. Such gross revenue is reduced for estimated contractual allowances for those patient visits covered by contractual insurance arrangements to result in estimated net revenues before provision for uncollectibles. Net revenues before provision for uncollectibles is then reduced for management’s estimate of uncollectible amounts. Fee for service net revenues represents estimated cash to be collected from such patient visits and is net of management’s estimate of account balances estimated to be uncollectible. The provision for uncollectible fee for service patient visits is based on historical experience resulting from approximately twenty-three million fee for service patient visits and procedures over the last twelve months. The significant volume of patient visits and the terms of thousands of commercial and managed care contracts and the various reimbursement policies relating to governmental healthcare programs do not make it feasible to evaluate fee for service accounts receivable on a specific account basis. Fee for service accounts receivable collection estimates are reviewed on a quarterly basis for each fee for service contract by period of accounts receivable origination. Such reviews include the use of historical cash collection percentages by contract adjusted for the lapse of time since the date of the patient visit. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectibility of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. Contract-related net revenues are billed based on the terms of the contract at amounts expected to be collected. Such billings are typically submitted on a monthly basis and aged trial balances are prepared. Allowances for estimated uncollectible amounts related to such contract billings are made based upon periodic reviews of specific accounts and invoices once it is concluded that such amounts are not likely to be collected. Approximately 98% of the Company’s allowance for doubtful accounts is related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is centered in self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. While the Company does not specifically allocate the allowance for doubtful accounts to individual accounts or specific payor classifications, the portion of the allowance, excluding IPC, associated with fee for service charges as of June 30, 2016 was equal to approximately 93% of outstanding self-pay fee for service patient accounts. The methodologies employed to compute allowances for doubtful accounts were unchanged between 2015 and 2016.

16

Note 7. Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill during the year ended December 31, 2015 and the six months ended June 30, 2016 were as follows (in thousands):

Goodwill	$	869,038
Accumulated impairment loss	(144,579		)
Additions through acquisitions	1,703,343
Balance, December 31, 2015	$	2,427,802
Goodwill	$	2,572,381
Accumulated impairment loss	(144,579		)
Increases from prior year acquisition purchase price allocation adjustments	3,453
Additions through current year acquisitions	16,601
Balance, June 30, 2016	$	2,447,856

The following is a summary of intangible assets and related amortization as of December 31, 2015 and June 30, 2016 (in thousands):

	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2015:
Contracts	$	494,569	$	(170,873	)
Other	21,716		(9,775		)
Total	$	516,285	$	(180,648	)
As of June 30, 2016:
Contracts	$	519,151	$	(211,829	)
Other	33,636		(15,674		)
Total	$	552,787	$	(227,503	)
Aggregate amortization expense:
For the six months ended June 30, 2016			$	47,653
Estimated amortization expense:
For the remainder of the year ended December 31, 2016			$	46,379
For the year ended December 31, 2017			88,051
For the year ended December 31, 2018			72,357
For the year ended December 31, 2019			63,326
For the year ended December 31, 2020			43,495
For the years ended December 31, 2021 and thereafter			11,676
Total			$	325,284

Intangible assets are amortized over their estimated life, which is approximately one to eight years. As of June 30, 2016, the weighted average remaining amortization period for intangible assets was 3.4 years.

17

Note 8. Long-Term Debt

Long-term debt as of June 30, 2016 consisted of the following (in thousands):

Tranche A Term Loan Facility	$	562,500
Tranche B Term Loan Facility	1,308,720
7.25% Senior Notes due 2023	545,000
Revolving Credit Facility	7,500
Total outstanding debt	2,423,720
Debt issuance costs	(50,252		)
	2,373,468
Less current portion	(61,870		)
	$	2,311,598

The Company's senior secured credit facilities (Credit Facility) consist of a $600.0 million tranche A term loan facility (Tranche A Term Loan Facility), a $1.31 billion tranche B term loan facility (Tranche B Term Loan Facility) and a $650.0 million revolving credit facility (Revolving Credit Facility). The Tranche A Term Loan and Revolving Credit Facility have a maturity date of October 2, 2019. The Tranche B Term Loan Facility has a maturity date of November 23, 2022. The maturity dates under the Credit Facility are subject to extension with lender consent according to the terms of the senior credit agreement (the Senior Credit Agreement).

The interest rate on any outstanding Revolving Credit Facility borrowings and Tranche A Term Loan Facility borrowings, and the commitment fee applicable to undrawn revolving commitments, is priced off a grid based upon the Company’s first lien net leverage ratio and is currently LIBOR + 2.00% in the case of revolving credit borrowings under the Revolving Credit Facility and Tranche A Term Loan Facility and 0.35% in the case of unused revolving commitments. The weighted average interest rate for the six months ended June 30, 2016 was 2.81% for amounts outstanding under the Tranche A Term Loan Facility.

On June 2, 2016, the Company amended its Senior Credit Agreement (the Amendment) to reduce the interest rate applicable to any outstanding Tranche B Term Loans from LIBOR plus 3.75% to LIBOR plus 3.00%. The Company effected this reduction in pricing through a refinancing of the existing Tranche B Term Loan Facility. The Amendment also requires the Company to pay a 1.0% prepayment penalty on any amount prepaid if the Tranche B Term Loan Facility is repriced in order to effect a reduction in pricing prior to December 2, 2016. Other significant terms and conditions of the Senior Credit Agreement, including the maturity date of November 23, 2022 and the LIBOR floor of 0.75%, did not change under the amendment.

The Company had $7.5 million borrowings outstanding under the Revolving Credit Facility as of June 30, 2016, and the Company had $6.8 million of standby letters of credit outstanding against the Revolving Credit Facility commitment.

The Credit Facility agreement contains both affirmative and negative covenants, including limitations on the Company’s ability to incur additional indebtedness, sell material assets, retire, redeem or otherwise reacquire its capital stock, acquire the capital stock or assets of another business and pay dividends, and requires the Company to comply with a maximum total leverage ratio, tested quarterly. At June 30, 2016, the Company was in compliance with all of its covenants under the senior credit facility agreement. The Credit Facility is secured by substantially all of the Company’s U. S. subsidiaries’ assets.

Senior Notes and Indenture

On November 23, 2015, Team Health, Inc., a wholly-owned subsidiary of the Company (the Issuer), completed the private placement of $545.0 million aggregate principal amount of 7.25% Senior Notes due 2023 (the Notes). The Notes are senior unsecured obligations and are fully and unconditionally guaranteed on a senior unsecured basis by the Company and, subject to certain exceptions, each of its existing and future material domestic wholly-owned restricted subsidiaries, referred to, collectively, as “Guarantors.”

The Notes bear interest at 7.25% per annum and mature on December 15, 2023. Interest is payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016, to holders of record at the close of business on June 1 or December 1, as the case may be, immediately preceding each such interest payment date.

Prior to December 15, 2018, the Issuer may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest to, but excluding, the redemption date, if any, plus

18

the “make-whole” premium set forth in the indenture. On and after December 15, 2018, the Company may redeem the Notes, in whole or in part, at the redemption prices set forth in the indenture, plus accrued and unpaid interest to, but excluding, the redemption date. In addition, prior to December 15, 2018, the Company may also redeem up to 40% of the aggregate principal amount of the Notes at a redemption price equal to 107.25% of the aggregate principal amount thereof, in each case, using an amount not to exceed the net cash proceeds from certain equity offerings, plus accrued and unpaid interest to, but excluding, the redemption date.

The indenture governing the Notes due 2023 contains restrictive covenants that limit among other things, the ability of us and our restricted subsidiaries to incur or guarantee additional debt or issue disqualified stock or certain preferred stock; pay dividends and make other distributions on, or redeem or repurchase, capital stock; make certain investments; incur certain liens; enter into certain transactions with affiliates; merge or consolidate; enter into agreements that restrict the ability of certain restricted subsidiaries to make dividends or other payments to us or each of our existing and future material domestic wholly-owned restricted subsidiaries, referred to, collectively, as “Guarantors”; designate restricted subsidiaries as unrestricted subsidiaries; and transfer or sell certain assets. These covenants are subject to a number of important limitations and exceptions. The Indenture also contains customary events of default which would permit the holders of the Notes to declare those Notes to be immediately due and payable if not cured within applicable grace periods, including the failure to make timely payments on the Notes or other material indebtedness, the failure to satisfy covenants and specified events of bankruptcy and insolvency.

Aggregate annual maturities of long-term debt as of June 30, 2016 are as follows (in thousands):

2016	$	61,870
2017	69,370
2018	73,120
2019	418,120
2020 and thereafter	1,801,240

Note 9. Professional Liability Insurance

The Company’s professional liability loss reserves included in other accrued liabilities and other non-current liabilities in the accompanying consolidated balance sheets consisted of the following (in thousands):

	December 31, 2015		June 30, 2016
Estimated losses under self-insured programs	$	245,070	$	257,751
Estimated losses under commercial insurance programs	126,751		139,713
	371,821		397,464
Less estimated payable within one year	105,028		104,578
	$	266,793	$	292,886

The changes to the Company’s estimated losses under self-insured programs as of June 30, 2016 were as follows (in thousands):

Balance, December 31, 2015	$	245,070
Reserves related to current period	37,049
Changes related to prior year reserves	14,284
Assumed liabilities	(1,812		)
Payments for current period reserves	(262		)
Payments for prior period reserves	(36,578		)
Balance, June 30, 2016	$	257,751

The Company provides for its estimated professional liability losses through a combination of self-insurance and commercial insurance programs. Losses under commercial insurance programs in excess of the limit of coverage remain as a

19

self-insured obligation of the Company. A portion of the professional liability loss risks that have been provided for through self-insurance (claims-made basis) are transferred to and funded into captive insurance companies. The accounts of the captive insurance companies are fully consolidated with those of the other operations of the Company in the accompanying consolidated financial statements.

The self-insurance components of our risk management program include reserves for future claims incurred but not reported (IBNR). As of December 31, 2015, of the $245.1 million of estimated losses under self-insured programs, approximately $157.4 million represented an estimate of IBNR claims and expenses and additional loss development, with the remaining $87.7 million representing specific case reserves. Of the specific case reserves as of December 31, 2015, $3.0 million represented case reserves that had settled but not yet funded, and $84.7 million reflected unsettled case reserves.

As of June 30, 2016, of the $257.8 million of estimated losses under self-insurance programs, approximately $154.2 million represented an estimate of IBNR claims and expenses and additional loss development, with the remaining $103.6 million representing specific case reserves. Of the specific case reserves as of June 30, 2016, $2.5 million represented case reserves that had been settled but not yet funded, and $101.1 million reflected unsettled case reserves.

The Company’s provisions for losses under its self-insurance components are estimated using the results of periodic actuarial studies. Such actuarial studies include numerous underlying estimates and assumptions, including assumptions as to future claim losses, the severity and frequency of such projected losses, loss development factors and others. The Company’s provisions for losses under its self-insured components are subject to subsequent adjustment should future actuarial projected results for such periods indicate projected losses greater or less than previously projected.

During the first quarter of 2016, the Company reserved $14.3 million to settle two separate professional liability claims originating from prior years in excess of coverage limits, which was fully funded as of June 30, 2016. See Note 10 for more information regarding these settlements.

The Company’s most recent actuarial valuation was completed in April 2016. Based on the results of the actuarial study completed in April 2016, management determined no additional change was necessary in the consolidated reserves for professional liability losses during the first quarter of 2016 related to prior year loss estimates. The discount rate on professional liability reserves (including IPC as noted below) was 0.9% at June 30, 2016 compared to 1.6% at December 31, 2015.

IPC Professional Liability Reserves

IPC is fully insured on a claims-made basis up to policy limits through a third party malpractice insurance policy, which ends December 31 of each year. The Company has established reserves for this segment for claims incurred and reported and IBNR during the policy period. These reserves of $25.4 million as of June 30, 2016 and the timing of payment of such amounts are estimated based upon actuarial loss projections, which are updated semi-annually, and discounted using the current weighted average Treasury rate over a 10 year period.

Note 10. Contingencies

Litigation

The Company is currently a party to various legal proceedings arising in the ordinary course of business. The legal proceedings the Company is involved in from time to time include lawsuits, claims, audits and investigations, including those arising out of services provided, personal injury claims, professional liability claims, the Company's billing, collection and marketing practices, employment disputes and contractual claims, and seek monetary and other relief, including statutory damages and penalties. While the Company currently believes that the ultimate outcome of such proceedings, individually and in the aggregate, will not have a material adverse effect on the Company's financial position or overall trends in results of operations, litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on the Company's net earnings in the period in which the ruling occurs. The estimate of the potential impact from such legal proceedings on the Company's financial position or overall results of operations could change in the future.

On August 14, 2015, prior to the closing of the IPC Transaction, a purported shareholder of IPC filed a complaint in the Delaware Court of Chancery captioned Smukler v. IPC Healthcare, Inc., et al. (Case No. 11392-CB), on behalf of a purported class of  IPC shareholders. The lawsuit names as defendants IPC, each of its directors at the time the merger with the Company was announced (the Individual Defendants), the Company, and Intrepid Merger Sub, Inc. (Sub). The August 14, 2015 complaint alleged that the Individual Defendants breached their fiduciary duties by, among other things, failing to take appropriate steps

20

to maximize the value of IPC to its shareholders, failing to value IPC properly, and taking steps to avoid competitive bidding by alternate potential acquirers. The complaint also alleged that IPC, the Company, and Sub aided and abetted those alleged breaches of fiduciary duties by the Individual Defendants. The complaint sought, among other things, certification of the action as a class action; injunctive relief enjoining the merger; an accounting of all damages purportedly suffered by the plaintiff and the class (including rescissory damages in favor of the plaintiff and the class); and the fees and costs associated with the litigation. On August 18, 2015, an additional lawsuit, Crescente v. Singer, et al. (Case No. 11405-CB), was filed in the Delaware Court of Chancery, asserting similar claims and allegations to those in the Smukler lawsuit and seeking similar relief on behalf of the same putative class.

Additionally, on August 19, 2015, prior to the closing of the IPC Transaction, a lawsuit was filed in the Superior Court for the State of California in Los Angeles County, Khemthong v. IPC Healthcare Networks, Inc., et al. (No. BC 591953). The lawsuit asserted similar claims and allegations to those in the Smukler lawsuit and sought similar relief on behalf of the same putative class. On August 27, 2015, the plaintiff filed a request for voluntary dismissal of the suit without prejudice, and on August 28, 2015, the court entered an order granting that request.

 Pursuant to a September 11, 2015 order from the Delaware Court of Chancery (the Consolidation Order), the Smukler and Crescente actions were consolidated, and all further litigation relating to or arising out of the Company’s merger with IPC were directed to be consolidated with such actions under the caption In re IPC Healthcare, Inc. Stockholders Litigation (Case No. 11392-CB) (the Consolidated Action).  On September 17, 2015, an action captioned Spencer v. IPC Healthcare, Inc. (Case. No. 11516-CB) was filed in the Delaware Court of Chancery. Under the Consolidation Order, such action is required to be consolidated with the previously-filed actions. On September 18, 2015, a verified consolidated class action complaint was filed in the Consolidated Action (the Consolidated Complaint).  The Consolidated Complaint alleges substantially the same breaches of fiduciary duty as the August 14, 2015 complaint in the Smukler action, and additionally alleges that the Individual Defendants breached their duty of disclosure by failing to disclose to IPC shareholders all material information necessary for them to evaluate the merger. On October 2, 2015, the defendants in the Consolidated Action moved to dismiss the Consolidated Complaint.

On November 6, 2015, the Company and the other defendants in the Consolidated Action entered into a Memorandum of Understanding with the plaintiffs in the Consolidated Action providing for the settlement and the release of all claims that were or could have been brought against the Company and the other defendants in the Consolidated Action based upon a duty arising under Delaware law to disclose or not omit material information in connection with the IPC Transaction, upon entry of a final order by the Delaware Court of Chancery approving the settlement. The Memorandum of Understanding contemplated that, subject to completion of certain confirmatory discovery by counsel to the plaintiffs, the parties would enter into a stipulation of settlement.

Following a series of rulings by the Court of Chancery in other lawsuits challenging mergers, the Company and the other defendants in the Consolidated Action agreed with the plaintiffs that the Memorandum of Understanding would be superseded and replaced by the voluntary dismissal of the Consolidated Action on the basis that it was mooted by the disclosures contained in the Current Report on the Form 8-K that the Company filed with the SEC on November 6, 2015. On April 12, 2016, the Court entered an order granting plaintiffs’ request to voluntarily dismiss the Consolidated Action as moot and setting a briefing schedule for plaintiffs to make an application to the Court for the payment of their attorneys’ fees and expenses. Plaintiffs filed their application for an award of fees and expenses, in the total amount of $350,000 on May 19, 2016. The Company filed its opposition to such application on June 30, 2016 and on July 14, 2016, plaintiffs filed their reply papers.

On November 13, 2015 the U.S. District Court for the Eastern District of Wisconsin ordered the unsealing and service of a qui tam complaint, filed on March 27, 2014, and captioned United States of America, ex rel. John Mamalakis, M.D., the States of California, Colorado, Delaware, Florida, Georgia, Hawaii, Iowa, Maryland, Michigan, Nevada, New Jersey, North Carolina, Oklahoma, Tennessee, Texas, Wisconsin and the District of Columbia v. Anesthetix Management, LLC, d/b/a Anesthetix of TeamHealth, Team Health Holdings, Inc., Sonya Pease, M.D., John Ippolito, M.D., Edward Lee, M.D., Howard Stroup, M.D., Sammy Dean, M.D., and Jacqueline Peters, M.D. (Defendents) (Case No. 2:14cv00349-CNC). On June 11, 2014, the United States gave notice of its intention, and the intention of all of the other states and the District of Columbia, not to intervene in the lawsuit. On March 10, 2016, Team Health Holdings, Inc. was served with the complaint. The complaint alleges that the defendants submitted false claims to federal and state health insurance programs for “medical direction” of anesthesia services (rather than “medical supervision”) that were provided at Wheaton Franciscan Hospital-All Saints Hospital (All Saints) in Racine, Wisconsin, as well as numerous other non-identified hospitals and clinics from 2010 to the present. Plaintiff also claims retaliatory termination, alleging that he was terminated from his employment for voicing his concerns about the anesthesia services. Plaintiff seeks recovery of all Medicare and Medicaid reimbursement that the defendants received as a result of the allegedly false claims and treble damages under the False Claims Act, as well as a civil penalty for each such false Medicare and Medicaid claim. On April 15, 2016, plaintiff amended his complaint, removing all of the individual defendants as well as the claims filed on behalf of Delaware, Georgia, Hawaii, Iowa, Maryland, Nevada, North Carolina, Oklahoma, Tennessee and Texas. On May 2, 2016, Defendants filed a motion to dismiss the entirety of the complaint pursuant to Federal Rules of Civil Procedure 9(b) and 12(b)(6), or in the alternative, to compel arbitration of the retaliatory

21

discharge claim. On July 1, 2016, Relator filed his opposition to the motion. Defendants filed their reply in support of the motion on July 18, 2016. The Company intends to vigorously defend against the allegations in this matter. The Company does not believe that the final outcome of this matter will be material.

In August 2011, a medical malpractice suit was filed against three of the Company’s affiliates and one of its physicians along with other co-defendants, including a hospital in the Superior Court of New Jersey, Camden County, alleging a failure to diagnose sepsis in 2010. In July 2012, a medical malpractice suit was filed in the Court of Common Pleas, Luzerne, Pennsylvania against one Company affiliate and one of its physicians and a co-defendant hospital, alleging a failure to diagnose a stroke in 2010. In March 2016, both cases resulted in settlements in excess of insurance coverage limits where the Company was required to fund a total of $14.3 million, which represents our contribution to the overall settlements that includes the other defendants. As of June 30, 2016, these settlements have been fully funded.

It is not possible to predict when the above matters may be resolved, the time or resources that the Company will need to devote to the matters, or what impact, if any, the outcome of the matters might have on the Company's business, consolidated financial position, results of operations, or cash flows.

Healthcare Regulatory Matters

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action. From time to time, governmental regulatory agencies will conduct inquiries and audits of the Company’s practices. It is the Company’s current practice and future intent to cooperate fully with such inquiries.

In addition to laws and regulations governing the Medicare and Medicaid programs, there are a number of federal and state laws and regulations governing such matters as the corporate practice of medicine and fee splitting arrangements, anti-kickback statutes, physician self-referral laws, false or fraudulent claims filing and patient privacy requirements. The failure to comply with any of such laws or regulations could have an adverse impact on the Company's operations and financial results. It is management’s belief that the Company is in substantial compliance in all material respects with such laws and regulations.

Government Claim

On June 7, 2010, the Company's subsidiary, IPC, received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that IPC had submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to IPC’s Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. IPC produced responsive documents and was in contact with representatives of the DOJ who informed IPC that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). The case is captioned United States ex rel. Oughatiyan v. IPC The Hospitalist Company, Inc. (Civ. No. 09-C-5418). IPC also was informed that several state attorneys general were examining its Medicaid claims in coordination with the DOJ.

On December 5, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket at that time included the whistleblower’s Complaint which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under common law theories of payment by mistake and unjust enrichment. On August 13, 2014, the Company's subsidiary, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC Healthcare, Inc., which remains the sole defendant in the lawsuit. The parties are engaged in negotiations to attempt to resolve the matter, but if a reasonable settlement cannot be reached, the Company intends to continue vigorously contesting the case.

Florida Medicaid Reimbursement Suspension

The Company's subsidiary, IPC, received notice on August 7, 2015 that the Florida Agency for Health Care Administration (AHCA) temporarily suspended Medicaid fee-for-service and Medicaid managed care payments to IPC’s Florida affiliate, InPatient Consultants of Florida, Inc. d/b/a IPC of Florida, because IPC of Florida is “under investigation by a state or federal agency.” Since receiving this notice, and based on its failure to contain the required specificity under the

22

applicable federal regulation, IPC has sought additional information from AHCA regarding the basis of the payment suspension, including through repeated discussions with the responsible AHCA officials; by submitting a request for documents through the Florida Public Records Law (PRL) on August 27, 2015; and by filing a petition for formal administrative review on September 4, 2015.

Following these actions, IPC received a revised letter on September 9, 2015 in which AHCA clarified that the investigation causing the payment suspension concerns IPC of Florida’s alleged “up-coding” and “billing for the highest level of inpatient hospital care, which may not be medically necessary.” Since receipt of this revised notice, which still failed to contain the required specificity, IPC has continued to engage with AHCA to obtain information that would enable IPC to rebut the basis for the payment suspension. These efforts have included submitting a second PRL request on September 18, 2015 and submitting a letter to AHCA providing information to support a determination by AHCA that it has “good cause” to discontinue the payment suspension, consistent with the applicable federal regulation. On October 23, 2015, IPC received an order dismissing IPC’s petition for formal administrative review on the grounds that there is no final agency action and because the suspension is a contract action not appropriate for an administrative hearing. The Company is continuing its discussions with AHCA officials in an effort to resolve this matter.

It is not possible to predict when any of the above matters may be resolved, the time or resources that the Company will need to devote to the matters, or what impact, if any, the outcome of any of the matters might have on the Company's business, consolidated financial position, results of operations, or cash flows.

Note 11. Equity-based Compensation

Equity Incentive Plans

In May 2013, the Company's shareholders approved the Team Health Holdings, Inc. Amended and Restated 2009 Stock Incentive Plan (the Stock Plan) that amended the 2009 Stock Incentive Plan.

In connection with the acquisition of IPC, the IPC replacement awards were issued based on a conversion ratio of the IPC common share value to Team Health weighted average share price immediately prior to the closing. The Company assumed and restated the Amended and Restated Team Health Holdings, Inc. 1997 Equity Participation Plan, the Amended and Restated 2002 Equity Participation Plan of Team Health Holdings, Inc., the Amended and Restated Team Health Holdings, Inc. 2007 Equity Participation Plan, and the Amended and Restated Team Health Holdings, Inc. 2012 Equity Participation Plan (collectively the IPC Plans) for the sole purpose of completing the exchange of equity awards. There will be no further issuances under these plans.

Purpose. The purpose of the Stock Plan is to aid in recruiting and retaining key employees, directors, consultants, and other service providers of outstanding ability and to motivate those employees, directors, consultants, and other service providers to exert their best efforts on behalf of the Company and its affiliates by providing incentives through the granting of options, stock appreciation rights and other stock-based awards.

Shares Subject to the Plan. The Stock Plan provides that the total number of shares of common stock that may be issued is 15,100,000, of which approximately 1,502,000 are available to grant as of June 30, 2016. Shares of the Company’s common stock covered by awards that terminate or lapse without the payment of consideration may be granted again under the Stock Plan.

23

The following table summarizes the status of options under the Stock Plan as of June 30, 2016:

	Shares (in thousands)		Weighted Average Exercise Price		Aggregate Intrinsic Value (in thousands)		Weighted Average Remaining Life in Years
Outstanding at beginning of year	4,780		$	28.07	$	86,342	5.3
Granted	301		42.70
Exercised	(780	)	19.93		15,547
Expired or forfeited	(69	)	34.80
Outstanding at end of period	4,232		$	30.50	$	57,223	5.2
Exercisable at end of period	3,190		$	24.10	$	56,917	4.7

Intrinsic value is the amount by which the stock price as of June 30, 2016 exceeds the exercise price of the options. The Company granted approximately 301,000 options during the six months ended June 30, 2016. The fair value of the options granted in 2016 was based on the grant date fair value as calculated by the Black-Scholes option pricing formula with the following assumptions: risk-free interest rate of 1.5%, implied volatility of 35.5% and an expected life of the options of 5 years. The expected life is the mid-point between the vesting date and the end of the contractual term. The Company uses this simplified method, as described in ASC 718, due to changes in option grant contractual terms causing insufficient historical exercise data. The Company will continue to evaluate the use of the simplified method as historical exercise data becomes more sufficient. The estimated fair value of options granted during 2016 was $14.26. As of June 30, 2016, the Company had approximately $13.5 million of unrecognized compensation expense, net of estimated forfeitures related to unvested options, which will be recognized over the remaining requisite service period.

Restricted awards are grants of restricted stock, restricted stock units and performance stock units that are not vested (Restricted Awards). The Company granted approximately 547,000 shares of Restricted Awards in 2016. The Company had $36.3 million of expense remaining to be recognized over the requisite service period for Restricted Awards at June 30, 2016. The Restricted Awards generally vest annually over a three to four-year period from the initial grant date for the grants made to the independent board members and management. The performance stock units vest at the end of three years from the initial grant date. The actual number of performance stock units to be awarded will be based on the achievement of certain predetermined financial and operational performance targets during the initial two year period starting in the year of the grant. The related expense will be tracked and adjusted as appropriate to reflect the actual shares issued.

A summary of changes in total outstanding unvested restricted awards for the six months ended June 30, 2016 is as follows (in thousands):

	Restricted Stock		Restricted Units		Performance Units	Total
Outstanding at beginning of year	100		766		—	866
Granted	—		403		144	547
Vested	(52	)	(224	)	—	(276	)
Forfeited and expired	(3	)	(34	)	—	(37	)
Outstanding at June 30, 2016	45		911		144	1,100

Stock Purchase Plans

In May 2010, the Company’s Board of Directors (the Board) adopted the 2010 Employee Stock Purchase Plan (ESPP) and the 2010 Nonqualified Stock Purchase Plan (NQSPP).

The ESPP provides for the issuance of up to 600,000 shares to the Company’s employees. All eligible employees are granted identical rights to purchase common stock in each Board authorized offering under the ESPP. Rights granted pursuant to any offering under the ESPP terminate immediately upon cessation of an employee’s employment for any reason. In general, an employee may reduce his or her contribution or withdraw from participation in an offering at any time during the purchase period for such offering. Employees receive a 5% discount on shares purchased under the ESPP. Rights granted under the plan are not transferable and may be exercised only by the person to whom such rights are granted. Offerings occur every six months in April and October. As of June 30, 2016, contributions under the ESPP totaled $1.4 million. In April 2016, approximately 86,000 shares of the Company’s common stock were issued to plan participants.

The NQSPP provides for the issuance of up to 800,000 shares to our independent contractors. All eligible contractors are granted identical rights to purchase common stock in each Board authorized offering under the NQSPP. Rights granted pursuant

24

to any offering under the NQSPP terminate immediately upon cessation of a contractor’s relationship with the Company for any reason. In general, a contractor may reduce his or her contribution or withdraw from participation in an offering at any time during the purchase period for such offering. Contractors receive a 5% discount on shares purchased under the NQSPP. Rights granted under the NQSPP are not transferable and may be exercised only by the person to whom such rights are granted. Offerings occur every six months in April and October. As of June 30, 2016, contributions under the NQSPP totaled $0.6 million. In April 2016, approximately 39,000 shares of the Company’s common stock were issued to plan participants.

Equity Based Compensation Expense

Equity based compensation expense and the resulting tax benefits were as follows (in thousands):

	Six Months Ended June 30,
	2015		2016
Stock options	$	5,166	$	3,844
Restricted awards	3,985		10,448
Stock purchase plan	62		82
Total equity based compensation expense	$	9,213	$	14,374
Tax benefit of equity based compensation expense	$	3,547	$	5,498

Note 12. Earnings Per Share

The Company computes basic earnings per share using the weighted average number of shares outstanding. The Company computes diluted earnings per share using the weighted average number of shares outstanding plus the dilutive effect of outstanding stock options, restricted awards, and stock purchase plans. The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
Net earnings attributable to Team Health Holdings, Inc. (numerator for basic and diluted earnings per share)	$	28,935	$	18,785	$	56,989	$	19,453
Denominator:
Weighted average shares outstanding	71,956		73,958		71,666		73,650
Effect of dilutive securities:
Stock options	1,374		1,050		1,220		1,058
Restricted awards	270		224		249		419
Stock purchase plans	2		2		2		2
Shares used for diluted earnings per share	73,602		75,234		73,137		75,129
Basic net earnings per share of Team Health Holdings, Inc.	$	0.40	$	0.25	$	0.80	$	0.26
Diluted net earnings per share of Team Health Holdings, Inc.	$	0.39	$	0.25	$	0.78	$	0.26
Securities excluded from diluted earnings per share of Team Health Holdings, Inc. because they were antidilutive:
Stock options	240		1,285		606		1,590
Restricted awards	—		260		—		270

Note 13. Noncontrolling Interests in Consolidated Entity

The Company is party to two joint venture arrangements. The joint ventures provide administrative management and billing services to certain existing and planned urgent care clinics the Company and joint venture partners operate. The consolidated financial statements include all assets, liabilities, revenues and expenses of the less than 100% owned entity that the Company controls. Accordingly, the Company has recorded noncontrolling interests in the earnings and equity of this entity.

25

In connection with these arrangements, the Company received joint venture contributions of $1.4 million during the six months ended June 30, 2016.

Note 14. Transaction, Integration and Reorganization Costs

For the six months ended June 30, 2016, the Company recognized certain transaction, integration, and reorganization costs in the amount of $27.5 million. These expenses include IPC severance and integration costs of $12.7 million, $9.2 million of professional, advisory, and legal costs associated with the activities of (i) the Board's special advisory committee (which is responsible for reviewing and evaluating possible strategic alternatives available to the Company) and (ii) the JANA agreement, $4.9 million of severance and lease impairment costs associated with a reorganization of the Company's legacy operations, and $0.7 million of legacy transaction costs.

Note 15. Accumulated Other Comprehensive Earnings

The changes in accumulated other comprehensive earnings related to available-for-sale securities were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Balance at beginning of period	$	1,668		$	1,786		$	1,695		$	1,503
Other comprehensive (loss) earnings:
Net unrealized (loss) gain	(896		)	979			(887		)	1,789
Tax benefit (expense)	340			(338		)	337			(492		)
Total other comprehensive (loss) earnings before reclassifications, net of tax	(556		)	641			(550		)	1,297
Net amount reclassified to earnings(1)	(17		)	(13		)	(50		)	(386		)
Tax benefit (expense)(2)	—			—			—			—
Total amount reclassified from accumulated other comprehensive earnings, net of tax(3)	(17		)	(13		)	(50		)	(386		)
Total other comprehensive (loss) earnings	(573		)	628			(600		)	911
Balance at end of period	$	1,095		$	2,414		$	1,095		$	2,414

(1) This amount was included in Other (income) expenses, net on the accompanying Consolidated Statement of Comprehensive Earnings.

(2) These amounts were included in Provision for income taxes on the accompanying Consolidated Statement of Comprehensive Earnings.

(3) A positive amount indicates a corresponding charge to earnings and a negative amount indicates a corresponding benefit to earnings.

26

Note 16. Segment Reporting

During the fourth quarter of 2015, the Company completed certain changes to its management reporting structure to better align its businesses with the Company objectives and operating strategies. These changes resulted in changes among the Company's previously reported operating and reportable segments. The second quarter 2015 segment results have been reclassified to conform to the current year reporting of these businesses. The Company determined, in accordance with segment reporting guidance, that it provides services through eight operating segments which are aggregated into four reportable segments: Hospital Based Services, IPC Healthcare, Specialty Services, and Other Services. The Hospital Based Services segment, which is an aggregation of emergency medicine, anesthesia, and the Company's legacy acute care services, provides comprehensive healthcare service programs to users of healthcare services on a fee for service as well as a cost plus or contract basis. The IPC Healthcare segment consists of the business acquired in connection with the IPC transaction and provides comprehensive acute hospital medicine and post-acute provider service programs to users of healthcare services. The Specialty Services segment, which is an aggregation of military and government healthcare staffing, clinical services, and nurse call center operations, provides comprehensive healthcare service programs to users of healthcare services in an outpatient setting or in a non-hospital based environment. The Other Services segment is an aggregation of locums staffing, scribes, and billing, collection and consulting services that provides a range of other comprehensive healthcare services. The operating segments included in the Specialty Services or Other Services reportable segments, while similar in the types of services provided by those operating segments included in the Hospital Based Services segment, do not meet the aggregation criteria prescribed by the segment reporting guidance nor do they meet the quantitative thresholds that would require a separate presentation.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies included in our annual report on Form 10-K for fiscal year 2015 filed with the SEC. Segment amounts disclosed are prior to any elimination entries made in consolidation, except in the case of net revenues, where intercompany charges have been eliminated. Certain corporate expenses are not allocated to the segments. These unallocated expenses are corporate expenses, net interest expense, depreciation and amortization, transaction costs and income taxes. The Company evaluates segment performance based on profit and loss before the aforementioned expenses.

The following table presents financial information for each reportable segment. Depreciation, amortization, management fee and other expenses separately identified in the consolidated statements of operations are included as a reduction to the respective segments’ operating earnings for each period below (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Net Revenues:
Hospital Based Services	$	806,584		$	865,564		$	1,575,075		$	1,737,712
IPC Healthcare	—			185,669			—			378,381
Specialty Services	45,857			44,803			101,688			70,910
Other Services	25,493			26,512			41,628			71,159
General Corporate	21			28			48			55
	$	877,955		$	1,122,576		$	1,718,439		$	2,258,217
Operating Earnings:
Hospital Based Services	$	76,585		$	75,170		$	146,612		$	126,923
IPC Healthcare	—			10,454			—			20,268
Specialty Services	6,385			5,653			11,884			10,924
Other Services	5,434			6,398			10,016			17,007
General Corporate	(33,765		)	(33,747		)	(60,689		)	(81,385		)
	$	54,639		$	63,928		$	107,823		$	93,737
Reconciliation of Operating Earnings to Net Earnings:
Operating earnings	$	54,639		$	63,928		$	107,823		$	93,737
Interest expense, net	4,571			30,437			8,560			61,730
Provision for income taxes	21,186			14,577			42,341			12,363
Net earnings	$	28,882		$	18,914		$	56,922		$	19,644

27

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introduction

We believe we are one of the largest suppliers of outsourced healthcare professional staffing and administrative services to hospitals and other healthcare providers in the United States, based upon revenues and patient visits. Our regional operating models also include comprehensive programs for inpatient care, anesthesiology, inpatient specialty care, pediatrics and other healthcare services, principally within hospital departments and other healthcare treatment facilities. We have historically focused, however, primarily on providing outsourced services to hospital emergency departments (EDs), which accounts for the majority of our net revenues.

Factors and Trends that Affect Our Results of Operations

In reading our financial statements, you should be aware of the following factors and trends we believe are important in understanding our financial performance.

General Economic Conditions

Any lingering effects of the recent economic conditions may adversely impact our ability to collect for the services we provide as higher unemployment and reductions in commercial managed care and governmental healthcare enrollment may increase the number of uninsured and underinsured patients seeking healthcare at one of our staffed EDs or other clinical facilities. We could be negatively affected if the federal government or the states reduce funding of Medicare, Medicaid and other federal and state healthcare programs in response to increasing deficits in their budgets. Also, patient volume trends in our staffed hospital clinical departments could be adversely affected as individuals potentially defer or forgo seeking care in such departments due to the loss or reduction of coverage previously available to such individuals under commercial insurance or governmental healthcare programs.

IPC Healthcare Acquisition

On November 23, 2015, we completed the acquisition of IPC Healthcare, Inc. (IPC), a national acute hospital medicine and post-acute provider organization. At closing, the Company paid approximately $1.60 billion in cash to the former owners of IPC in exchange for all of the outstanding equity interests of IPC.

In connection with this transaction, we obtained assets and assumed liabilities resulting in the recognition of $1.58 billion of goodwill. On an ongoing basis, we evaluate whether facts and circumstances indicate any impairment of the value of this goodwill. As circumstances change, we cannot be certain that the value of this goodwill will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of this goodwill, which could have a material adverse effect on our results of operations in the period in which the write-off occurs. See Note 3 for more information related to the IPC acquisition.

IPC reported revenue of $185.7 million and $378.4 million in the second quarter and first six months of 2016, respectively.

Healthcare Reform

In 2010, the President of the United States and the U.S. Congress enacted significant reforms to the U.S. healthcare system. These reforms, contained primarily in the Patient Protection and Affordable Care Act, Pub.L. 111-148 (PPACA) and its companion act, the Health Care Education and Reconciliation Act, Pub.L. 111-152, (HCERA), (collectively, the Healthcare Reform Laws) have significantly altered the U.S. healthcare system by establishing, among many other things; (i) increased access to health insurance benefits for the uninsured and underinsured populations; (ii) new facilitators and providers of health insurance as well as new health insurance purchasing access points (i.e., exchanges); (iii) incentives for certain employer groups to purchase health insurance for their employees; (iv) opportunities for subsidies to certain qualifying individuals to help defray the cost of premiums and other out-of-pocket costs associated with the purchase of health insurance; and (v) over the longer term, mechanisms to foster alternative payment and reimbursement methodologies focused on outcomes, quality and care coordination.

Since its passage in 2010, the Healthcare Reform Laws have faced several challenges. Notably, in June 2012, the U.S. Supreme Court upheld the constitutionality of the requirement in the PPACA that individuals maintain health insurance or be required by law to pay a penalty (known as the individual mandate). In that ruling, the individual mandate was upheld by the U.S. Supreme Court under Congress's taxing power. Additionally, the U.S. Supreme Court held in the same ruling that states were not obligated to expand their Medicaid programs as stipulated in the PPACA to eligible recipients based solely on income.  Consequently, the ruling held that each state retained the option to expand their Medicaid rolls or not. States that choose not to

28

expand their Medicaid rolls will forego a 100% federal matching fund made available to states through 2020 and 90% thereafter for the expanded Medicaid population, but those states that do not expand will not lose their existing federal Medicaid matching payments. Currently, 32 states (including the District of Columbia) have implemented or announced their intention to expand their Medicaid programs for individuals with incomes at or less than 138% of the Federal Poverty Limit (FPL), and 19 states have elected not to expand. In addition, in June 2015, the U.S. Supreme Court upheld the provision of tax credits and federal subsidies available to individuals who purchase health insurance through a federally-facilitated exchange, irrespective of whether the exchange is run by the state or the federal government.

The Healthcare Reform Laws triggered numerous other changes to the U.S. healthcare system, some of which have already gone into effect, such as the individual mandate which went into effect on January 1, 2014, while others have been delayed until 2016 and beyond. For instance, the requirement that mid-size employers (defined as groups between 50 and 99 employees) and large size employers (defined as 100 or more employees) provide health insurance to their employees or pay an employee fine, per employee (the employer mandate) has been delayed several times and is now not scheduled to be fully implemented until 2016. Additionally, in December 2015, Congress, as part of the Consolidated Appropriations Act for 2016; (i) suspended the health insurance industry fee (the health insurance tax) which applies to employer purchased insured plans, not self-insured plans, for one year, 2017; (ii) defunded the Independent Payment Advisory Board (IPAB), which is a 15-member panel of health care experts created by the PPACA and tasked with making annual cost-cutting recommendations for Medicare if Medicare spending exceeds a specified growth rate, for one year, 2016; (iii) eliminated the Medical Device Excise Tax (Medical Device Tax), which imposed a 2.3% tax on manufacturers of certain medical devices, for two years, 2016 and 2017; and (iv) delayed the implementation of the “Cadillac Tax”, which imposed an excise tax of 40% on premiums for individuals and families that exceeded a certain minimum threshold of $10,200 for individuals and $27,500 for families until 2020.

Most recently, in January 2016, and for the first time since the inception of the Healthcare Reform Laws, Congress sent a bill to the President of the United States, repealing, in full, the Healthcare Reform Laws. President Obama vetoed this bill and Congress failed to override the President’s veto, but notwithstanding, further challenges to the Healthcare Reform Laws are expected which could impact further implementation of these laws, or the law itself. Consequently, the outcome of the upcoming 2016 presidential elections will likely be determinative on the long-term future of the Healthcare Reform Laws.

Changes in Payor Mix

Since implementation of the Healthcare Reform Laws, many of the patients presenting to the Company’s affiliated health care professionals have experienced increased access to health benefits either through the expansion of state Medicaid programs or through access to exchange enrollment opportunities. Since 2014, the Company has realized a decline in the percentage of self-pay visits for our consolidated fee for service volume and an increase in the percentage of Medicaid visits which we believe is attributable to healthcare reform. Other provisions, however, such as Medicare payment reforms and reductions that could potentially reduce provider payments, may have an adverse effect on the reimbursement rates we receive for services provided by affiliated healthcare professionals.

Medicare and Medicaid Payments for Physician Services

The Centers for Medicare & Medicaid Services (CMS) reimburses for our services to Medicare beneficiaries based upon the rates in the Medicare Physician Fee Schedule (MPFS), which were updated each year based on the Sustainable Growth Rate (SGR) formula enacted under the Balanced Budget Act of 1997. Many private payors use the MPFS to determine their own reimbursement rates. The application of the SGR formula to the MPFS yielded negative updates every year beginning in 2002, although CMS was able to take administrative steps to avoid a reduction in 2003 and Congress took a series of legislative actions to prevent reductions each year from 2004 through March 31, 2015.

On April 14, 2015, Congress enacted legislation known as the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) that permanently repealed the SGR formula, replacing it with a formula that calls for annual updates of 0.5% for a 5-year period (starting July 1, 2015 through the end of 2019). Starting in 2020 and through the end of 2025, there will be no annual updates to the MPFS payment rates. Physicians will have the opportunity to receive additional payment adjustments through the Merit-Based Incentive Payment System (MIPS) starting in 2019. MIPS is an incentive-based payment program that rewards quality performance related to four assessment categories: quality of care measures, resource use, meaningful use of electronic health records (EHRs), and clinical practice improvement activities. Physicians will receive a positive or negative payment adjustment based on how their composite performance score for each of the four assessment categories compares to the relevant performance threshold. Negative payment adjustments are capped at 4% in 2019, increasing each year, up to 9% in 2022 and beyond. Positive payment adjustments must be paid out in an amount equal to the negative payment adjustments and can reach up to a maximum of three times the annual cap for negative payment adjustments in a particular year. Additional incentive payments will be available for “exceptional performers”. Alternatively, physicians who receive a significant share of their revenue through participation in alternative payment models (APMs) that involve risk of financial losses, use of EHRs,

29

and a quality measurement component will receive a 5% bonus each year from 2019 through 2024. These physicians are excluded from participation in the MIPS. In 2026 and subsequent years, annual updates will differ based on whether a physician is participating in an APM that meets certain criteria. Physicians participating in qualifying APMs will receive a 0.75% update, and all other physicians will receive a 0.25% update. APMs include models being tested by the Center for Medicare and Medicaid Innovation (other than health care innovation awards), the Medicare Shared Savings Program, under the Health Care Quality Demonstration Program, and other demonstrations required by Federal law. On May 9, 2016, CMS published a proposed rule detailing how it plans to implement the MIPS program and incentives for participation in APMs. In addition to these changes to the Medicare physician payment system, the law also extends funding for the Children's Health Insurance Program (CHIP). The CHIP program, which covers more than eight million children and pregnant women in families that earn income above Medicaid eligibility levels, is currently authorized through 2019. Funding for the program has been extended for two years, through fiscal year 2017.

2016 Medicare Physician Fee Schedule (2016 MPFS)

In November 2015, CMS released the final rule to update the 2016 MPFS. This was the first final regulatory update to the MPFS since the SGR formula was repealed in April 2015. The 2016 MPFS final rule resulted in a blended adjustment, impacted not just by MACRA, but also by the Protecting Access to Medicare Act of 2014 (PAMA) and the Achieving a Better Life Experience Act of 2014 (ABLE). A reduction in the 2016 Conversion Factor (CF), offset against a slightly reduced adjustment to the respective specialties' Practice Expense Relative Value Units (PE RVUs), will result in a slight negative adjustment to the 2016 MPFS.

2017 Medicare Physician Fee Schedule (2017 MPFS)

On July 15, 2016, CMS published a proposed rule to update the 2017 MPFS. The proposed rule addresses changes to the MPFS payment rates and other Medicare Part B payment policies. For 2017, the Conversion Factor is estimated to decrease slightly, due to application of the 0.5% update factor offset by an RVU budget neutrality adjustment and a multiple procedure payment reduction (MPPR) adjustment for advanced imaging services. MPFS payment rates for Anesthesiology and Emergency Medicine are expected to stay the same for 2017.

Out-of-Network Emergency Care: State Statutes Prohibiting Balance Billing and the Greatest of Three

Over the last several years, the practice of balance billing has gained significant attention in the media from consumers and their advocacy groups. Balance billing is the practice whereby physicians and providers who do not hold managed care provider contracts with certain health insurance plans, bill patients who have accessed their services at amounts above the amount the managed care plan elects to pay the non-participating provider for such services. Recently, the term “surprise billing” has taken a prominent position in the print and digital media particularly among consumer advocacy groups. Surprise billing refers to instances where patients present for medical care at in-network, participating hospitals but unknowingly receive care from out-of-network, non-participating hospital-based physicians such as emergency physicians, anesthesiologists, radiologists or pathologists. This can result in the patient or consumer experiencing claims processing discrepancies and potentially higher out-of-pocket costs, including their receipt of balance bills. The reimbursement amount the provider receives from the plan varies dramatically from plan to plan, region to region and even by insurance product line. The variable and often changing amounts paid by health insurance plans for out-of-network services are referred by the plans as "usual, customary & reasonable", “UCR”, or are also referred to as "usual, customary cost", or "UCC" reimbursement amounts.

In response to the needs of its patients, and as a means to avoid the practice of balance and/or surprise billing, we make a concerted effort to contract with as many health insurance plans as possible, as well as actively engage with our hospital partners to ensure, by all means possible, that we are contracted with those health plans our hospitals contracts with, notwithstanding the many variables that exist relative to managed care contracting, either with respect to market conditions, rates, plan enrollment, or even hospital relationships. On occasion, we find ourselves out-of-network with a particular health insurance plan either because (i) the plan has expressed unwillingness to contract with us, (ii) the plan chooses not to enter into business arrangements with “wrap” or “repricing network” providers, or (iii) we and the plan have been unable to reach agreement on reimbursement amounts sufficient to allow us to participate with the plan and become a network provider. Although it is generally a rare occurrence, in such cases we may choose to balance bill patients for amounts that the health plan fails to reimburse citing UCR or UCC as the basis for its payment amount.

Recently, several states have passed statutes, or are currently engaged in legislative efforts, to prohibit the practice of balance and/or surprise billing. Over the last year, balance/surprise billing statutes have passed in New York, Connecticut and most recently in Florida. Florida's law expanded an existing balance billing statute to include Preferred Provider Organization(PPO) as well as Health Maintenance Organization (HMO) insurance products. Other states such as California, Tennessee and New Jersey are considering balance/surprise billing restrictions as well, or like Texas, have implemented mediation dispute resolution processes for the benefit of patients and consumers. Additionally, many of those states are also engaging in network

30

adequacy discussions with health plans as a means to address the issue of narrow or limited participating provider networks, generally referred to as “narrow networks.” This, coupled with high deductible health benefit plans, compounds the concerns and frequency associated with balance/surprise billing. However, by incorporating certain provider network standards into statute and regulation, states are able to ensure health plans build provider networks of sufficient size and scope to meet the geographic and financial needs of their members and patients, which in turn, frequently drives favorable contract discussions between plans and providers sufficient to allow for our in-network participation with plans.

Given the highly limited number of medical claims that are both out-of-network and balance billed to patients by the Company, the effect of balance/surprise billing statutes on the Company are anticipated to be minimal. Notwithstanding, the Company supports state and federal efforts to develop benchmark standards for defining UCR and UCC in conjunction with statutes that prohibit balance/surprise billing. The Company supports state statutes like those in New York and Connecticut which adopted the 80^th percentile of physician charges as the benchmark standard for UCC. The Company supports the adopted standard in the Florida law defining the benchmark standard as the “usual and customary” physician charges in the community, but believes the legislation did not go far enough in that it failed to establish the 80^th percentile of physician charges as the benchmark as was done in New York and Connecticut.

Further, in response to the November, 2015, CMS, DoL and IRS published Final Rule relative to the patient protections for out-of-network emergency services, with specific reference to the three prong “test” which determined fair payment to providers for the reimbursement of such out-of-network emergency services (commonly known as the “Greater of Three”). The Company, along with its industry partners, continues to advocate for a defined benchmark standard to supplement the final rule representing the 80^th percentile of physician charges, geographically adjusted and specialty specific as determined by an independently produced, commercially available and publicly accessible source of physician charges, aggregated in the form of a licensed database representing a composite of physician charges in a community

Bundled Payments for Care Improvement (BPCI) Program

In July of 2015, we began participating in an alternative payment model demonstration project with CMS. The BPCI program requires participating providers to manage the care delivered to certain qualified Medicare beneficiaries during an acute hospitalization and for 90 days thereafter with the end goals of improving quality and reducing costs. The program, which is comprised of four broadly defined models of care, requires participants to go “at-risk” by guaranteeing CMS 2% savings on the costs under management with the remaining savings paid to the participants as an incentive for participation. The various models of care cover acute care hospital stays, post-acute care, or both. We participate primarily in Model 2: Retrospective Acute Care Hospital Stay plus Post-Acute Care.

In connection with our participation in the BPCI program we have contracted with a convening organization that brings together multiple health care providers to participate in BPCI. Currently, 31 of our provider groups (TINs) participate in the BPCI program in several different geographic locations. We significantly expanded our participation in BPCI through the acquisition of IPC Healthcare, Inc. (IPC). During the initial reconciliation process in April 2016 related to the first performance quarter of participation, CMS discovered errors in their physician data set that prevented an accurate reconciliation of performance. As a result, CMS announced in July 2016 that it has waived collection of any guaranteed payments related to downside risk for program performance in 2015 but will remit calculated savings to participants to the extent savings are achieved. At this time, there is not sufficiently accurate information available to measure any gains or losses to date from this program. We anticipate accurate data will be available from CMS in the fall of 2016. We have not recognized any benefit or expense associated with the risk elements of the BPCI program, although we have incurred a modest amount of administrative expense as we continue to build out our support operations for the program.

Critical Accounting Policies and Estimates

The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States, which requires us to make estimates and assumptions. Management believes the following critical accounting policies, among others, affect its more significant judgments and estimates used in the preparation of the Company’s consolidated financial statements.

There have been no material changes to these critical accounting policies or their application during the six months ended June 30, 2016.

31

Revenue Recognition

Net Revenues Before Provision for Uncollectibles. Net revenues before provision for uncollectibles consist of fee for service revenue, contract revenue and other revenue. Net revenues before provision for uncollectibles are recorded in the period services are rendered. Our net revenues before provision for uncollectibles are principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of our billing arrangements and how net revenues before provision for uncollectibles are recognized for each.

A significant portion (approximately 88% of our net revenues before provision for uncollectibles for the six months ended June 30, 2016 and 87% for the year ended December 31, 2015) resulted from fee for service patient visits. Fee for service revenue represents revenue earned under contracts in which we bill and collect the professional component of charges for medical services rendered by our contracted and employed physicians. Under the fee for service arrangements, we bill patients for services provided and receive payment from patients or their third-party payors. Fee for service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenues before provision for uncollectibles in the financial statements. Fee for service revenue is recognized in the period that the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenues before provision for uncollectibles (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to one of our billing centers for medical coding and entering into our billing systems and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Net revenues before provision for uncollectibles is recorded based on the information known at the time of entering such information into our billing systems as well as an estimate of the net revenues before provision for uncollectibles associated with medical charts for a given service period that have not yet been processed into our billing systems. The above factors and estimates are subject to change. For example, patient payor information may change following an initial attempt to bill for services due to a change in payor status. Such changes in payor status have an impact on recorded net revenues before provision for uncollectibles due to differing payors being subject to different contractual allowance amounts. Such changes in net revenues before provision for uncollectibles are recognized in the period that such changes in the payor become known. Similarly, the actual volume of medical charts not processed into our billing systems may be different from the amounts estimated. Such differences in net revenues before provision for uncollectibles are adjusted the following month based on actual chart volumes processed.

Contract revenue represents revenue generated under contracts in which we provide physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. In these contractual arrangements we are the principal in the transaction and therefore recognize contract revenue on a gross basis. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed upon hourly rates. Revenue in such cases is recognized as the hours worked by our staff and contractors. Additionally, contract revenue includes supplemental revenue from hospitals where we may have a fee for service contract arrangement. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provide for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or actual patient collections compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement.

Other revenue consists primarily of revenue from management and billing services provided to outside parties. Revenue is recognized for such services pursuant to the terms of the contracts with customers. Generally, such contracts consist of fixed monthly amounts with revenue recognized in the month services are rendered or as hourly consulting fees recognized as revenue as hours worked in accordance with such arrangements. Additionally, we derive a portion of our revenues from providing billing services that are contingent upon the collection of third-party physician billings by us on behalf of such customers. Revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.

Net Revenues. Net revenues reflect management’s estimate of billed amounts to be ultimately collected. Management, in estimating the amounts to be collected resulting from approximately 23 million fee for service patient visits and procedures over the last 12 months, considers such factors as prior contract collection experience, current period changes in payor mix and patient acuity indicators, reimbursement rate trends in governmental and private sector insurance programs, resolution of overprovision account balances, the estimated impact of billing system effectiveness improvement initiatives, and trends in collections from self-pay patients and external collection agencies. In developing our estimate of collections per visit or procedure, we consider the amount of outstanding gross accounts receivable by period of service and by payor class, but do not use an accounts receivable aging schedule to establish estimated collection valuations. Individual estimates of net revenues by

32

contractual location are monitored and refreshed each month as cash receipts are applied to existing accounts receivable balances and other current trends that have an impact upon the estimated collections per visit are observed. Such estimates are substantially formulaic in nature. In the ordinary course of business we experience changes in our initial estimates of net revenues during the year following commencement of services. Such provisions and any subsequent changes in estimates may result in adjustments to our operating results with a corresponding adjustment to our accounts receivable allowance for uncollectibles on our balance sheet. Differences between amounts ultimately realized and the initial estimates of net revenues have historically not been material. Beginning in the first quarter of 2016, we modified our reporting metric for hospital medicine volume from cases to encounters and have presented prior year information on the same basis. Encounters represent the individual billable services by the provider during the course of a patient's hospital stay while cases represents the total hospital stay. On average, there may be approximately four to five encounters per case for a typical hospital stay. Encounters are the volume metric that has been reported by IPC and this change is consistent with their historical reporting format. The change in the hospital medicine volume metric did not have a material impact on the reported results in either period.

The table below summarizes our approximate payor mix as a percentage of consolidated fee for service volume excluding IPC, for the periods indicated:

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
Payor:
Medicare	27.3	%	27.9	%	27.2	%	27.9	%
Medicaid	30.5		30.3		30.6		30.3
Commercial and managed care	26.0		25.7		26.0		25.8
Self-pay	14.9		14.7		14.9		14.6
Other	1.3		1.4		1.3		1.4
Total	100.0	%	100.0	%	100.0	%	100.0	%

Estimated net revenues derived from commercial and managed care plans were approximately 40% in both the six months ended June 30, 2016 and 2015. Estimated net revenues derived from the Medicare program were approximately 20% of total net revenues in the six months ended June 30, 2016 and 19% in 2015. Estimated net revenues derived from the Medicaid program were approximately 12% of total net revenues in the six months ended June 30, 2016 and 11% in 2015. In addition, net revenues derived from within the Military Health System, which is the U.S. military’s dependent healthcare program, and other government agencies were approximately 3% in both the six months ended June 30, 2016 and 2015.

Accounts Receivable. As described above and below, we determine the estimated value of our accounts receivable based on estimated cash collection run rates of estimated future collections by contract for patient visits under our fee for service revenue. Accordingly, we are unable to report the payor mix composition on a dollar basis of its outstanding net accounts receivable. However, a 1% change in the estimated carrying value of our net fee for service patient accounts receivable before consideration of the allowance for uncollectible accounts at June 30, 2016 could have an after tax effect of approximately $8.1 million on our financial position and results of operations. Our days revenue outstanding at December 31, 2015 and June 30, 2016 were 62.7 days and 64.2 days, respectively, excluding the effect of the IPC accounts receivable. Our days revenue outstanding including IPC at December 31, 2015 and June 30, 2016 were 69.6 days and 64.0 days, respectively. The number of days outstanding will fluctuate over time due to a number of factors, including, the timing of cash collections and valuation adjustments recorded during the period and increases in average revenue per day that are primarily attributed to an increase in gross charges and patient volumes and increased pricing with managed care plans. Our allowance for doubtful accounts totaled $655.1 million as of June 30, 2016.

Approximately 98% of our allowance for doubtful accounts is related to gross fees for fee for service patient visits. Our principal exposure for uncollectible fee for service visits is centered in self-pay patients and in co-payments and deductibles from patients with insurance. While we do not specifically allocate the allowance for doubtful accounts to individual accounts or specific payor classifications, the portion of the allowance, excluding IPC, associated with fee for service charges as of June 30, 2016 was equal to approximately 93% of outstanding self-pay fee for service patient accounts.

The majority of our fee for service patient visits are for the provision of emergency care in hospital settings. Due to federal government regulations governing the provision of such care, we are obligated to provide emergency care regardless of the patient’s ability to pay or whether or not the patient has insurance or other third-party coverage for the costs of the services rendered. While we attempt to obtain all relevant billing information at the time emergency care services are rendered, there are

33

numerous patient encounters where such information is not available at time of discharge. In such cases where detailed billing information relative to insurance or other third-party coverage is not available at discharge, we attempt to obtain such information from the patient or client hospital billing record information subsequent to discharge to facilitate the collections process. Collections at the time of rendering such services (emergency room discharge as an example) are not significant. The primary responsibility for collection of fee for service accounts receivable resides within our internal billing operations. Once a claim has been submitted to a payor or an individual patient, employees within our billing operations are responsible for the follow-up collection efforts. The protocol for follow-up differs by payor classification. For self-pay patients, our billing system will automatically send a series of dunning letters on a prescribed time frame requesting payment or the provision of information reflecting that the balance due is covered by another payor, such as Medicare or a third-party insurance plan. Generally, the dunning cycle on a self-pay account will run from 90 to 120 days. At the end of this period, if no collections or additional information is obtained from the patient, the account is no longer considered an active account and is transferred to a collection agency. Upon transfer to a collection agency, the patient account is written-off as a bad debt. Any subsequent cash receipts on accounts previously written-off are recorded as a recovery. For non-self-pay accounts, billing personnel will follow-up and respond to any communication from payors such as requests for additional information or denials until collection of the account is obtained or other resolution has occurred. At the completion of our collection cycle, selected accounts may be transferred to collection agencies under a contingent collection basis. The projected value of future contingent collection proceeds expected to be collected over a multi-year period are considered in the estimation of our overall accounts receivable valuation. For contract accounts receivable, invoices for services are prepared in our various operating locations and mailed to our customers, generally on a monthly basis. Contract terms under such arrangements generally require payment within 30 days of receipt of the invoice. Outstanding invoices are periodically reviewed and operations personnel with responsibility for the customer relationship will contact the customer to follow-up on any delinquent invoices. Contract accounts receivable will be considered as bad debt and written-off based upon the individual circumstances of the customer situation after all collection efforts have been exhausted, including legal action if warranted, and it is the judgment of management that the account is not expected to be collected.

Methodology for Computing Allowance for Doubtful Accounts. We employ several methodologies for determining our allowance for doubtful accounts depending on the nature of the net revenues before provision for uncollectibles recognized. We initially determine gross revenue for our fee for service patient visits based upon established fee schedule prices. Such gross revenue is reduced for estimated contractual allowances for those patient visits covered by contractual insurance arrangements to result in net revenues before provision for uncollectibles. Net revenues before provision for uncollectibles are then reduced for our estimate of uncollectible amounts. Fee for service net revenue represents our estimated cash to be collected from such patient visits and is net of our estimate of account balances estimated to be uncollectible. The provision for uncollectible fee for service patient visits is based on historical experience resulting from approximately 23 million fee for service patient visits and procedures over the last 12 months. The significant volume of patient visits and the terms of thousands of commercial and managed care contracts and the various reimbursement policies relating to governmental healthcare programs do not make it feasible to evaluate fee for service accounts receivable on a specific account basis. Fee for service accounts receivable collection estimates are reviewed on a quarterly basis for each of our fee for service contracts by period of accounts receivable origination. Such reviews include the use of historical cash collection percentages by contract adjusted for the lapse of time since the date of the patient visit. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by our billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectibility of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. Contract-related net revenue is billed based on the terms of the contract at amounts expected to be collected. Such billings are typically submitted on a monthly basis and aged trial balances prepared. Allowances for estimated uncollectible amounts related to such contract billings are made based upon specific accounts and invoice periodic reviews once it is concluded that such amounts are not likely to be collected. The methodologies employed to compute allowances for doubtful accounts were unchanged between 2015 and 2016.

34

Insurance Reserves

The nature of our business is such that it is subject to professional liability claims and lawsuits. Historically, to mitigate a portion of this risk, we have maintained insurance for individual professional liability claims with per incident and annual aggregate limits per physician for all incidents. Prior to March 12, 2003, we obtained such insurance coverage from commercial insurance providers. Subsequent to March 12, 2003, we have provided for a significant portion of our professional liability loss exposures through the use of captive insurance subsidiaries and through greater utilization of self-insurance reserves. Since March 12, 2003, the most significant cost element within our professional liability program has consisted of the actuarial estimates of losses by occurrence period. In addition to the estimated actuarial losses, other costs that are considered by management in the estimation of professional liability costs include program costs such as brokerage fees, claims management expenses, program premiums and taxes, and other administrative costs of operating the program, such as the costs to operate the captive insurance subsidiaries. Net costs in any period reflect our estimate of net losses to be incurred in that period as well as any changes to our estimates of the reserves established for net losses of prior periods.

The accounts of the captive insurance subsidiaries are fully consolidated with those of our other operations in the accompanying financial statements.

The estimation of medical professional liability losses is inherently complex. Medical professional liability claims are typically resolved over an extended period of time, often as long as ten years or more. The combination of changing conditions and the extended time required for claim resolution results in a loss estimation process that requires actuarial skill and the application of judgment, and such estimates require periodic revision. A report of actuarial loss estimates is prepared at least semi-annually. Management’s estimate of our professional liability costs resulting from such actuarial studies is significantly influenced by assumptions and assessments regarding expectations of several factors. These factors include, but are not limited to: historical paid and incurred loss development trends; hours of exposure as measured by hours of physician and related professional staff services; trends in the frequency and severity of claims, which can differ significantly by jurisdiction due to the legislative and judicial climate in such jurisdictions; coverage limits of third-party insurance; the effectiveness of our claims management process; and the outcome of litigation. As a result of the variety of factors that must be considered by management, there is a risk that actual incurred losses may develop differently from estimates.

The underlying information that serves as the foundational basis for making our actuarial estimates of professional liability losses is our internal database of incurred professional liability losses. We have captured extensive professional liability loss data going back, in some cases, over 25 years, that is maintained and updated on an ongoing basis by our internal claims management personnel. Our database contains comprehensive incurred loss information for our existing operations as far back as fiscal year 1997 (reflecting the initial timeframe in which we migrated to a consolidated professional liability program concurrent with the consummation of several significant acquisitions), and, in addition, we possess additional loss data that predates 1997 dates of occurrence for certain of our operations. Loss information reflects both paid and reserved losses incurred when we were covered by outside commercial insurance programs as well as paid and reserved losses incurred under our self-insurance program. Because of the comprehensive nature of the loss data and our comfort with the completeness and reliability of the loss data, this is the information that is used in the development of our actuarial loss estimates. We believe this database is one of the largest repositories of physician professional liability loss information available in our industry and provides us and our actuarial consultants with sufficient data to develop reasonable estimates of the ultimate losses under our self-insurance program. In addition to the estimated losses, as part of the actuarial process, we obtain revised payment pattern assumptions that are based upon our historical loss and related claims payment experience. Such payment patterns reflect estimated cash outflows for aggregate incurred losses by period based upon the occurrence date of the loss as well as the report date of the loss. Although variances have been observed in the actuarial estimate of ultimate losses by occurrence period between actuarial studies, the estimated payment patterns have shown much more limited variability. We use these payment patterns to develop our estimate of the discounted reserve amounts. The relative consistency of the payment pattern estimates provides us with a foundation in which to develop a reasonable estimate of the discount value of the professional liability reserves based upon the most current estimate of ultimate losses to be paid and the reasonable likelihood of the related cash flows over the payment period. Our estimated loss reserves were discounted at 1.6% as of December 31, 2015 and 0.9% as of June 30, 2016, which was the current weighted average Treasury rate, over a 10 year period at December 31, 2015 and June 30, 2016, which reflects the risk free interest rate over the expected period of claims payments.

In establishing our initial reserves for a given loss period, management considers the results of the actuarial loss estimates for such periods as well as assumptions regarding loss retention levels and other program costs to be incurred. On a semi-annual basis, we will review our professional liability reserves considering not only the reserves and loss estimates associated with the current period, but also the reserves established in prior periods based upon revised actuarial loss estimates. The actuarial estimation process employed utilizes a frequency severity simulation model to estimate the ultimate cost of claims for each loss period. The results of the simulation model are then validated by a comparison to the results from several different actuarial methods (paid loss development, incurred loss development, incurred Bornhuetter-Ferguson method, paid

35

Bornhuetter-Ferguson method) for reasonableness. Each method contains assumptions regarding the underlying claims process. Actuarial loss estimates at various confidence levels capture the variability in the loss estimates for process risk but assume that the underlying model and assumptions are correct. Adjustments to professional liability loss reserves will be made as needed to reflect revised assumptions and emerging trends and data. Any adjustments to reserves are reflected in the current operations. Due to the size of our reserve for professional liability losses, even a small percentage adjustment to these estimates can have a material effect on the results of operations for the period in which the adjustment is made. Given the number of factors considered in establishing the reserves for professional liability losses, it is neither practical nor meaningful to isolate a particular assumption or parameter of the process and calculate the impact of changing that single item. The actuarial reports provide a variety of loss estimates based upon statistical confidence levels reflecting the inherent uncertainty of the medical professional liability claims environment in which we operate. Initial year loss estimates are generally recorded using the actuarial expected loss estimate, but aggregate professional liability loss reserves may be carried at amounts in excess of the expected loss estimates provided by the actuarial reports due to the expectation that we believe additional adjustments to prior year estimates may occur. In addition, we are subject to the risk of claims in excess of insured limits as well as unlimited aggregate risk of loss in certain loss periods. As our self-insurance program continues to mature and additional stability is noted in the loss development trends in the program, we expect to continue to review and evaluate the carried level of reserves and make adjustments as needed.

During the first quarter of 2016, we reserved $14.3 million to settle two separate professional liability claims originating from prior years excess of coverage limits, which was fully funded as of June 30, 2016. See Note 10 for more information regarding these settlements.

Our most recent semi-annual actuarial study was completed in April 2016. Based on the results of the revised actuarial loss estimates, management determined that no additional change was necessary in our consolidated reserves for professional liability losses related to prior year loss estimates associated with our self-insured programs.

The following reflects the current reserves for professional liability costs as of June 30, 2016 (in millions) as well as the sensitivity of the reserve estimates at a 65%, 75% and 90% confidence level:

As reported	$	257.8
At 65% confidence level	$	260.9
At 75% confidence level	$	267.2
At 90% confidence level	$	282.9

With the exception of specific settlement or claim issues, it is not possible to quantify the amount of the change in our estimate of prior year losses (when required) by individual fiscal period due to the nature of the professional liability loss estimates that are provided to us on an occurrence period basis and the nature of the coverage that is obtained in the commercial insurance market which is generally underwritten on a claims made or report period basis. Even though we are self-insured for a significant portion of our risk, due to customer contracting requirements and state insurance regulations, we still, at times, must place coverage on a claims made or report period basis with commercial insurance carriers. In a limited number of markets, commercial coverage may be obtained on an occurrence basis. When evaluating the appropriate carrying level of our self-insured professional liability reserves, management considers the current estimates of occurrence period loss estimates as well as how such loss estimates and related future claims will interact with previous or current commercial insurance programs when projecting future cash flows. However, the complexity that is associated with multiple occurrence periods interacting with multiple report periods that contain risks and related reserves retained by us, as well as transferred to commercial insurance carriers, makes it impossible to allocate the change in prior year loss estimates to individual occurrence periods. Instead, we evaluate the future expected cash flows for all historical loss periods in the aggregate and compare such estimates to the current carrying value of our professional liability reserves. This process provides the basis for us to conclude that our reserves for professional liability losses are reasonable and properly stated. Management considers the results of actuarial studies when estimating the appropriate level of professional liability reserves and no adjustments to prior year loss estimates were made in periods where updated actuarial loss estimates were not available.

Due to the complexity of the actuarial estimation process, there are many factors, trends and assumptions that must be considered in the development of the actuarial loss estimates, and we are not able to quantify and disclose which specific elements are primarily contributing to changes in the revised loss estimates of historical occurrence periods when such adjustments may be recorded. However, we believe that our internal investments in enhanced risk management and claims management resources and initiatives, such as the employment of additional claims and litigation management personnel and practices, and an expansion of programs such as root cause loss analysis, early claim evaluation, and litigation support for

36

insured providers have contributed to the generally stable trends in loss development estimates noted during the most recent periods.

Impairment of Intangible Assets

In assessing the recoverability of our intangibles, we must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the respective assets. If these estimates or their related assumptions change in the future, we may be required to record impairment charges for these assets.

Results of Operations

The following discussion provides an analysis of our results of operations and should be read in conjunction with our unaudited consolidated financial statements. Net revenues are an estimate of future cash collections and as such it is a key measurement by which management evaluates performance of individual contracts as well as the Company as a whole. The following table sets forth the components of net earnings as a percentage of net revenues for the periods indicated:

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
Net revenues	100.0	%	100.0	%	100.0	%	100.0	%
Professional service expenses	78.3		79.4		78.6		79.4
Professional liability costs	3.1		3.0		3.1		3.6
General and administrative expenses	9.0		8.5		8.9		8.8
Other (income) expenses, net	0.1		(0.1	)	(0.1	)	(0.1	)
Depreciation	0.6		0.7		0.6		0.7
Amortization	2.4		2.2		2.4		2.1
Interest expense, net	0.5		2.7		0.5		2.7
Loss on refinancing of debt	—		0.1		—		—
Transaction, integration, and reorganization costs	0.3		0.5		0.2		1.2
Earnings before income taxes	5.7		3.0		5.8		1.4
Provision for income taxes	2.4		1.3		2.5		0.5
Net earnings	3.3	%	1.7	%	3.3	%	0.9	%
Net (loss) earnings attributable to noncontrolling interests	—	%	—	%	—	%	—	%
Net earnings attributable to Team Health Holdings, Inc.	3.3	%	1.7	%	3.3	%	0.9	%

Three Months Ended June 30, 2016 Compared to the Three Months Ended June 30, 2015

Net Revenues Before Provision for Uncollectibles. Net revenues before provision for uncollectibles in the three months ended June 30, 2016increased $348.9 million, or 23.8%, to $1.82 billion from $1.47 billion in the three months ended June 30, 2015. The increase in net revenues before provision for uncollectibles resulted from increases in fee for service revenue of $317.8 million, contract revenue of $22.4 million and other revenue of $8.8 million. In the three months ended June 30, 2016, fee for service revenue was 87.6% of net revenues before provision for uncollectibles compared to 86.8% in the same period of 2015, contract revenue was 11.4% of net revenues before provision before uncollectibles compared to 12.5% in the same period of 2015 and other revenue was 1.0% and 0.7% in 2016 and 2015, respectively. The increase in fee for service revenue before provision for uncollectibles was primarily a result of a 55.3% increase in total fee for service visits between periods.

Provision for Uncollectibles. The provision for uncollectibles in the three months ended June 30, 2016increased $104.3 million, or 17.7%, to $693.3 million from $589.0 million in the three months ended June 30, 2015. The provision for uncollectibles as a percentage of net revenues before provision for uncollectibles declined to 38.2% in the three months ended June 30, 2016 compared with 40.2% in the corresponding quarter of 2015. The provision for uncollectibles is primarily related to revenue generated under fee for service contracts that is not expected to be fully collected. The increase in the provision for uncollectibles was due primarily to annual increases in gross fee schedules and increases in patient volumes and procedures. Changes in payor mix, particularly the level of self-pay fee for service visits, also have an impact on the provision for uncollectibles. For the three months ended June 30, 2016, self-pay fee for service visits (excluding IPC) were approximately 14.7% of the total fee for service visits compared to approximately 14.9% in the same quarter of 2015, which constrained the growth in the provision for uncollectibles between quarters.

37

Net Revenues. Net revenues in the three months ended June 30, 2016increased $244.6 million, or 27.9%, to $1.12 billion from $878.0 million in the three months ended June 30, 2015. IPC contributed 21.1%, non-IPC (legacy) acquisitions contributed 3.1%, same contract revenue contributed 2.4%, and net sales growth contributed 1.2% of the increase in quarter over quarter growth in net revenues.

Total same contract revenue, which consists of contracts under management in both quarters, increased $21.0 million, or 2.6%, to $826.9 million in the three months ended June 30, 2016 compared to $805.9 million in the three months ended June 30, 2015. Fee for service volume increased 2.5%, which contributed 1.9% of same contract revenue growth between quarters. Increases in estimated collections on same contract fee for service visits provided a 0.1% increase in same contract revenue growth. Same contract pricing growth was constrained by a decline in unbilled revenue between periods that reflects an estimate of the value of unprocessed claims at the end of the reporting period. Also, a reduction in prior year revenue estimates in the second quarter of 2016 compared to a favorable change in prior year revenue estimates recognized in the second quarter of 2015 impacted pricing. The negative change in prior year revenue estimates recognized in 2016 is due in part to an elevated level of claim writeoffs realized in the quarter associated with provider credentialing and claims adjudication on an increased level of new and acquired contract relationships that commenced in 2014 and 2015. Same contract pricing growth was also impacted by changes in payor mix and a reduced contribution from managed care revenue growth offset by an increase in average acuity between periods. Contract and other revenue contributed 0.6% of same contract revenue growth between quarters. IPC reported revenue of $185.7 million in the second quarter of 2016 while legacy acquisitions contributed $27.5 million of growth in net revenues and net new contract revenue increased $10.4 million between quarters.

We typically gain new contracts by replacing competitors at hospitals that currently outsource such services, obtaining new contracts from facilities that do not currently outsource and responding to contracting opportunities within the military healthcare system. Factors influencing new contracting opportunities include the depth and breadth of our service offerings, our reputation and experience, our ability to recruit and retain qualified clinicians, and pricing considerations when a subsidy or contract payment is required. Contracts are typically terminated due to economic considerations, a change in hospital administration or ownership, dissatisfaction with our service offerings or, primarily relating to our military staffing arrangements, at the end of the contract term.

The components of net revenues include revenue from contracts that have been in effect for prior periods (same contract) and from net, new and acquired contracts during the periods, as set forth in the table below:

	Three Months Ended June 30,
	2015		2016
	(in thousands)
Same contract:
Fee for service revenue	$	631,080	$	647,069
Contract and other revenue	174,809		179,841
Total same contract	805,889		826,910
New contracts, net of terminations:
Fee for service revenue	50,522		55,031
Contract and other revenue	16,240		22,153
Total new contracts, net of terminations	66,762		77,184
Acquired contracts:
Fee for service revenue	4,182		196,692
Contract and other revenue	1,122		21,790
Total acquired contracts	5,304		218,482
Consolidated:
Fee for service revenue	685,784		898,792
Contract and other revenue	192,171		223,784
Total net revenues	$	877,955	$	1,122,576

38

The following table reflects the visits and procedures included within fee for service revenues described in the table above:

	Three Months Ended June 30,
	2015	2016
	(in thousands)
Fee for service visits and procedures:
Same contract	3,848	3,943
New and acquired contracts, net of terminations	375	2,617
Total fee for service visits and procedures	4,223	6,560

Professional Service Expenses. Professional service expenses, which include physician and provider costs, billing and collection expenses, and other professional expenses, totaled $891.1 million in the three months ended June 30, 2016 compared to $687.5 million in the three months ended June 30, 2015, an increase of $203.6 million, or 29.6%. This increase between quarters is primarily related to our acquisitions and net new contracts and a 3.3% increase in same contract professional service expenses primarily associated with increases in provider compensation. Professional service expenses as a percentage of net revenues was 79.4% in the three months ended June 30, 2016 compared to 78.3% in the three months ended June 30, 2015.

Professional Liability Costs. Professional liability costs were $33.5 million in the three months ended June 30, 2016 compared to $27.3 million in the three months ended June 30, 2015, an increase of $6.2 million or 22.6%. The increase was primarily attributed to an increase in provider hours, including increases from acquisitions and new contracts between periods. Professional liability costs as a percentage of net revenues were 3.0% in the second quarter of 2016 and 3.1% in 2015.

General and Administrative Expenses. General and administrative expenses increased $17.0 million, or 21.6%, to $95.5 million for the three months ended June 30, 2016 from $78.6 million in the three months ended June 30, 2015. General and administrative expenses included contingent purchase compensation expense of $9.8 million for the three months ended June 30, 2016 compared to $7.9 million for the three months ended June 30, 2015. Excluding the contingent purchase compensation expense, general and administrative expense increased $15.1 million or 21.3%, to $85.8 million for the three months ended June 30, 2016 from $70.7 million in the three months ended June 30, 2015. The increase in general and administrative expenses between periods was due primarily to the impact of the IPC operations, offset by a decline of same contract costs of $6.7 million. Total general and administrative expenses as a percentage of net revenues were 8.5% in the second quarter of 2016 and 9.0% in the same quarter in 2015. Excluding contingent purchase compensation expense, general and administrative expenses as a percentage of net revenues were 7.6% in the second quarter of 2016 compared to 8.1% in the second quarter of 2015.

Other (Income) Expenses, Net. In the three months ended June 30, 2016, we recognized other income of $0.9 million compared to expense of $1.0 million in the same quarter in 2015. The increase of $1.8 million is primarily due the change in the fair value of assets related to our non-qualified deferred compensation plan in 2016. Additionally, there was a loss in 2015 related to the sale of certain assets related to our outsourced medical coding practice. This increase was partially offset by a loss on asset disposal in 2016.

Depreciation. Depreciation expense was $8.1 million in the three months ended June 30, 2016 compared to $5.6 million for the three months ended June 30, 2015. The increase of $2.5 million was primarily due to capital expenditures in 2016 and 2015.

Amortization. Amortization expense was $24.1 million in the three months ended June 30, 2016 compared to $21.2 million for the three months ended June 30, 2015. The increase of $3.0 million was primarily a result of an increase in other intangibles recognized in connection with our acquisitions in 2016 and 2015.

Interest Expense, Net. Net interest expense increased $25.9 million to $30.4 million in the three months ended June 30, 2016 compared to $4.6 million in the corresponding quarter in 2015 primarily related to the addition of the Tranche B Term Loan facility and the issuance of $545.0 million of 7.25% Senior Notes due in 2023 (Notes) and an increase in the amortization of deferred financing costs, partially offset by a reduction in borrowings pursuant to our senior secured revolving credit facility (the revolving credit facility).

Loss on Refinancing of Debt. In connection with the refinancing of our debt facility in June 2016, we recognized a loss of $1.1 million. The loss consists of the write-off of previously recognized deferred financing costs as well as certain fees and expenses associated with the refinancing.

39

Transaction, Integration, and Reorganization Costs. Transaction, integration, and reorganization costs were $6.1 million for the three months ended June 30, 2016 and $2.2 million for the three months ended June 30, 2015. These expenses include ongoing IPC severance and integration costs of $4.1 million, $1.4 million of severance and other costs associated with our ongoing restructuring and reduction in force, and $0.5 million of legacy transaction costs during the quarter.

Earnings (Loss) before Income Taxes. Loss before income taxes in the three months ended June 30, 2016 was $33.5 million compared to earnings of $50.1 million in the three months ended June 30, 2015.

Provision for Income Taxes. The provision for income taxes was $14.6 million in the three months ended June 30, 2016 compared to a provision of $21.2 million in the three months ended June 30, 2015.

Net Earnings. Net earnings were $18.9 million in the three months ended June 30, 2016 compared to $28.9 million in the three months ended June 30, 2015.

Net Earnings (Loss) Attributable to Noncontrolling Interests. Earnings (loss) attributable to noncontrolling interests were earnings of $129,000 for the three months ended June 30, 2016 compared to a loss of $53,000 for the three months ended June 30, 2015.

Net Earnings Attributable to Team Health Holdings, Inc. Net earnings attributable to Team Health Holdings, Inc. were $18.8 million and $28.9 million for the three months ended June 30, 2016 and June 30, 2015, respectively.

Six Months Ended June 30, 2016 Compared to the Six Months Ended June 30, 2015

Net Revenues Before Provision for Uncollectibles. Net revenues before provision for uncollectibles in the six months ended June 30, 2016increased $790.2 million, or 27.6%, to $3.66 billion from $2.87 billion in the six months ended June 30, 2015. The increase in net revenues before provision for uncollectibles resulted from increases in fee for service revenue of $732.6 million, contract revenue of $39.6 million and other revenue of $17.9 million. In the six months ended June 30, 2016, fee for service revenue was 87.9% of net revenues before provision for uncollectibles compared to 86.5% in the same period of 2015, contract revenue was 11.1% of net revenues before provision before uncollectibles compared to 12.8% in the same period of 2015 and other revenue was 1.0% in 2016 and 0.7% in 2015. The increase in fee for service revenue before provision for uncollectibles was primarily a result of a 60.2% increase in total fee for service visits and procedures. The increase in contract revenue was due primarily to the impact of new and acquired contracts.

Provision for Uncollectibles. The provision for uncollectibles increased $250.4 million or 21.8%, to $1.40 billion in the six months ended June 30, 2016 from $1.15 billion in the corresponding period in 2015. The provision for uncollectibles as a percentage of net revenues before provision for uncollectibles declined to 38.2% in the six months ended June 30, 2016 compared with 40.0% in the corresponding period of 2015. The provision for uncollectibles is primarily related to revenue generated under fee for service contracts that is not expected to be fully collected. The period-over-period increase in the provision for uncollectibles was due primarily to annual increases in gross fee schedules and increases in patient volumes and procedures. Changes in payor mix, particularly the level of self-pay fee for service visits, also have an impact on the provision for uncollectibles. For the six months ended June 30, 2016, self-pay fee for service visits were approximately 14.6% of the total fee for service visits compared to approximately 14.9% in the same period of 2015, which constrained the growth in the provision for uncollectibles between periods.

Net Revenues. Net revenues in the six months ended June 30, 2016increased $539.8 million or 31.4%, to $2.26 billion from $1.72 billion in the six months ended June 30, 2015. IPC contributed 22.0%, non-IPC (legacy) acquisitions contributed 4.7%, same contract revenue contributed 3.7%, and net sales growth contributed 1.1% of the increase in period-over-period growth in net revenues. Within the acquisitions category, new hospital contracting opportunities that were initially developed by our sales and marketing process contributed 1.2% of overall net revenues growth between periods.

Total same contract revenue, which consists of contracts under management in both periods, increased $62.7 million, or 4.2%, to $1.57 billion in the six months ended June 30, 2016 compared to $1.50 billion in the six months ended June 30, 2015. Fee for service volume increases of 3.4% increased same contract revenue growth by 2.6%, while increases in same contract estimated collections on fee for service visits provided a 0.9% increase in same contract revenue growth between periods. The increase in the estimated collections per visit was supported by increases in commercial and managed care reimbursement as well as increases in average patient acuity levels offset by unfavorable changes in prior year revenue collections, a decline in unbilled revenue, and changes in payor mix in the six moths ended 2016. Contract and other revenue contributed 0.7% of same contract revenue growth between periods. IPC reported revenue of $378.4 million while legacy acquisitions contributed $79.9 million of growth in net revenues and net new contract revenue increased $18.7 million between periods.

40

We typically gain new contracts by replacing competitors at hospitals that currently outsource such services, obtaining new contracts from facilities that do not currently outsource and responding to contracting opportunities within the military healthcare system. Factors influencing new contracting opportunities include the depth and breadth of our service offerings, our reputation and experience, our ability to recruit and retain qualified clinicians, and pricing considerations when a subsidy or contract payment is required. Contracts are typically terminated due to economic considerations, a change in hospital administration or ownership, dissatisfaction with our service offerings or, primarily relating to our military staffing arrangements, at the end of the contract term.

The components of net revenues include revenue from contracts that have been in effect for prior periods (same contracts) and from net, new and acquired contracts during the periods, as set forth in the table below:

	Six Months Ended June 30,
	2015		2016
	(in thousands)
Same contracts:
Fee for service revenue	$	1,164,744	$	1,217,230
Contract and other revenue	339,197		349,440
Total same contracts	1,503,941		1,566,670
New contracts, net of terminations:
Fee for service revenue	126,294		137,888
Contract and other revenue	42,060		49,191
Total new contracts, net of terminations	168,354		187,079
Acquired contracts:
Fee for service revenue	44,944		461,738
Contract and other revenue	1,200		42,730
Total acquired contracts	46,144		504,468
Consolidated:
Fee for service revenue	1,335,982		1,816,856
Contract and other revenue	382,457		441,361
Total net revenues	$	1,718,439	$	2,258,217

The following table reflects the visits and procedures included within fee for service revenues described in the table above:

	Six Months Ended June 30,
	2015	2016
	(in thousands)
Fee for service visits and procedures:
Same contracts	6,991	7,227
New and acquired contracts, net of terminations	1,220	5,929
Total fee for service visits and procedures	8,211	13,156

Professional Service Expenses. Professional service expenses, which include physician and provider costs, billing and collection expenses, and other professional expenses, totaled $1.79 billion in the six months ended June 30, 2016 compared to $1.35 billion in the six months ended June 30, 2015, an increase of $442.7 million, or 32.8%. This increase between periods is primarily related to our acquisitions and net new contract growth and a 5.0% increase in same contract professional service expenses primarily associated with increases in provider compensation. Professional service expenses as a percentage of net revenues increased to 79.4% in the six months ended June 30, 2016 from 78.6% in the six months ended June 30, 2015.

Professional Liability Costs. Professional liability costs were $80.4 million in the six months ended June 30, 2016 compared to $53.9 million in the six months ended June 30, 2015, an increase of $26.5 million or 49.2%. Professional liability

41

costs for the six months ended June 30, 2016 included an increase in prior year professional liability loss reserves of $14.3 million. Excluding the prior year reserve adjustment in 2016, professional liability costs increased $12.3 million, or 22.7%, between periods. The increase was primarily attributed to an increase in provider hours including increases from acquisitions and new contracts. Professional liability costs as a percentage of net revenues were 3.6% in the six months ended June 30, 2016 and 3.1% in the six months ended June 30, 2015. Excluding the prior year revenue adjustments in 2016, professional liability costs as a percentage of net revenues were 2.9% in the six months ended June 30, 2016.

General and Administrative Expenses. General and administrative expenses increased $47.5 million or 31.2% to $199.6 million for the six months ended June 30, 2016 from $152.1 million in the six months ended June 30, 2015. General and administrative expenses included contingent purchase compensation expense of $18.9 million for the six months ended June 30, 2016 compared to $15.8 million of expense for the six months ended June 30, 2015. Excluding the contingent purchase compensation expense, general and administrative expense increased $44.4 million or 32.5%, to $180.8 million for the six months ended June 30, 2016 from $136.4 million in the six months ended June 30, 2015. The increase in general and administrative expenses between periods was due primarily to the impact of IPC operations and other acquisitions, offset by a decline in same contract costs of $1.4 million. Total general and administrative expenses as a percentage of net revenues were 8.8% in the six months ended June 30, 2016 and 8.9% in the six months ended June 30, 2015. Excluding contingent purchase compensation expense, general and administrative expenses as a percentage of net revenues were 8.0% in the six months ended June 30, 2016 compared to 7.9% in the six months ended June 30, 2015.

Other (Income) Expenses, Net. In the six months ended June 30, 2016, we recognized other income of $1.6 million compared to $2.3 million in the same period in 2015. The decrease of $0.7 million in income is primarily primarily related to the sale of our equity investment in a hospital-based telemedicine consultation provider and certain assets that were held for sale in 2015, and loss on asset disposal in 2016, partially offset by the sale of certain assets related to our outsourced medical coding practice in 2015, and decreased gains from the change in fair value of assets held related to the non-qualified deferred compensation plan and gains related to increased realized gains on investments in 2016.

Depreciation. Depreciation expense was $16.1 million in the six months ended June 30, 2016 compared to $11.1 million for the six months ended June 30, 2015. The increase of $5.0 million was primarily due to capital expenditures in 2016 and 2015.

Amortization. Amortization expense was $47.7 million in the six months ended June 30, 2016 compared to $41.5 million for the six months ended June 30, 2015. The increase of $6.2 million was primarily a result of an increase in other intangibles recognized in connection with our acquisitions in 2016 and 2015.

Net Interest Expense. Net interest expense increased $53.2 million to $61.7 million in the six months ended June 30, 2016, compared to $8.6 million in the corresponding period in 2015, primarily related to the addition of the tranche B term loan and the issuance of $545.0 million of 7.25% Senior Notes due in 2023 and an increase in the amortization of deferred financing costs, partially offset by a reduction in borrowings pursuant to our senior secured revolving credit facility (the revolving credit facility).

Loss on Refinancing of Debt. In connection with the refinancing of our debt facility in June 2016, we recognized a loss of $1.1 million. The loss consists of the write-off of previously recognized deferred financing costs as well as certain fees and expenses associated with the refinancing.

Transaction, Integration, and Reorganization Costs. Transaction, integration, and reorganization costs were $27.5 million for the six months ended June 30, 2016 and $3.3 million for the six months ended June 30, 2015. These expenses include IPC severance and integration costs of $12.7 million, $9.2 million of professional, advisory, and legal costs associated with the activities of (i) the Board's special advisory committee (which is responsible for reviewing and evaluating possible strategic alternatives available to the Company) and (ii) the JANA agreement, $4.9 million of severance and lease impairment costs associated with a reorganization of the Company's legacy operations, and $0.7 million of legacy transaction costs during the quarter.

Earnings before Income Taxes. Earnings before income taxes in the six months ended June 30, 2016 were $32.0 million compared to $99.3 million in the six months ended June 30, 2015.

Provision for Income Taxes. The provision for income taxes was $12.4 million in the six months ended June 30, 2016 compared to $42.3 million in the six months ended June 30, 2015.

Net Earnings. Net earnings were $19.6 million in the six months ended June 30, 2016 compared to $56.9 million in the six months ended June 30, 2015.

42

Net Earnings (Loss) Attributable to Noncontrolling Interests. Earnings (loss) attributable to noncontrolling interests were earnings of $191,000 for the six months ended June 30, 2016 and a loss of $67,000.0 in the six months ended June 30, 2015.

Net Earnings Attributable to Team Health Holdings, Inc. Net earnings attributable to Team Health Holdings, Inc. were $19.5 million and $57.0 million for the six months ended June 30, 2016 and June 30, 2015, respectively.

Liquidity and Capital Resources

Our principal ongoing uses of cash are to meet working capital requirements, to fund debt obligations and to finance our capital expenditures and acquisitions. We believe that our cash needs, other than for significant acquisitions, will continue to be met through the use of existing available cash, cash flows derived from future operating results and borrowings under our senior secured revolving credit facility.

Cash flow provided by operations for the six months ended June 30, 2016 was $54.4 million compared to $18.2 million in the same period in 2015. Included in operating cash flow were contingent purchase price payments of $2.6 million and $8.9 million in the six months ended June 30, 2016 and June 30, 2015, respectively. Operating cash flow was also impacted by $14.0 million of cash transaction and integration costs associated with the IPC transaction in the six months ended June 30, 2016. Excluding the impact of the contingent purchase payments and the IPC transaction and integration costs, operating cash flow in 2016 increased $44.0 million to $71.1 million compared to $27.1 million in 2015. Operating cash flow in the first six months of 2016 reflects a reduced level of accounts receivable funding and a net income tax refund offset by an increased level of interest payments when compared to the prior year. Cash used in investing activities in the six months ended June 30, 2016 was $42.9 million compared to $89.1 million in the same period of 2015. The $46.2 million decrease in cash used in investing activities was principally due to a decrease in cash used for acquisitions between periods. Cash used in financing activities in the six months ended June 30, 2016 was $23.8 million compared to cash provided of $102.1 million in the six months ended June 30, 2015. The change in financing activities between periods was primarily related to changes in net revolving credit facility borrowings and payments between periods and an increase in term loan payments in 2016 and reduced equity proceeds and related tax benefit from exercise of stock options.

We spent $15.3 million in the first six months of 2016 and $17.4 million in the first six months of 2015 on capital expenditures. These expenditures were primarily for billing and information technology investments and related development projects along with projects in support of operational initiatives.

As of June 30, 2016, we had cash and cash equivalents of approximately $16.3 million and total outstanding debt of $2.42 billion (excluding the impact of $50.3 million of deferred financing costs). There were no known liquidity restrictions or impairments on our cash and cash equivalents as of June 30, 2016. We had $7.5 million borrowings under our revolving credit facility outstanding as of June 30, 2016 and had $642.5 million of available borrowings under our revolving credit facility (without giving effect to $6.8 million of undrawn letters of credit).

In June 2016, we completed the repricing of our Tranche B Term Loan facility. The repricing amendment reduced the interest rate applicable to the Tranche B Loans by 75 basis points to LIBOR plus 3.00% from LIBOR plus 3.75% (in each case subject to a minimum LIBOR floor of 75 basis points). See Note 8 of the accompanying consolidated financial statements for a discussion of our indebtedness.

Our senior credit facility agreement, as amended, contains both affirmative and negative covenants, including limitations on our ability to incur additional indebtedness, sell material assets, retire, redeem or otherwise reacquire our capital stock, acquire the capital stock or assets of another business and pay dividends, and require us to comply with a maximum total net leverage ratio, tested quarterly. At June 30, 2016, we were in compliance with all covenants under the senior credit facility agreement. The senior credit facility is secured by substantially all of our and our U.S. subsidiaries’ assets.

The indenture governing our Notes contains restrictive covenants that limit among other things, the ability of us and our restricted subsidiaries to incur or guarantee additional debt or issue disqualified stock or certain preferred stock; pay dividends and make other distributions on, or redeem or repurchase, capital stock; make certain investments; incur certain liens; enter into certain transactions with affiliates; merge or consolidate; enter into agreements that restrict the ability of certain restricted subsidiaries to make dividends or other payments to us or each of our existing and future material domestic wholly-owned restricted subsidiaries, referred to, collectively, as “Guarantors;” designate restricted subsidiaries as unrestricted subsidiaries; and transfer or sell certain assets. These covenants are subject to a number of important limitations and exceptions. The indenture also contains customary events of default which would permit the holders of the Notes to declare those Notes to be immediately due and payable if not cured within applicable grace periods, including the failure to make timely payments on the Notes or other material indebtedness, the failure to satisfy covenants and specified events of bankruptcy and insolvency.

43

Subject to any contractual restrictions, we and our subsidiaries or affiliates may from time to time, in their sole discretion, purchase, repay, redeem or retire any of our outstanding equity or debt securities in privately negotiated or open market transactions, by tender offer or otherwise.

We have historically been an acquirer of other physician staffing businesses and related interests. For the six months ended June 30, 2016, total net cash used in acquisitions, including contingent payments, was $39.4 million. As of June 30, 2016, we estimate future contingent payment obligations to be approximately $101.1 million for acquisitions made prior to June 30, 2016, which we expect to fund over a period of three years. $69.2 million was recorded as a liability on our balance sheet as of June 30, 2016, while the remaining estimated liability of $31.9 million will be recorded as contingent purchase and other acquisition compensation expense over the remaining performance period. See Note 3 of the accompanying consolidated financial statements for a discussion of our acquisitions and related contingent payment obligations.

We are currently in discussions with certain physician staffing businesses regarding potential acquisition opportunities. If we consummate any of these potential acquisitions, we would expect to fund such acquisitions using our existing cash, through borrowings under our revolving credit facility, or through the issuance of additional debt or equity. See Note 3 of the accompanying consolidated financial statements for a discussion of the Company's acquisition activity and related contingent purchase obligations.

Effective March 12, 2003, we began providing for professional liability risks in part through captive insurance subsidiary. Prior to such date, we insured such risks principally through the commercial insurance market. The change in the professional liability insurance program initially resulted in increased cash flow due to the retention of cash formerly paid out in the form of insurance premiums to a commercial insurance company coupled with a long period (typically 2-4 years or longer on average) before cash payout of such losses occurs. A portion of such cash retained is retained within our captive insurance subsidiaries and therefore is not immediately available for general corporate purposes. Investments held by the Company and our captive insurance subsidiaries are carried at fair market value. As of June 30, 2016, these investments totaled approximately $111.4 million, including a $3.6 million net unrealized gain. See Note 5 of the accompanying consolidated financial statements for a discussion of the investments held by the Company and our captive insurance subsidiaries.

Effective June 1, 2014, we renewed our fronting carrier program with a commercial insurance carrier through May 31, 2016. In June 2016, we paid cash premiums of approximately $2.5 million to the commercial insurance carrier, which was the first quarterly payment for the annual premium of $9.8 million. For the six months ended June 30, 2016, we funded approximately $18.8 million of premiums to our captive insurance subsidiaries.

We present Adjusted EBITDA as a supplemental measure of our performance. We define Adjusted EBITDA as net earnings attributable to Team Health Holdings, Inc. before interest expense, taxes, depreciation and amortization, as further adjusted to exclude the non-cash items and the other adjustments shown in the table below. We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. We believe that the presentation of Adjusted EBITDA is appropriate to provide additional information to investors about the calculation of and compliance with our debt agreements. Adjusted EBITDA is a material component of these covenants.

Adjusted EBITDA is not a measurement of financial performance or liquidity under generally accepted accounting principles. In evaluating our performance as measured by Adjusted EBITDA, management recognizes and considers the limitations of this measure. Adjusted EBITDA does not reflect certain cash expenses that we are obligated to make, and although depreciation and amortizations are non-cash charges, assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements. In addition, other companies in our industry may calculate Adjusted EBITDA differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure. Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for net earnings, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles.

44

The following table sets forth a reconciliation of net earnings attributable to Team Health Holdings, Inc. to Adjusted EBITDA:

	Three Months Ended June 30,					Six Months Ended June 30,
	2015		2016			2015			2016
	(in thousands)
Net earnings attributable to Team Health Holdings, Inc.	$	28,935	$	18,785		$	56,989		$	19,453
Interest expense, net	4,571		30,437			8,560			61,730
Provision for income taxes	21,186		14,577			42,341			12,363
Depreciation	5,560		8,066			11,134			16,103
Amortization	21,175		24,142			41,452			47,653
Other (income) expenses, net(a)	961		(879		)	(2,321		)	(1,611		)
Contingent purchase and other acquisition compensation expense(b)	7,856		9,762			15,760			18,851
Transaction, integration, and reorganization costs(c)	2,215		6,106			3,301			27,501
Equity based compensation expense(d)	5,670		6,417			9,213			14,000
Loss on refinancing of debt(e)	—		1,069			—			1,069
Insurance subsidiaries interest income	519		501			1,023			1,080
Professional liability loss reserve adjustments associated with prior years	—		—			—			14,284
Severance and other charges	729		195			1,247			541
Adjusted EBITDA	$	99,377	$	119,178		$	188,699		$	233,017

(a) Reflects gain or loss on sale of assets, realized gains on investments, and changes in fair value of investments associated with the Company’s non-qualified retirement plan.

(b) Reflects expense recognized for historical and estimated future contingent payments and other compensation expense associated with acquisitions.

(c) Reflects transaction and integration costs, reorganization expenses, and advisory, legal and other professional service fees from the Board's special advisory committee process and JANA agreement.

(d) Reflects costs related to equity awards granted under the Company's equity based compensation plans.

(e) Reflects the write-off of deferred financing costs of $0.9 million from the previous Tranche B term loan facility as well as certain fees and expenses associated with the repricing amendment of the Tranche B term loan facility.

Inflation

We do not believe that general inflation in the U.S. economy has had a material impact on our financial position or results of operations.

Seasonality

Historically, our revenues and operating results have reflected minimal seasonal variation due to the significance of revenues derived from patient visits to emergency departments, which are generally open on a year-round basis, and also due to our geographic diversification. Revenue from our non-emergency department staffing lines is dependent on a healthcare facility being open during selected time periods. Revenue in such instances will fluctuate depending upon such factors as the number of holidays in the period.

Recently Issued Accounting Standards

See Note 2 of the notes to the consolidated financial statements for a discussion of recently issued accounting standards.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company is exposed to market risk related to changes in interest rates. The Company does not use derivative financial instruments for speculative or trading purposes.

45

The Company’s earnings are affected by changes in short-term interest rates as a result of its borrowings under its term loan facility.

At June 30, 2016, the fair value of the Company’s total debt was approximately $2.47 billion, which had a carrying value of $2.42 billion, all of which was variable debt. If the market interest rates for the Company’s variable rate borrowings had averaged 1% more subsequent to December 31, 2015, the Company’s interest expense would have increased, and earnings before income taxes would have decreased, by approximately $8.8 million for the six months ended June 30, 2016. This analysis does not consider the effects of the reduced level of overall economic activity that could exist in such an environment. Further, in the event of a change of such magnitude, management could take actions in an attempt to further mitigate its exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, the sensitivity analysis assumes no changes in the Company’s financial structure.

Item 4. Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's (SEC) rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving desired objectives. As of June 30, 2016, we conducted an evaluation under the supervision and with the participation of our management, including our President and Chief Executive Officer and Executive Vice President and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. As a result of the completion of the IPC Healthcare, Inc. (IPC) acquisition on November 23, 2015, we have begun our analysis of the systems of disclosure controls and procedures and internal controls over financial reporting of IPC and to integrate them within our broader framework of controls. The SEC’s rules require us to include acquired entities in our assessment of the effectiveness of internal control over financial reporting no later than the annual management report following the first anniversary of the acquisition. We plan to complete the evaluation and the integration of IPC within the required time frames and report management’s assessment of our internal control over financial reporting in our first annual report in which such assessment is required for this acquisition. Accordingly, as permitted by the SEC, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of its newly-acquired IPC operations, which are included in the consolidated financial statements for the period ending June 30, 2016. IPC represents $1.88 billion and $1.67 billion of total and net assets, respectively, as of June 30, 2016 and $378.4 million and $12.6 million of net revenues and net earnings, respectively, for the six months then ended. Based on that evaluation, our Chief Executive Officer and Executive Vice President and Chief Financial Officer concluded that as of June 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting: There were no changes in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended June 30, 2016 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

46

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The information required with respect to this item can be found under “Litigation” in note 10 of the notes to the Company's consolidated financial statements contained in this quarterly report on Form 10-Q and is incorporated by reference into this Item 1.

Item 1A. Risk Factors

For a discussion of our potential risks and uncertainties, please see “Risk Factors” in Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on February 22, 2016. In addition, please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Risk Factors and Trends that Affect Our Results of Operations” herein and the 2015 Form 10-K. In addition to the risk factors disclosed in Part 1, Item 1A of the 2015 Form 10-K and Part II, Item 1A of our Form 10-Q filed on May 9, 2016, the following is a certain additional risk factor related to our business:

Risks Related to Our Business

We may write-off intangible assets, such as goodwill, related to the IPC transaction.

As a result of purchase accounting for our IPC acquisition transaction, our balance sheet at June 30, 2016 contained intangible assets designated as either goodwill or other intangibles totaling approximately $1.58 billion in goodwill and approximately $22.5 million in other intangibles. On an ongoing basis, we evaluate whether facts and circumstances indicate any impairment of the value of intangible assets. As circumstances change, we cannot assure you that the value of these intangible assets will be realized by us. If we determine that a significant impairment has occurred, we will be required to write-off the impaired portion of intangible assets, which could have a material adverse effect on our results of operations in the period in which the write-off occurs.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

47

Item 6. Exhibits

3.1	Certificate of Incorporation of Team Health Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K, filed on December 18, 2009: File No. 001-34583)
3.2	Amended and Restated By-laws of Team Health Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K, filed on December 23, 2014: File No. 001-34583)
10.1	Amendment No. 1 dated as of June 2, 2016 to the Second Amended and Restated Credit Agreement dated as of November 23, 2015, among TeamHealth, Inc., Team Health Holdings, Inc., JPMorgan Chase Bank, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, each lender from time to time party thereto and Citigroup Clobal Markets, Inc., as Syndication Agent (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, filed on June 3, 2016: File No. 001-34583)
10.2	Form of Performance Stock Unit Award Agreement (filed herewith)*
10.3	Form of Restricted Stock Unit Award Agreement for members of the Board of Directors (filed herewith)*
10.4	Form of Nonqualified Stock Option Agreement (filed herewith)*
10.5	Form of Restricted Stock Unit Award Agreement for management (filed herewith)*
31.1	Certification by Michael D. Snow for Team Health Holdings, Inc. dated August 2, 2016 as required by Section 302 of the Sarbanes-Oxley Act of 2002. (filed herewith)
31.2	Certification by David P. Jones for Team Health Holdings, Inc. dated August 2, 2016 as required by Section 302 of the Sarbanes-Oxley Act of 2002. (filed herewith)
32.1	Certification by Michael D. Snow for Team Health Holdings, Inc. dated August 2, 2016 as required by Section 906 of the Sarbanes-Oxley Act of 2002. (filed herewith)
32.2	Certification by David P. Jones for Team Health Holdings, Inc. dated August 2, 2016 as required by Section 906 of the Sarbanes-Oxley Act of 2002. (filed herewith)
101	The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets at June 30, 2016 and December 31, 2015, (ii) Consolidated Statement of Comprehensive Earnings for the three and six months ended June 30, 2016 and 2015, (iii) Consolidated Statement of Cash Flows for the six months ended June 30, 2016 and 2015, and (iv) Notes to Consolidated Financial Statements.

* Management contracts or compensatory plans or arrangements

48

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TEAM HEALTH HOLDINGS, INC.
August 2, 2016	/S/    MICHAEL D. SNOW
	Michael D. Snow President and Chief Executive Officer
August 2, 2016	/S/    DAVID P. JONES
	David P. Jones Executive Vice President and Chief Financial Officer

49

EX-10.2

PERFORMANCE STOCK UNIT AWARD AGREEMENT

THIS AGREEMENT (the “Agreement”), is made effective as of the 10^th day of March, 2016, (hereinafter called the “Date of Grant”), between Team Health Holdings Inc., a Delaware corporation (hereinafter called the “Company”), and [PARTICIPANT NAME] (hereinafter called the “Participant”):

R E C I T A L S:

WHEREAS, the Company has adopted the Team Health Holdings Inc. Amended and Restated 2009 Stock Incentive Plan (the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement. Capitalized terms not otherwise defined herein shall have the same meanings as in the Plan; and

WHEREAS, the Committee has determined that it would be in the best interests of the Company and its shareholders to grant the performance stock unit award provided for herein (the “PSU Award”) to the Participant pursuant to the Plan and the terms set forth herein.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties agree as follows:

1.Grant of the PSUs. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth in this Agreement, the Company hereby grants to the Participant a PSU Award consisting of a contractual right to receive a number of Shares set forth in the Performance Stock Unit Grant Notice, attached hereto as Exhibit A (the “Grant Notice”) (hereinafter called the “PSUs”), subject to vesting requirements. The PSUs shall vest and become nonforfeitable and provide for delivery of the Shares underlying such PSUs in accordance with Sections 2 and 3 hereof.

2.Vesting.

(a)Subject to the conditions contained herein and the Plan, the PSUs shall vest and the restrictions on such PSUs shall lapse as provided in the Grant Notice, subject to satisfaction of the applicable “Service Vesting Condition” and “Performance Vesting Conditions”, as defined in the Grant Notice attached hereto. Notwithstanding the foregoing, in the event the Participant’s Employment with the Company is terminated (x) by the Company without Cause following the one year anniversary of the Date of Grant, or (y) due Participant’s death or disability (any such termination under clause (x) or (y), a “Qualified Termination”) prior to the Scheduled Vesting Date (as defined in the Grant Notice), then the PSUs shall remain subject to the Performance Vesting Conditions (to the extent not previously achieved) and shall be deemed to have satisfied a pro-rata portion of the Service Vesting Condition, determined on a pro-rata daily basis over the three-year period commencing on the Date of Grant through the date of such Qualified Termination.

(b)If the Participant’s Employment with the Company terminates for any reason other than due to a Qualified Termination prior to the Scheduled Vesting Date, all PSUs, to the extent not previously vested, shall be forfeited by the Participant without consideration.

(c)Notwithstanding any other provision of this Agreement to the contrary, in the event of a Change in Control, the PSUs shall, to the extent not then vested and not previously

1

forfeited, immediately vest (i) at deemed “Target” level performance (as set forth in the Grant Notice) to the extent the Performance Period is not completed prior to the Change in Control or (ii) based on actual performance to the extent the Performance Period is completed on or prior to the Change in Control.

3.Delivery of Shares Underlying the PSUs. Upon or as soon as practicable following the vesting of PSUs based on satisfaction of both the Performance Vesting Conditions and the Service Vesting Condition, or upon a Change in Control, as applicable under Section 2 above, the Company shall deliver to the Participant a number of Shares corresponding to such vested number of PSUs in satisfaction of the Company’s obligations to the Participant in respect of such PSUs. Accordingly, in the event of a Qualified Termination, such delivery shall occur upon or as soon as practicable following the later to occur of such Qualified Termination or the end of the Performance Period and, in any event, no later than 2½ months following such later date. Certificates evidencing the Shares delivered upon settlement of the PSUs as described in the preceding sentence shall be issued by the Company and shall be registered in the Participant’s name on the stock transfer books of the Company promptly after the relevant Share delivery date; and no certificates shall be issued for fractional Shares. Notwithstanding the foregoing, the Company may elect to recognize the Participant’s ownership of Shares through uncertificated book entry. The Participant shall not be entitled to receive any Shares or other payments with respect to forfeited PSUs.

4.No Rights as a Stockholder Prior to Settlement; Dividend Equivalent Rights. The Participant shall have no voting or other shareholder rights with respect to the Shares underlying the PSUs unless and until such Shares are delivered to the Participant in accordance with Sections 2 and 3 hereof. Notwithstanding the forgoing, the Participant shall be entitled to receive dividend equivalent payments with respect to outstanding PSUs as described in this Section 4. In the event that the Company pays any cash or in-kind dividends (including dividends paid in Shares) on Shares while the PSUs are outstanding, the Company shall credit to a notional account the cash and in-kind payments that would have been payable on the Shares underlying the PSUs if such Shares would have been outstanding at the time of dividend payment, and then the Company shall pay to the Participant such cash or in‑kind amounts (adjusted for any performance components) when, and if, such corresponding Shares underlying the PSUs are delivered to the Participant pursuant to Section 3. In the event that the PSUs are forfeited pursuant to Section 2, any corresponding dividend equivalent payment rights shall also be forfeited.

5.No Right to Continued Employment. The granting of the PSUs evidenced by this Agreement shall impose no obligation on the Company or any Affiliate to continue the Employment of the Participant and shall not lessen or affect the Company’s or its Affiliate’s right to terminate the Employment of such Participant.

6.Transferability. The PSUs may not, at any time prior to settlement of the underlying Shares pursuant to Section 3, be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance.

7.Withholding. The Participant may be required to pay to the Company or any Affiliate and the Company shall have the right and is hereby authorized to withhold, any applicable withholding taxes in respect of the PSUs, their grant or vesting or any payment or transfer with respect to the PSUs, to include withholding of vested shares, and to take such additional action as

2

may be necessary in the opinion of the Committee to satisfy all obligations for the payment of such withholding taxes.

8.Securities Laws. Upon the vesting and settlement of any PSUs, the Participant will make or enter into such written representations, warranties and agreements as the Committee may reasonably request in order to comply with applicable securities laws or with this Agreement.

9.Notices. Any notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to the Participant at the address appearing in the personnel records of the Company for such Participant or to either party at such other address as either party hereto may hereafter designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

10.Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the state of Delaware without regard to conflicts of laws.

11.PSU Award Subject to Plan. By entering into this Agreement the Participant agrees and acknowledges that the Participant has received and read a copy of the Plan. The PSU Award and the PSUs granted hereunder are subject to the Plan. The terms and provisions of the Plan, as it may be amended from time to time, are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

12.Signature in Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

[Signatures on next page.]

3

IN WITNESS WHEREOF, the parties have caused this Agreement to be effective as of the day and year first above written.

Team Health Holdings Inc.

___________________________________

Name: Steven E. Clifton
Title: Executive Vice President and General Counsel

Participant

[PARTICIPANT NAME]

4

EXHIBIT A

TEAM HEALTH HOLDINGS INC. AMENDED AND RESTATED
2009 STOCK INCENTIVE PLAN

PERFORMANCE STOCK UNIT GRANT NOTICE[Employees]

Team Health Holdings Inc. (the “Company”), pursuant to its Amended and Restated 2009 Stock Incentive Plan (the “Plan”), hereby grants to the Participant set forth below the number of performance stock units (the “PSUs”) set forth below. The PSUs are subject to all of the terms and conditions as set forth herein, in the Performance Stock Unit Award Agreement, and in the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the same meaning as set forth in the Plan or Performance Stock Unit Award Agreement, as applicable.

Participant:	[Insert Participant Name]
Date of Grant:	[Insert Date of Grant]
Number of Performance Stock Units:	[Insert No. of Shares] Shares
Scheduled Vesting Date: Performance Period:	Third anniversary of the Date of Grant January 1, 2016 to December 31, 2017

Vesting Schedule:                     

1.    Performance Criteria. Subject to the Participant meeting the Service Vesting Condition, and the achievement of the Performance Components, on the Scheduled Vesting Date the applicable number of PSUs (determined based on the applicable Achievement Percentage with respect to each Performance Component), if any, shall vest. All determinations with respect to each Performance Component shall be made by the Committee and the applicable Performance Components shall not be achieved and the PSUs shall not be eligible to vest until the Committee certifies that such Performance Components have been met.

(a) Revenue Performance Component. The total number of PSUs that become vested based on the Performance Period Revenue shall be equal to (x) the total number of PSUs granted hereunder multiplied by (y) a Performance Component relative weighting factor equal to 40%, multiplied by (z) the applicable Achievement Percentage, determined as follows, and rounded down to the nearest whole PSU:

Level of Achievement	Performance Period Revenue	Achievement Percentage
Below Threshold	Less than $9.191B	0%
Threshold	$9.191B	50%
Target	$10.213B	100%
Maximum	$11.234B or above	200%

(b) EBITDA Performance Component. The total number of PSUs that become vested based on the Performance Period EBITDA shall be equal to (x) the total number of PSUs granted hereunder multiplied by (y) a Performance Component relative weighting factor equal to

5

40%, multiplied by (z) the applicable Achievement Percentage, determined as follows, and rounded down to the nearest whole PSU:

Level of Achievement	Performance Period EBITDA	Achievement Percentage
Below Threshold	Less than $1.015B	0%
Threshold	$1.015B	50%
Target	$1.128B	100%
Maximum	$1.240B or above	200%

(c) ROIC Performance Component. The total number of PSUs that become vested based on the Company’s ROIC shall be equal to (x) the total number of PSUs granted hereunder multiplied by (y) a Performance Component relative weighting factor equal to 20%, multiplied by (z) the applicable Achievement Percentage, determined as follows, and rounded down to the nearest whole PSU:

Level of Achievement	ROIC	Achievement Percentage
Below Threshold	Less than 10.8%	0%
Threshold	10.8%	50%
Target	12%	100%
Maximum	13.2% or above	200%

2.    Termination of Employment. Upon a termination of Employment, the Participant shall be treated in accordance with the Performance Stock unit Award Agreement.

3.    Definitions. For the purposes of this Grant Notice:

(a)“Achievement Percentage” means the percentage multiplier specified above with respect to the “Below Threshold,” “Threshold,” “Target” and “Maximum” levels for each Performance Component, or a percentage determined using linear interpolation if actual performance falls between any two levels. Notwithstanding the foregoing, in the event that actual performance does not meet the “Threshold” level for any Performance Component, as applicable, the “Achievement Percentage” with respect to such Performance Component shall be zero.

(b)“Adjusted EBITDA” means the Company’s adjusted earnings before interest, taxes, depreciation and amortization, as reported in (or otherwise calculated in a manner consistent with) the Company’s Form 10-Ks and Form 10-Qs as filed with the Securities and Exchange Commission.

(c) “Net Revenue” means the Company’s net revenue, as reported in (or otherwise calculated in a manner consistent with) the Company’s Form 10-Ks and Form 10-Qs as filed with the Securities and Exchange Commission.

(d)“Performance Components” means the Performance Period EBITDA, Performance Period Revenue and ROIC performance criteria applicable to the PSU Award.

(e) “Performance Period EBITDA” means the cumulative Adjusted EBITDA over the Performance Period.

6

(f) “Performance Vesting Conditions” means the achievement of the Performance Components as determined under this Exhibit A, at levels at or above threshold level performance.

(g) “Performance Period Revenue” means the cumulative Net Revenue over the Performance Period.

(h)“ROIC” means the Company’s percentage rate of return on invested capital over the Performance Period calculated as follows: net operating profit after taxes divided by Average Invested Capital.

(i)“Service Vesting Condition” means the Participant’s continued Employment with the Company through the Scheduled Vesting Date.

*    *    *

7

EX-10.3

RESTRICTED STOCK UNIT AWARD AGREEMENT

THIS AGREEMENT (the “Agreement”), is made effective as of the 3rd day of March, 2016, (hereinafter called the “Date of Grant”), between Team Health Holdings Inc., a Delaware corporation (hereinafter called the “Company”), and [PARTICIPANT NAME] (hereinafter called the “Participant”):

R E C I T A L S:

WHEREAS, the Company has adopted the Team Health Holdings Inc. Amended and Restated 2009 Stock Incentive Plan (the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement. Capitalized terms not otherwise defined herein shall have the same meanings as in the Plan; and

WHEREAS, the Committee has determined that it would be in the best interests of the Company and its shareholders to grant the restricted stock unit award provided for herein (the “RSU Award”) to the Participant pursuant to the Plan and the terms set forth herein.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties agree as follows:

1.     Grant of the RSUs. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth in this Agreement, the Company hereby grants to the Participant a RSU Award consisting of a contractual right to receive 3,320 Shares (hereinafter called the “RSUs”). The RSUs shall vest and become nonforfeitable and provide for delivery of the Shares underlying such RSUs in accordance with Sections 2 and 3 hereof.

2.     Vesting

(a)    Subject to the Participant’s continued service on the board of directors of the Company (“Board Service”), the RSUs shall vest and become non-forfeitable with respect to thirty-three and one-third percent (33.333%) of the RSUs on each of the first, second, and third anniversaries of the Grant Date (the “Scheduled Vesting Dates”). Notwithstanding the foregoing, in the event the Participant’s Board Service ends (i) due to Participant’s resignation from Board Service, or (ii) due to Participant’s death or disability (any such termination under clause (i) or (ii), a “Qualified Termination”), then the RSUs shall be deemed to vest on a pro-rata daily basis over the three-year period commencing on the Date of Grant through the date of resignation, death or disability, as applicable.

(b)    If the Participant’s Board Service with the Company ends for any reason other than the reasons set forth in 2(a) above, all RSUs, to the extent not previously vested, shall be forfeited by the Participant without consideration.

(c)    Notwithstanding any other provision of this Agreement to the contrary, in the event of a Change in Control, the RSUs shall, to the extent not then vested and not previously forfeited, immediately become fully vested.

3.     Delivery of Shares Underlying the RSUs. Upon or as soon as practicable following the vesting of RSUs on a Scheduled Vesting Date, a Qualified Termination or upon a Change in Control, as applicable under Section 2 above, the Company shall deliver to the Participant a number of Shares corresponding to such vested number of RSUs in satisfaction of the Company’s

1

obligations to the Participant in respect of such RSUs. Certificates evidencing the Shares delivered upon settlement of the RSUs as described in the preceding sentence shall be issued by the Company and shall be registered in the Participant’s name on the stock transfer books of the Company promptly after the relevant Share delivery date; and no certificates shall be issued for fractional Shares. Notwithstanding the foregoing, the Company may elect to recognize the Participant’s ownership of Shares through un-certificated book entry. The Participant shall not be entitled to receive any Shares or other payments with respect to forfeited RSUs.

4.      No Rights as a Stockholder Prior to Settlement; Dividend Equivalent Rights. The Participant shall have no voting or other shareholder rights with respect to the Shares underlying the RSUs unless and until such Shares are delivered to the Participant in accordance with Sections 2 and 3 hereof. Notwithstanding the forgoing, the Participant shall be entitled to receive dividend equivalent payments with respect to outstanding RSUs as described in this Section 4. In the event that the Company pays any cash or in-kind dividends (including dividends paid in Shares) on Shares while the RSUs are outstanding, the Company shall credit to a notional account the cash and in-kind payments that would have been payable on the Shares underlying the RSUs if such Shares would have been outstanding at the time of dividend payment, and then the Company shall pay to the Participant such cash or in‑kind amounts when, and if, such corresponding Shares underlying the RSUs are delivered to the Participant pursuant to Section 3. In the event that the RSUs are forfeited pursuant to Section 2, any corresponding dividend equivalent payment rights shall also be forfeited.

5.      No Right to Continued Board Service. The granting of the RSUs evidenced by this Agreement shall impose no obligation on the Company or any Affiliate to continue the Board Service of the Participant and shall not lessen or affect the Company’s or its Affiliate’s right to terminate the Board Service of such Participant

6.     Transferability. The RSUs may not, at any time prior to settlement of the underlying Shares pursuant to Section 3, be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance.

7.     Withholding. The Participant may be required to pay to the Company or any Affiliate and the Company shall have the right and is hereby authorized to withhold, any applicable withholding taxes in respect of the RSUs, their grant or vesting or any payment or transfer with respect to the RSUs and to take such action as may be necessary in the opinion of the Committee to satisfy all obligations for the payment of such withholding taxes.

8.     Securities Laws. Upon the vesting and settlement of any RSUs, the Participant will make or enter into such written representations, warranties and agreements as the Committee may reasonably request in order to comply with applicable securities laws or with this Agreement.

9.     Notices. Any notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to the Participant at the address appearing in the personnel records of the Company for such Participant or to either party at such other address as either party hereto may hereafter designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

2

10.    Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the state of Delaware without regard to conflicts of laws.

11.    RSU Award Subject to Plan. By entering into this Agreement the Participant agrees and acknowledges that the Participant has received and read a copy of the Plan. The RSU Award and the RSUs granted hereunder are subject to the Plan. The terms and provisions of the Plan, as it may be amended from time to time, are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

12.    Signature in Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

[Signatures on next page.]

3

IN WITNESS WHEREOF, the parties have caused this Agreement to be effective as of the day and year first above written.

Team Health Holdings Inc.

__________________________________

Name: Steven E. Clifton
Title: Executive Vice President and General Counsel

Participant

[PARTICIPANT NAME]

4

EX-10.4

NONQUALIFIED STOCK OPTION AGREEMENT

THIS AGREEMENT (the “Agreement”) is made between Team Health Holdings, Inc., a Delaware corporation (hereinafter called the “Company”), and [PARTICIPANT NAME] (hereinafter called the “Participant”):

RECITALS:

WHEREAS, the Company has adopted the Team Health Holdings Inc. Amended and Restated 2009 Stock Incentive Plan (the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement. Capitalized terms not otherwise defined herein shall have the same meanings as in the Plan; and

WHEREAS, the Compensation Committee and the Board of Directors have determined that it would be in the best interests of the Company and its shareholders to grant the option provided for herein to the Participant pursuant to the Plan and the terms set forth herein.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties agree as follows:

1.Grant of the Option. The Company hereby grants to the Participant, effective as of the 10^th day of March, 2016 (the “Grant Date”), the right and option (the “Option”) to purchase, on the terms and conditions hereinafter set forth, all or any part of an aggregate of [NUMBER OF SHARES] Shares, subject to adjustment as set forth in the Plan. The purchase price of the Shares subject to the Option shall be the Fair Market Value on the Grant Date (the “Option Price”), which was $42.70per share. The Option is intended to be a non-qualified stock option, and is not intended to be treated as an option that complies with Section 422 of the Internal Revenue Code of 1986, as amended.

2.    Vesting.

(a)    Subject to the Participant’s continued Employment with the Company, the Option shall vest and become non-forfeitable with respect to thirty-three and one-third percent (33.3%) of the stock options on each of the first, second and third anniversaries of the Date of Grant. Notwithstanding the foregoing, in the event the Participant’s Employment is terminated (i) by the Company without Cause, or (ii) due to death or Disability, then the Option shall be deemed to vest on a pro-rata daily basis over the four-year period commencing on the Date of Grant through the date of termination.

At any time, the portion of the Option which has become vested and exercisable as described above (or pursuant to Section 2(c) below) is hereinafter referred to as the “Vested Portion”.

(b)    If the Participant’s Employment with the Company is terminated for any reason, the Option shall, to the extent not then vested, be canceled by the Company without consideration and the Vested Portion of the Option shall remain exercisable for the period set forth in Section 3(a). Notwithstanding the foregoing, if the Participant breaches any of the terms or restrictive covenants set forth in any applicable agreement between the Company and the Participant, including but not limited to any employment agreement, non-compete agreement or non-solicitation agreement, either during or following the Participant’s Employment, the entire Option (including,

1

without limitation, the Vested Portion of the Option) shall be cancelled by the Company without consideration and no portion of the Option shall remain exercisable.

(c)    Notwithstanding any other provisions of this Agreement to the contrary, in the event of a Change in Control the Option shall, to the extent not then vested and not previously forfeited, immediately become fully vested and exercisable.

3.    Exercise of Option.

(a)    Period of Exercise. Subject to the provisions of the Plan and this Agreement, the Participant may exercise all or any part of the Vested Portion of the Option at any time prior to the earliest to occur of:

(i) the eighth (8^th) anniversary of the Date of Grant;

(ii) one (1) year following the date of the Participant’s termination of Employment due to death or Disability;

(iii) ninety (90) days following the date of the Participant’s termination of Employment by the Company without Cause or by the Participant for any reason; and

(iv) the date of the Participant’s termination of Employment by the Company for Cause; and

(v) the first date on which the Participant breaches any of the terms or restrictive covenants set forth in any applicable agreement between the Company and the Participant, including but not limited to any employment agreement, non-compete agreement or non-solicitation agreement.

For purposes of this agreement, “Cause” shall mean “Cause” as defined in any employment agreement then in effect between the Participant and the Company or if not defined therein or, if there shall be no such agreement, (i)    Participant’s commission of an act of fraud, theft or dishonesty against the Company or any of its subsidiaries or affiliated companies, or if Participant shall be indicted for, or convicted of (or plead no contest to) any felony or be convicted of (or plead no contest to) any misdemeanor involving, fraud, dishonesty or moral turpitude, or any action or inaction of Participant that in the reasonable opinion of the Company either adversely affects Participant’s ability to perform his or her obligations or duties to the Company in any material respect or adversely affects the Company’s reputation, relationships with clients, or ability to conduct its business activities in any jurisdiction, (ii) Participant’s gross negligence, misconduct, insubordination, or refusal to perform or abide by any lawful and ethical direction of a superior in the Company (iii) Participant fails to comply with the written rules, regulations and policies of the Company or any conduct inconsistent with the policies and procedures of the Company; or (iv) Participant willfully impedes or endeavors to influence, obstruct or impede or fails to materially cooperate with an investigation authorized by the Company, a self-regulatory organization or a governmental department or agency.

The determination of the existence of Cause shall be made by the Committee in good faith.

2

(b)    Method of Exercise.

(i) Subject to Section 3(a), the Vested Portion of the Option may be exercised by either delivering to the Company at its principal office written notice of intent to so exercise or by providing such notice to the Company’s designated contact person for the Plan; provided that, the Option may be exercised with respect to whole Shares only. Such notice shall specify the number of Shares for which the Option is being exercised and shall be accompanied by payment in full of the Option Price. The payment of the Option Price may be made at the election of the Participant (i) in cash or its equivalent (e.g., by check), (ii) to the extent permitted by the Committee, in Shares having a Fair Market Value equal to the aggregate Option Price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee; provided, that such Shares have been held by the Participant for no less than six months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying generally accepted accounting principles), (iii) partly in cash and, to the extent permitted by the Committee, partly in such Shares, (iv) if there is a public market for the Shares at such time, through the delivery of irrevocable instructions to a broker, who has been either approved or, if applicable, designated by the Committee, to sell Shares obtained upon the exercise of the Option and to deliver promptly to the Company an amount out of the proceeds of such Sale equal to the aggregate option price for the Shares being purchased, or (v) through a “net settlement” as described in Section 6(c) of the Plan. No Participant shall have any rights to dividends or other rights of a stockholder with respect to Shares subject to an Option until the Participant has given written notice of exercise of the Option, paid in full for such Shares and, if applicable, has satisfied any other conditions imposed by the Committee pursuant to the Plan.

(ii) Notwithstanding any other provision of the Plan or this Agreement to the contrary, the Option may not be exercised prior to the completion of any registration or qualification of the Option or the Shares under applicable state and federal securities or other laws, or under any ruling or regulation of any governmental body or national securities exchange that the Committee shall in its sole discretion determine to be necessary or advisable.

(iii) Upon the Company’s determination that the Option has been validly exercised as to any of the Shares, the Company shall issue certificates in the Participant’s name for such Shares. However, the Company shall not be liable to the Participant for damages relating to any delays in issuing the certificates to him, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in the certificates themselves. Notwithstanding the foregoing, the Company may elect to recognize the Participant’s ownership through uncertificated book entry.

(iv) In the event of the Participant’s death, the Vested Portion of the Option shall remain exercisable by the Participant’s executor or administrator, or the person or persons to whom the Participant’s rights under this Agreement shall pass by will or by the laws of descent and distribution as the case may be, to the extent set forth in Section 3(a). Any heir or legatee of the Participant shall take rights herein granted subject to the terms and conditions hereof.

4.    No Right to Continued Employment. The granting of the Option evidenced hereby and this Agreement shall impose no obligation on the Company or any Affiliate to continue

3

the Employment of the Participant and shall not lessen or affect the Company’s or its Affiliate’s right to terminate the Employment of such Participant.

5.    Legend on Certificates. To the extent applicable, the certificates representing the Shares purchased by exercise of the Option shall be subject to the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such Shares are listed, and any applicable Federal or state laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

6.    Transferability. The Option may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant otherwise than by will or by the laws of descent and distribution, and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance. No such permitted transfer of the Option to heirs or legatees of the Participant shall be effective to bind the Company unless the Committee shall have been furnished with written notice thereof and a copy of such evidence as the Committee may deem necessary to establish the validity of the transfer and the acceptance by the transferee or transferees of the terms and conditions hereof. During the Participant’s lifetime, the Option is exercisable only by the Participant.

7.    Withholding. The Participant may be required to pay to the Company or any Affiliate and the Company shall have the right and is hereby authorized to withhold, any applicable withholding taxes in respect of the Option, its exercise or any payment or transfer under or with respect to the Option and to take such other action as may be necessary in the opinion of the Committee to satisfy all obligations for the payment of such withholding taxes.

8.    Securities Laws. Upon the acquisition of any Shares pursuant to the exercise of the Option, the Participant will make or enter into such written representations, warranties and agreements as the Committee may reasonably request in order to comply with applicable securities laws or with this Agreement.

9.    Notices. Any notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to the Participant at the address appearing in the personnel records of the Company for the Participant or to either party at such other address as either party hereto may hereafter designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

10.    Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the state of Delaware without regard to conflicts of laws.

11.    Option Subject to Plan. By entering into this Agreement the Participant agrees and acknowledges that the Participant has received and read a copy of the Plan. The Option is subject to the Plan. The terms and provisions of the Plan, as they may be amended from time to time, are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

12.    Signature in Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

4

IN WITNESS WHEREOF, the parties have caused this Agreement to be effective as of the day and year first above written.

Team Health Holdings Inc.

____________________________________

Name: Steven E. Clifton
Title: Executive Vice President and General Counsel

Participant

[PARTICIPANT NAME]

5

EX-10.5

RESTRICTED STOCK UNIT AWARD AGREEMENT

THIS AGREEMENT (the “Agreement”), is made effective as of the 10^th day of March, 2016, (hereinafter called the “Date of Grant”), between Team Health Holdings Inc., a Delaware corporation (hereinafter called the “Company”), and [PARTICIPANT NAME] (hereinafter called the “Participant”):

R E C I T A L S:

WHEREAS, the Company has adopted the Team Health Holdings Inc. Amended and Restated 2009 Stock Incentive Plan (the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement. Capitalized terms not otherwise defined herein shall have the same meanings as in the Plan; and

WHEREAS, the Committee has determined that it would be in the best interests of the Company and its shareholders to grant the restricted stock unit award provided for herein (the “RSU Award”) to the Participant pursuant to the Plan and the terms set forth herein.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties agree as follows:

1.Grant of the RSUs. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth in this Agreement, the Company hereby grants to the Participant an RSU Award consisting of a contractual right to receive [# OF SHARES] Shares (hereinafter called the “RSUs”). The RSUs shall vest and become nonforfeitable and provide for delivery of the Shares underlying such RSUs in accordance with Sections 2 and 3 hereof.

2.    Vesting

(a)    Subject to the Participant’s continued employment with the Company (“Employment”), the RSUs shall vest and become non-forfeitable with respect to thirty-three and one-third percent (33.3%) of the RSUs on each of the first, second and third anniversaries of the Date of Grant. Notwithstanding the foregoing, in the event the Participant’s Employment is terminated (x) by the Company without Cause following the first Scheduled Vesting Date, or (y) due Participant’s death or disability (any such termination under clause (x) or (y), a “Qualified Termination”), then the RSUs shall be deemed to vest on a pro-rata daily basis over the four-year period commencing on the Date of Grant through the date of such Qualified Termination.

(b)    If the Participant’s Employment with the Company terminates for any reason other than for the reasons stated in Section 2(a) above, all RSUs, to the extent not previously vested, shall be forfeited by the Participant without consideration.

(c)    Notwithstanding any other provision of this Agreement to the contrary, in the event of a Change in Control, the RSUs shall, to the extent not then vested and not previously forfeited, immediately become fully vested.

3.    Delivery of Shares Underlying the RSUs. Upon or as soon as practicable following the vesting of RSUs on a Scheduled Vesting Date, a Qualified Termination or upon a Change in Control, as applicable under Section 2 above, the Company shall deliver to the Participant a number of Shares corresponding to such vested number of RSUs in satisfaction of the Company’s obligations to the Participant in respect of such RSUs. Certificates evidencing the Shares delivered upon settlement of the RSUs as described in the preceding sentence shall be issued by the Company

1

and shall be registered in the Participant’s name on the stock transfer books of the Company promptly after the relevant Share delivery date; and no certificates shall be issued for fractional Shares. Notwithstanding the foregoing, the Company may elect to recognize the Participant’s ownership of Shares through uncertificated book entry. The Participant shall not be entitled to receive any Shares or other payments with respect to forfeited RSUs.

4.     No Rights as a Stockholder Prior to Settlement; Dividend Equivalent Rights. The Participant shall have no voting or other shareholder rights with respect to the Shares underlying the RSUs unless and until such Shares are delivered to the Participant in accordance with Sections 2 and 3 hereof. Notwithstanding the forgoing, the Participant shall be entitled to receive dividend equivalent payments with respect to outstanding RSUs as described in this Section 4. In the event that the Company pays any cash or in-kind dividends (including dividends paid in Shares) on Shares while the RSUs are outstanding, the Company shall credit to a notional account the cash and in-kind payments that would have been payable on the Shares underlying the RSUs if such Shares would have been outstanding at the time of dividend payment, and then the Company shall pay to the Participant such cash or in‑kind amounts when, and if, such corresponding Shares underlying the RSUs are delivered to the Participant pursuant to Section 3. In the event that the RSUs are forfeited pursuant to Section 2, any corresponding dividend equivalent payment rights shall also be forfeited.

5.     No Right to Continued Employment. The granting of the RSUs evidenced by this Agreement shall impose no obligation on the Company or any Affiliate to continue the Employment of the Participant and shall not lessen or affect the Company’s or its Affiliate’s right to terminate the Employment of such Participant

6.    Transferability. The RSUs may not, at any time prior to settlement of the underlying Shares pursuant to Section 3, be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance.

7.    Withholding. The Participant may be required to pay to the Company or any Affiliate and the Company shall have the right and is hereby authorized to withhold, any applicable withholding taxes in respect of the RSUs, their grant or vesting or any payment or transfer with respect to the RSUs, to include withholding of vested shares, and to take such additional action as may be necessary in the opinion of the Committee to satisfy all obligations for the payment of such withholding taxes.

8.    Securities Laws. Upon the vesting and settlement of any RSUs, the Participant will make or enter into such written representations, warranties and agreements as the Committee may reasonably request in order to comply with applicable securities laws or with this Agreement.

9.    Notices. Any notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to the Participant at the address appearing in the personnel records of the Company for such Participant or to either party at such other address as either party hereto may hereafter designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

2

10.    Choice of Law. This Agreement shall be governed by and construed in accordance with the laws of the state of Delaware without regard to conflicts of laws.

11.    RSU Award Subject to Plan. By entering into this Agreement the Participant agrees and acknowledges that the Participant has received and read a copy of the Plan. The RSU Award and the RSUs granted hereunder are subject to the Plan. The terms and provisions of the Plan, as it may be amended from time to time, are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

12.    Signature in Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

[Signatures on next page.]

3

IN WITNESS WHEREOF, the parties have caused this Agreement to be effective as of the day and year first above written.

Team Health Holdings Inc.

___________________________________

Name: Steven E. Clifton
Title: Executive Vice President and General Counsel

Participant

[PARTICIPANT NAME]

4

EX-31.1

Exhibit 31.1

Certifications

I, Michael D. Snow, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2016 of Team Health Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By:	/S/    MICHAEL D. SNOW
	Michael D. Snow President and Chief Executive Officer

Date: August 2, 2016

EX-31.2

Exhibit 31.2

Certifications

I, David P. Jones, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2016 of Team Health Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

By:	/S/    DAVID P. JONES
	David P. Jones Executive Vice President and Chief Financial Officer

Date: August 2, 2016

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Team Health Holdings, Inc. (the “Company”) on Form 10-Q (“Form 10-Q”) for the quarter ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof, I, Michael D. Snow, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/    MICHAEL D. SNOW        

Michael D. Snow

President and Chief Executive Officer

Date: August 2, 2016

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Team Health Holdings, Inc. (the “Company”) on Form 10-Q (“Form 10-Q”) for the quarter ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof, I, David P. Jones, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

/S/    DAVID P. JONES        

David P. Jones

Executive Vice President and Chief Financial Officer

Date: August 2, 2016

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 28, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	TEAM HEALTH HOLDINGS INC.
Entity Central Index Key	0001082754
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		74,157,535

XML

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 16,281	$ 28,563
Short-term Investments	1,581	1,985
Accounts receivable, less allowance for uncollectibles of $500,645 and $655,050 in 2015 and 2016, respectively	787,169	730,459
Prepaid expenses and other current assets	66,492	73,807
Receivables under insured programs	40,801	36,004
Income tax receivable	13,526	28,791
Total current assets	925,850	899,609
Insurance subsidiaries' and other investments	111,390	111,940
Property and equipment, net	86,727	87,907
Other intangibles, net	325,284	335,637
Goodwill	2,447,856	2,427,802
Deferred income taxes	40,369	50,250
Receivables under insured programs	98,912	90,747
Other	65,364	56,950
Total Assets	4,101,752	4,060,842
Current liabilities:
Accounts payable	57,000	66,358
Accrued compensation and physician payable	316,404	337,455
Other accrued liabilities	299,509	257,651
Current maturities of long-term debt	61,870	68,900
Total current liabilities	734,783	730,364
Long-term debt, less current maturities	2,311,598	2,337,363
Other non-current liabilities	357,302	346,427
Shareholders’ equity:
Common stock, ($0.01 par value; 100,000 shares authorized, 73,092 and 74,156 shares issued and outstanding at December 31, 2015 and June 30, 2016, respectively)	742	731
Additional paid-in capital	865,896	836,458
Accumulated deficit	(176,691)	(196,144)
Accumulated other comprehensive earnings	2,414	1,503
Team Health Holdings, Inc. shareholders’ equity	692,361	642,548
Noncontrolling interests	5,708	4,140
Total shareholders' equity including noncontrolling interests	698,069	646,688
Total liabilities and shareholders' equity	$ 4,101,752	$ 4,060,842

XML

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for uncollectibles	$ 655,050	$ 500,645
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	74,156,000	73,092,000
Common stock, shares issued	74,156,000	73,092,000

XML

Consolidated Statements of Comprehensive Earnings (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net revenue before provision for uncollectibles	$ 1,815,904	$ 1,466,984	$ 3,655,435	$ 2,865,273
Provision for uncollectibles	693,328	589,029	1,397,218	1,146,834
Net revenue	1,122,576	877,955	2,258,217	1,718,439
Cost of services rendered (exclusive of depreciation and amortization shown separately below)
Professional service expenses	891,141	687,540	1,793,724	1,351,005
Professional liability costs	33,455	27,279	80,439	53,897
General and administrative expenses (includes contingent purchase compensation expense)	95,548	78,586	199,602	152,148
Other (income) expense, net	(879)	961	(1,611)	(2,321)
Depreciation	8,066	5,560	16,103	11,134
Amortization	24,142	21,175	47,653	41,452
Interest expense, net	30,437	4,571	61,730	8,560
Transaction, integration, and reorganization costs	6,106	2,215	27,501	3,301
Gains (Losses) on Restructuring of Debt	1,069	0	1,069	0
Earnings before income taxes	33,491	50,068	32,007	99,263
Provision for income taxes	14,577	21,186	12,363	42,341
Net earnings	18,914	28,882	19,644	56,922
Net (loss) earnings attributable to noncontrolling interests	129	(53)	191	(67)
Net earnings attributable to Team Health Holdings, Inc.	$ 18,785	$ 28,935	$ 19,453	$ 56,989
Net earnings per share of Team Health Holdings, Inc.
Basic	$ 0.25	$ 0.40	$ 0.26	$ 0.80
Diluted	$ 0.25	$ 0.39	$ 0.26	$ 0.78
Weighted average shares outstanding
Basic (shares)	73,958	71,956	73,650	71,666
Diluted (shares)	75,234	73,602	75,129	73,137
Net change in fair value of investments, net of tax	$ 628	$ (573)	$ 911	$ (600)
Comprehensive earnings	19,542	28,309	20,555	56,322
Comprehensive (loss) earnings attributable to noncontrolling interests	129	(53)	191	(67)
Comprehensive earnings attributable to Team Health Holdings, Inc.	$ 19,413	$ 28,362	$ 20,364	$ 56,389

XML

Consolidated Statements of Comprehensive Earnings (Parenthetical) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Contingent purchase and other acquisition compensation expense recognized	$ 9,762	$ 7,856	$ 18,851	$ 15,760
Net change in fair value of investments, tax	$ 338	$ (340)	$ 492	$ (337)

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Activities
Net earnings	$ 19,644	$ 56,922
Adjustments to reconcile net earnings:
Depreciation	16,103	11,134
Amortization	47,653	41,452
Amortization of deferred financing costs	4,394	727
Equity based compensation expense	14,374	9,213
Provision for uncollectibles	1,397,218	1,146,834
Deferred income taxes	2,794	(14,578)
Non-cash loss on refinancing of debt	905	0
(Gain) loss on sale of investments and other assets	94	(400)
Equity in joint venture income	(2,990)	(1,714)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,459,597)	(1,244,045)
Prepaids and other assets	715	(9,753)
Income tax accounts	11,319	3,967
Accounts payable	(8,950)	5,555
Accrued compensation and physician payable	(14,972)	(10,710)
Contingent purchase liabilities	16,237	6,872
Other accrued liabilities	(4,586)	(2,178)
Professional liability reserves	14,067	18,870
Net cash provided by operating activities	54,422	18,168
Investing Activities
Purchases of property and equipment	(15,333)	(17,364)
Net proceeds from disposition of assets held for sale and property and equipment	50	269
Cash paid for acquisitions, net of cash acquired	(29,930)	(84,792)
Payments for the purchase of investments	(458)	0
Proceeds from the sale of investments	1,169	6,560
Purchases of investments at insurance subsidiaries	(46,539)	(44,935)
Proceeds from investments at insurance subsidiaries	48,184	51,187
Net cash used in investing activities	(42,857)	(89,075)
Financing Activities
Payments on long-term debt	(21,568)	(7,500)
Proceeds from note payable	288	0
Payments on revolving credit facility	(463,200)	(631,000)
Proceeds from revolving credit facility	448,700	701,500
Payments of financing costs	(1,587)	0
Payments related to contingent purchase obligations	(6,888)	0
Contributions from noncontrolling interests	1,377	1,377
Proceeds from the issuance of common stock under stock purchase plans	4,952	3,445
Proceeds from exercise of stock options	15,756	20,519
Tax benefit from exercise of stock options	1,075	13,775
Payments related to settlement of equity based awards	(2,752)	0
Net cash provided by (used in) financing activities	(23,847)	102,116
Net increase (decrease) in cash and cash equivalents	(12,282)	31,209
Cash and cash equivalents, beginning of period	28,563	20,094
Cash and cash equivalents, end of period	16,281	51,303
Interest paid	61,562	9,380
Taxes paid, net of refunds	$ (2,368)	$ 37,160

XML

Organization and Basis of Presentation

6 Months Ended

Jun. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

Organization and Basis of Presentation

The accompanying unaudited consolidated financial statements include the accounts of Team Health Holdings, Inc. (the Company) its subsidiaries and its affiliates, including its affiliated medical groups, and have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial reporting, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements.

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring items) necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. The consolidated balance sheet of the Company at December 31, 2015 has been derived from the audited financial statements at that date, but does not include all of the information and disclosures required by U.S. GAAP for complete financial statements. These financial statements and the notes thereto should be read in conjunction with the December 31, 2015 audited consolidated financial statements and the notes thereto included in our annual report on Form 10-K for fiscal year 2015 filed with the Securities and Exchange Commission (the SEC).

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements and notes. Actual results could differ from those estimates. Certain amounts for the prior year have been reclassified to conform to the current year’s presentation.

XML

Recently Adopted and Recently Issued Accounting Guidance

6 Months Ended

Jun. 30, 2016

Accounting Changes and Error Corrections [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles

Recently Adopted and Recently Issued Accounting Guidance

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which establishes a comprehensive revenue recognition standard for virtually all industries under U.S. GAAP. The standard is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein, with early adoption permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which will change how companies account for and present lease arrangements. The guidance requires companies to recognize leased assets and liabilities for both capital and operating leases. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods therein, and early adoption is permitted. Companies are required to adopt the guidance on a modified retrospective method. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting,” which requires companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled (i.e., additional paid-in-capital pools will be eliminated). In addition, the new guidance changes the limit that companies are allowed to withhold for employees without triggering liability classification and allows companies to make a policy election to either recognize forfeitures as they occur or estimate them. The new guidance is  effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods, and early adoption is permitted. The required transition methods for each aspect of the new guidance varies between prospective, retrospective and modified retrospective. The Company has not yet determined which method of adoption it will select and is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

The Company has implemented all new accounting pronouncements that are in effect and that could materially impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued, but are not yet effective, that might have a material impact on the consolidated financial statements of the Company unless otherwise noted in prior updates or above.

XML

Acquisitions and Contingent Purchase Obligations

6 Months Ended

Jun. 30, 2016

Business Combinations [Abstract]

Acquisitions and Contingent Purchase Obligations

Acquisitions and Contingent Purchase Obligations

Acquisitions

During the six months ended June 30, 2016, the Company completed three acquisitions of emergency medicine businesses with operations in Rhode Island, Connecticut, California and Ohio for a total of $29.9 million, which expanded the Company's emergency medicine presence in those respective markets. The results of operations of the acquired businesses have been included in the Company’s consolidated financial statements beginning on the acquisition date. Pro forma results of operations have not been presented because the effect of these acquisitions is not material to the Company’s consolidated results of operations individually or in the aggregate.

The purchase price for these acquisitions was allocated, based on management’s estimates, in accordance with ASC Topic 805, “Business Combinations” (ASC 805). The Company’s purchase price allocation for business combinations completed during recent periods is preliminary and may be subject to revision as additional information about the fair value of acquired working capital becomes available. Additional information, which existed as of the acquisition date but at that time was unknown to the Company, may become known to the Company during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. The purchase price for these acquisitions completed during the six months ended June 30, 2016 was allocated as shown in the table below (in thousands):

	June 30, 2016
Accounts receivable	$	1,286
Prepaid expenses and other assets	3
Other intangibles (consisting of physician and hospital agreements)	15,600
Goodwill (of which $3.8 million is tax deductible)	16,601
Accounts payable	(41		)
Accrued compensation and physician payable	(291		)
Other accrued liabilities	(241		)
Net deferred income taxes	(2,987		)
Total purchase price	$	29,930

IPC Healthcare, Inc. (IPC) Acquisition

On November 23, 2015, the Company completed the acquisition of IPC in a cash transaction. At closing, the Company paid approximately $1.60 billion in cash to the former owners of IPC in exchange for all of the outstanding equity interests of IPC.

The accounting for the acquisition of IPC will be completed within the timeframe prescribed by the provisions of ASC 805. The Company continues to obtain information relative to the fair values of assets acquired and liabilities assumed. Acquired assets and assumed liabilities include, but are not limited to, accounts receivable, other intangible assets, current and noncurrent taxes payable, deferred taxes, contingent purchase liabilities, and other accrued liabilities. The valuations are based on appraisal reports or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed.

During 2016, factors became known that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of the IPC transaction. The estimated fair values of assets acquired and liabilities assumed, specifically accounts receivable, current and noncurrent taxes payable, deferred taxes, contingent purchase liability and other intangible assets, may be subject to change as additional information is received. The purchase price allocation adjustments for this acquisition are summarized as follows (in thousands):

	As of			Adjustments to			As of
	December 31, 2015			Purchase Price Allocation			June 30, 2016
Short term investments	$	1,985		$	—		$	1,985
Accounts receivable	127,265			(6,955		)	120,310
Prepaid expenses and other assets	6,347			(316		)	6,031
Receivables under insured programs	36,255			—			36,255
Property and equipment	10,541			216			10,757
Income tax receivable	12,528			—			12,528
Net deferred income taxes	64,301			(3,608		)	60,693
Other intangibles (consisting of marketing-related and technology-based intangibles and physician and hospital agreements)	4,975			21,700			26,675
Goodwill (of which the tax deductible amount was $368,283)	1,574,757			3,212			1,577,969
Accounts payable	(15,627		)	(33		)	(15,660		)
Accrued compensation and physician payable	(43,856		)	—			(43,856		)
Other accrued liabilities	(63,809		)	(13,260		)	(77,069		)
Contingent purchase liability	(30,639		)	(2,768		)	(33,407		)
Assumed notes payable	(148,249		)	—			(148,249		)
Other non-current liabilities	(61,894		)	1,812			(60,082		)
Total consideration paid, net of acquired cash and cash equivalents of $28,059	$	1,474,880		$	—		$	1,474,880

Subsequent Acquisition

In July 2016, the Company completed the acquisition of the operations of an anesthesiology business located in Florida. This acquisition will add approximately 18,000 patient visits annually to the Company's existing anesthesia operations. The Company is still in the process of completing the purchase price allocation for this acquisition.

Contingent Purchase Obligations

In accordance with ASC 805, the Company records its contingent consideration as a component of the opening balance sheet unless there is a continuing employment provision. Contingent consideration with a continuing employment provision is recognized ratably over the defined performance period as compensation expense which is included as a component of general and administrative expense (and parenthetically disclosed with other acquisition-related compensation expense) in the results of the Company’s operations. The payment of contingent purchase obligations is included as a component of financing, unless there is a continuing employment provision, in which case it is included as a component of operating cash flows.

As of June 30, 2016, the Company estimates it may have to pay $101.1 million in future contingent payments for acquisitions made prior to June 30, 2016, based upon the current projected performance of the acquired operations of which $69.2 million is recorded as a liability in other liabilities and other non-current liabilities on the Company’s consolidated balance sheet. The remaining estimated liability of $31.9 million will be recorded as contingent purchase compensation expense over the remaining performance periods. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over the respective performance periods. These payments will be made should the acquired operations achieve the financial targets or certain contract terms as agreed to in the respective acquisition agreements, including the requirements for continuing employment. When measured on a recurring basis, this liability is considered Level 3 in the fair value hierarchy due to the use of unobservable inputs to measure fair value.

The contingent purchase and other acquisition compensation expense recognized for the six months ended June 30,2015 and 2016 was $15.8 million and $18.9 million, respectively.

The changes to the Company’s accumulated contingent purchase liability for the six months ended June 30, 2016 are as follows (in thousands):

Contingent purchase liability at December 31, 2015	$	57,080
Payments	(9,501		)
Contingent purchase and other acquisition compensation expense recognized	18,851
Adjustments to contingent purchase liability recognized at acquisition date	2,781
Contingent purchase liability at June 30, 2016	$	69,211

Estimated unrecognized contingent purchase compensation expense as of June 30, 2016 is as follows (in thousands):

For the remainder of the year ended December 31, 2016	$	16,409
For the year ended December 31, 2017	9,681
For the year ended December 31, 2018	3,635
For the year ended December 31, 2019	1,515
For the year ended December 31, 2020	625
	$	31,865

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

The Company applies the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (ASC Topic 820), in determining the fair value of its financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements.

ASC Topic 820 prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2	Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;
Level 3	Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The following table provides information on those assets and liabilities the Company currently measures at fair value on a recurring basis as of December 31, 2015 and June 30, 2016 (in thousands):

	Carrying Amount in Consolidated Balance Sheet December 31, 2015		Fair Value December 31, 2015		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	18,238	$	18,238	$	18,238	$	—	$	—
Municipal bonds	87,121		87,121		—		87,121		—
Mutual funds	64		64		—		64		—
Private investments	2,818		2,818		—		—		2,818
Corporate bonds	3,699		3,699		—		3,699		—
Total investments of insurance subsidiaries	$	111,940	$	111,940	$	18,238	$	90,884	$	2,818
Supplemental employee retirement plan investments:
Mutual funds	$	45,868	$	45,868	$	—	$	45,868	$	—

	Carrying Amount in Consolidated Balance Sheet June 30, 2016		Fair Value June 30, 2016		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	14,654	$	14,654	$	14,654	$	—	$	—
Municipal bonds	86,389		86,389		—		86,389		—
Mutual funds	54		54		—		54		—
Private investments	2,185		2,185		—		—		2,185
Corporate bonds	8,108		8,108		—		8,108		—
Total investments of insurance subsidiaries	$	111,390	$	111,390	$	14,654	$	94,551	$	2,185
Supplemental employee retirement plan investments:
Mutual funds	$	52,237	$	52,237	$	—	$	52,237	$	—

The Company’s insurance subsidiaries' and other investments are valued using market prices on active markets (Level 1) and less active markets (Level 2), in addition to using alternative information when market data is not available (Level 3). Level 1 investment valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets. Level 2 investment valuations are obtained from readily available pricing sources for comparable investments or identical investments in less active markets. The fair values of the Company’s supplemental employee retirement investments are based on quoted prices. Level 3 investment valuations require significant management judgment and are based on transaction price, company performance, and market conditions. For the six months ended June 30, 2016 there were no transfers between Levels 1, 2 or 3. See Note 5 for more information regarding the Company’s investments.

The Company classified its municipal bonds, mutual funds, and corporate bonds within Level 2 because these securities were valued based on quoted prices in markets that are less active, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency.

The Company classified its private investments within Level 3 because active market pricing is not readily available and, as such, the Company uses net asset values as an estimate of fair value as a practical expedient. The valuation of non-public private equity investments requires significant management judgment due to the absence of observable quoted market prices, inherent lack of liquidity, and the long-term nature of such assets. These investments are valued initially based upon transaction price. In determining valuation adjustments resulting from the investment review process, emphasis is placed on current company performance and market conditions.

In addition to the preceding disclosures prescribed by the provisions of FASB ASC Topic 820, ASC Topic 825 “Financial Instruments” requires the disclosure of the estimated fair value of financial instruments. The Company’s short term financial instruments include cash and cash equivalents, short term investments, accounts receivable, and accounts payable. The carrying value of the short term financial instruments approximates the fair value due to their short term nature. These financial instruments have no stated maturities or the financial instruments have short term maturities that approximate market.

The fair value of the Company's debt is estimated using quoted market prices when available. When quoted market prices are not available, fair value is estimated based on current market interest rates for debt with similar maturities (Level 2). At June 30, 2016, the estimated fair value of the Company’s outstanding debt was $2.47 billion compared to a carrying value of $2.42 billion.

XML

Investments

6 Months Ended

Jun. 30, 2016

Investments [Abstract]

Investments

Investments

Investments are primarily comprised of securities held by the Company and its captive insurance subsidiaries in connection with its participant directed supplemental employee retirement plan. Investments held by the Company and its captive insurance subsidiaries are classified as available-for-sale securities. The unrealized gains or losses of investments held by the Company and its captive insurance subsidiaries are included in accumulated other comprehensive earnings as a separate component of shareholders’ equity, unless the decline in value is deemed to be other-than-temporary and the Company does not have the intent and ability to hold such securities until their full cost can be recovered, in which case such securities are written down to fair value and the loss is charged to current period earnings.

The investments held by the Company in connection with its participant directed supplemental employee retirement plan are classified as trading securities; therefore, changes in fair value associated with these investments are recognized as a component of earnings.

At December 31, 2015 and June 30, 2016, amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by investment type were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Money market funds	$	18,238	$	—	$	—		$	18,238
Municipal bonds	84,983		2,411		(273		)	87,121
Mutual funds	64		—		—			64
Private investments	2,712		106		—			2,818
Corporate bonds	3,718		6		(25		)	3,699
	$	109,715	$	2,523	$	(298	)	$	111,940
June 30, 2016
Money market funds	$	14,654	$	—	$	—		$	14,654
Municipal bonds	83,100		3,432		(143		)	86,389
Mutual funds	54		—		—			54
Private Investments	1,982		203		—			2,185
Corporate bonds	7,974		134		—			8,108
	$	107,764	$	3,769	$	(143	)	$	111,390

At December 31, 2015 and June 30, 2016, the amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by contractual maturities were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Due in less than one year	$	24,099	$	35	$	(54	)	$	24,080
Due after one year through five years	57,537		1,647		(79		)	59,105
Due after five years through ten years	23,389		674		(56		)	24,007
Due after ten years	1,914		61		(109		)	1,866
Total	$	106,939	$	2,417	$	(298	)	$	109,058
June 30, 2016
Due in less than one year	$	24,816	$	122	$	(17	)	$	24,921
Due after one year through five years	58,911		2,235		(25		)	61,121
Due after five years through ten years	20,001		1,204		—			21,205
Due after ten years	2,000		5		(101		)	1,904
Total	$	105,728	$	3,566	$	(143	)	$	109,151

A summary of the Company’s temporarily impaired available-for-sale investment securities as of December 31, 2015 and June 30, 2016 follows (in thousands):

	Impaired Less Than 12 Months						Impaired Over 12 Months					Total
	Fair Value		Unrealized Losses				Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
December 31, 2015
Municipal bonds	$	13,189	$	(103	)		$	2,575	$	(170	)	$	15,764	$	(273	)
Corporate bonds	3,120		(25		)		—		—			3,120		(25		)
Total investment	$	16,309	$	(128	)		$	2,575	$	(170	)	$	18,884	$	(298	)
June 30, 2016
Municipal bonds	$	2,405	$	(30	)		$	2,782	$	(113	)	$	5,187	$	(143	)
Corporate bonds	1,048		—			(a)	—		—			1,048		—
Total investment	$	3,453	$	(30	)		$	2,782	$	(113	)	$	6,235	$	(143	)

(a) Unrealized loss is less than $1,000.

The unrealized losses resulted from changes in market interest rates, not from changes in the probability of contractual cash flows. Because the Company has the ability and intent to hold the investments until a recovery of carrying value and full collection of the amounts due according to the contractual terms of the investments is expected, the Company does not consider these investments to be other-than-temporarily impaired at June 30, 2016.

During the six months ended June 30, 2016, the Company recorded a gain of approximately $0.4 million on the sale of specifically identified investments.

As of December 31, 2015 and June 30, 2016, the investments related to the participant directed supplemental employee retirement plan totaled $45.9 million and $52.2 million, respectively, and are included in other assets in the accompanying consolidated balance sheets. The net trading gains on those investments for the six months ended June 30, 2015 and June 30, 2016 that were still held by the Company as of June 30, 2015 and June 30, 2016 are as follows (in thousands):

	2015		2016
Net gains (losses) recognized during the six months ended June 30, 2015 and 2016, respectively on trading securities	$	1,066	$	(530	)
Less: Net gains (losses) recognized during the period on trading securities sold during the six months ended June 30, 2015 and 2016, respectively	20		(207		)
Unrealized gains (losses) recognized on trading securities still held at June 30, 2015 and 2016, respectively	$	1,046	$	(323	)

XML

Net Revenue

6 Months Ended

Jun. 30, 2016

Revenue, Net [Abstract]

Net Revenue

Net Revenues

Net revenues consists of fee for service revenue, contract revenue and other revenue. The Company’s net revenues are principally derived from the provision of healthcare staffing services to patients within healthcare facilities and is recorded in the period the services are rendered. Under the fee for service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payors. Fee for service revenue reflects gross fee for service charges less contractual allowances and policy discounts, where applicable. Contractual adjustments represent the Company’s estimate of discounts and other adjustments to be recognized from gross fee for service charges under contractual payment arrangements, primarily with commercial, managed care and governmental payment plans such as Medicare and Medicaid when the Company’s providers participate in such plans. Contractual adjustments are not reflected in self-pay fee for service revenue. Contract revenue represents revenue generated under contracts in which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates, monthly contractual rates, or certain operational or financial metrics. Revenue in such cases is recognized as the hours are worked by the Company’s affiliated staff and contractors or as metrics are realized. Other revenue consists primarily of revenue from management and billing services provided to outside parties. Revenue is recognized for such services pursuant to the terms of the contracts with customers. The Company also records a provision for uncollectible accounts based primarily on historical collection experience to record accounts receivables at the estimated amounts expected to be collected.

Net revenues consisted of the following (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2015					2016					2015					2016
Medicare	$	178,168		20.3	%	$	339,092		30.2	%	$	346,927		20.2	%	$	687,863		30.5	%
Medicaid	157,601			18.0		202,918			18.1		310,136			18.0		399,810			17.7
Commercial and managed care	448,043			51.0		526,954			46.9		860,000			50.0		1,060,089			46.9
Self-pay	464,089			52.9		505,687			45.0		908,342			52.9		1,014,549			44.9
Other	19,921			2.3		23,147			2.1		40,202			2.3		46,961			2.1
Unbilled	5,523			0.6		(6,695		)	(0.6	)	13,609			0.8		2,583			0.1
Net fee for service revenue before provision for uncollectibles	1,273,345			145.0		1,591,103			141.7		2,479,216			144.3		3,211,855			142.3
Contract revenue before provision for uncollectibles	183,727			20.9		206,117			18.4		367,367			21.4		406,945			18.0
Other	9,912			1.2		18,684			1.7		18,690			1.0		36,635			1.6
Net revenues before provision for uncollectibles	1,466,984			167.1		1,815,904			161.8		2,865,273			166.7		3,655,435			161.9
Provision for uncollectibles	(589,029		)	(67.1	)	(693,328		)	(61.8	)	(1,146,834		)	(66.7	)	(1,397,218		)	(61.9	)
Net revenues	$	877,955		100.0	%	$	1,122,576		100.0	%	$	1,718,439		100.0	%	$	2,258,217		100.0	%

The Company employs several methodologies for determining its allowance for uncollectibles depending on the nature of the net revenues before provision for uncollectibles recognized. The Company initially determines gross revenue for its fee for service patient visits based upon established fee schedule prices. Such gross revenue is reduced for estimated contractual allowances for those patient visits covered by contractual insurance arrangements to result in estimated net revenues before provision for uncollectibles. Net revenues before provision for uncollectibles is then reduced for management’s estimate of uncollectible amounts. Fee for service net revenues represents estimated cash to be collected from such patient visits and is net of management’s estimate of account balances estimated to be uncollectible. The provision for uncollectible fee for service patient visits is based on historical experience resulting from approximately twenty-three million fee for service patient visits and procedures over the last twelve months. The significant volume of patient visits and the terms of thousands of commercial and managed care contracts and the various reimbursement policies relating to governmental healthcare programs do not make it feasible to evaluate fee for service accounts receivable on a specific account basis. Fee for service accounts receivable collection estimates are reviewed on a quarterly basis for each fee for service contract by period of accounts receivable origination. Such reviews include the use of historical cash collection percentages by contract adjusted for the lapse of time since the date of the patient visit. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectibility of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. Contract-related net revenues are billed based on the terms of the contract at amounts expected to be collected. Such billings are typically submitted on a monthly basis and aged trial balances are prepared. Allowances for estimated uncollectible amounts related to such contract billings are made based upon periodic reviews of specific accounts and invoices once it is concluded that such amounts are not likely to be collected. Approximately 98% of the Company’s allowance for doubtful accounts is related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is centered in self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. While the Company does not specifically allocate the allowance for doubtful accounts to individual accounts or specific payor classifications, the portion of the allowance, excluding IPC, associated with fee for service charges as of June 30, 2016 was equal to approximately 93% of outstanding self-pay fee for service patient accounts. The methodologies employed to compute allowances for doubtful accounts were unchanged between 2015 and 2016.

XML

Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill during the year ended December 31, 2015 and the six months ended June 30, 2016 were as follows (in thousands):

Goodwill	$	869,038
Accumulated impairment loss	(144,579		)
Additions through acquisitions	1,703,343
Balance, December 31, 2015	$	2,427,802
Goodwill	$	2,572,381
Accumulated impairment loss	(144,579		)
Increases from prior year acquisition purchase price allocation adjustments	3,453
Additions through current year acquisitions	16,601
Balance, June 30, 2016	$	2,447,856

The following is a summary of intangible assets and related amortization as of December 31, 2015 and June 30, 2016 (in thousands):

	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2015:
Contracts	$	494,569	$	(170,873	)
Other	21,716		(9,775		)
Total	$	516,285	$	(180,648	)
As of June 30, 2016:
Contracts	$	519,151	$	(211,829	)
Other	33,636		(15,674		)
Total	$	552,787	$	(227,503	)
Aggregate amortization expense:
For the six months ended June 30, 2016			$	47,653
Estimated amortization expense:
For the remainder of the year ended December 31, 2016			$	46,379
For the year ended December 31, 2017			88,051
For the year ended December 31, 2018			72,357
For the year ended December 31, 2019			63,326
For the year ended December 31, 2020			43,495
For the years ended December 31, 2021 and thereafter			11,676
Total			$	325,284

Intangible assets are amortized over their estimated life, which is approximately one to eight years. As of June 30, 2016, the weighted average remaining amortization period for intangible assets was 3.4 years.

XML

Long-Term Debt

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Long-Term Debt

Long-Term Debt

Long-term debt as of June 30, 2016 consisted of the following (in thousands):

Tranche A Term Loan Facility	$	562,500
Tranche B Term Loan Facility	1,308,720
7.25% Senior Notes due 2023	545,000
Revolving Credit Facility	7,500
Total outstanding debt	2,423,720
Debt issuance costs	(50,252		)
	2,373,468
Less current portion	(61,870		)
	$	2,311,598

The Company's senior secured credit facilities (Credit Facility) consist of a $600.0 million tranche A term loan facility (Tranche A Term Loan Facility), a $1.31 billion tranche B term loan facility (Tranche B Term Loan Facility) and a $650.0 million revolving credit facility (Revolving Credit Facility). The Tranche A Term Loan and Revolving Credit Facility have a maturity date of October 2, 2019. The Tranche B Term Loan Facility has a maturity date of November 23, 2022. The maturity dates under the Credit Facility are subject to extension with lender consent according to the terms of the senior credit agreement (the Senior Credit Agreement).

The interest rate on any outstanding Revolving Credit Facility borrowings and Tranche A Term Loan Facility borrowings, and the commitment fee applicable to undrawn revolving commitments, is priced off a grid based upon the Company’s first lien net leverage ratio and is currently LIBOR + 2.00% in the case of revolving credit borrowings under the Revolving Credit Facility and Tranche A Term Loan Facility and 0.35% in the case of unused revolving commitments. The weighted average interest rate for the six months ended June 30, 2016 was 2.81% for amounts outstanding under the Tranche A Term Loan Facility.

On June 2, 2016, the Company amended its Senior Credit Agreement (the Amendment) to reduce the interest rate applicable to any outstanding Tranche B Term Loans from LIBOR plus 3.75% to LIBOR plus 3.00%. The Company effected this reduction in pricing through a refinancing of the existing Tranche B Term Loan Facility. The Amendment also requires the Company to pay a 1.0% prepayment penalty on any amount prepaid if the Tranche B Term Loan Facility is repriced in order to effect a reduction in pricing prior to December 2, 2016. Other significant terms and conditions of the Senior Credit Agreement, including the maturity date of November 23, 2022 and the LIBOR floor of 0.75%, did not change under the amendment.

The Company had $7.5 million borrowings outstanding under the Revolving Credit Facility as of June 30, 2016, and the Company had $6.8 million of standby letters of credit outstanding against the Revolving Credit Facility commitment.

The Credit Facility agreement contains both affirmative and negative covenants, including limitations on the Company’s ability to incur additional indebtedness, sell material assets, retire, redeem or otherwise reacquire its capital stock, acquire the capital stock or assets of another business and pay dividends, and requires the Company to comply with a maximum total leverage ratio, tested quarterly. At June 30, 2016, the Company was in compliance with all of its covenants under the senior credit facility agreement. The Credit Facility is secured by substantially all of the Company’s U. S. subsidiaries’ assets.

Senior Notes and Indenture

On November 23, 2015, Team Health, Inc., a wholly-owned subsidiary of the Company (the Issuer), completed the private placement of $545.0 million aggregate principal amount of 7.25% Senior Notes due 2023 (the Notes). The Notes are senior unsecured obligations and are fully and unconditionally guaranteed on a senior unsecured basis by the Company and, subject to certain exceptions, each of its existing and future material domestic wholly-owned restricted subsidiaries, referred to, collectively, as “Guarantors.”

The Notes bear interest at 7.25% per annum and mature on December 15, 2023. Interest is payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2016, to holders of record at the close of business on June 1 or December 1, as the case may be, immediately preceding each such interest payment date.

Prior to December 15, 2018, the Issuer may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus accrued and unpaid interest to, but excluding, the redemption date, if any, plus the “make-whole” premium set forth in the indenture. On and after December 15, 2018, the Company may redeem the Notes, in whole or in part, at the redemption prices set forth in the indenture, plus accrued and unpaid interest to, but excluding, the redemption date. In addition, prior to December 15, 2018, the Company may also redeem up to 40% of the aggregate principal amount of the Notes at a redemption price equal to 107.25% of the aggregate principal amount thereof, in each case, using an amount not to exceed the net cash proceeds from certain equity offerings, plus accrued and unpaid interest to, but excluding, the redemption date.

The indenture governing the Notes due 2023 contains restrictive covenants that limit among other things, the ability of us and our restricted subsidiaries to incur or guarantee additional debt or issue disqualified stock or certain preferred stock; pay dividends and make other distributions on, or redeem or repurchase, capital stock; make certain investments; incur certain liens; enter into certain transactions with affiliates; merge or consolidate; enter into agreements that restrict the ability of certain restricted subsidiaries to make dividends or other payments to us or each of our existing and future material domestic wholly-owned restricted subsidiaries, referred to, collectively, as “Guarantors”; designate restricted subsidiaries as unrestricted subsidiaries; and transfer or sell certain assets. These covenants are subject to a number of important limitations and exceptions. The Indenture also contains customary events of default which would permit the holders of the Notes to declare those Notes to be immediately due and payable if not cured within applicable grace periods, including the failure to make timely payments on the Notes or other material indebtedness, the failure to satisfy covenants and specified events of bankruptcy and insolvency.

Aggregate annual maturities of long-term debt as of June 30, 2016 are as follows (in thousands):

2016	$	61,870
2017	69,370
2018	73,120
2019	418,120
2020 and thereafter	1,801,240

XML

Professional Liability Insurance

6 Months Ended

Jun. 30, 2016

Malpractice Insurance [Abstract]

Professional Liability Insurance

Professional Liability Insurance

The Company’s professional liability loss reserves included in other accrued liabilities and other non-current liabilities in the accompanying consolidated balance sheets consisted of the following (in thousands):

	December 31, 2015		June 30, 2016
Estimated losses under self-insured programs	$	245,070	$	257,751
Estimated losses under commercial insurance programs	126,751		139,713
	371,821		397,464
Less estimated payable within one year	105,028		104,578
	$	266,793	$	292,886

The changes to the Company’s estimated losses under self-insured programs as of June 30, 2016 were as follows (in thousands):

Balance, December 31, 2015	$	245,070
Reserves related to current period	37,049
Changes related to prior year reserves	14,284
Assumed liabilities	(1,812		)
Payments for current period reserves	(262		)
Payments for prior period reserves	(36,578		)
Balance, June 30, 2016	$	257,751

The Company provides for its estimated professional liability losses through a combination of self-insurance and commercial insurance programs. Losses under commercial insurance programs in excess of the limit of coverage remain as a self-insured obligation of the Company. A portion of the professional liability loss risks that have been provided for through self-insurance (claims-made basis) are transferred to and funded into captive insurance companies. The accounts of the captive insurance companies are fully consolidated with those of the other operations of the Company in the accompanying consolidated financial statements.

The self-insurance components of our risk management program include reserves for future claims incurred but not reported (IBNR). As of December 31, 2015, of the $245.1 million of estimated losses under self-insured programs, approximately $157.4 million represented an estimate of IBNR claims and expenses and additional loss development, with the remaining $87.7 million representing specific case reserves. Of the specific case reserves as of December 31, 2015, $3.0 million represented case reserves that had settled but not yet funded, and $84.7 million reflected unsettled case reserves.

As of June 30, 2016, of the $257.8 million of estimated losses under self-insurance programs, approximately $154.2 million represented an estimate of IBNR claims and expenses and additional loss development, with the remaining $103.6 million representing specific case reserves. Of the specific case reserves as of June 30, 2016, $2.5 million represented case reserves that had been settled but not yet funded, and $101.1 million reflected unsettled case reserves.

The Company’s provisions for losses under its self-insurance components are estimated using the results of periodic actuarial studies. Such actuarial studies include numerous underlying estimates and assumptions, including assumptions as to future claim losses, the severity and frequency of such projected losses, loss development factors and others. The Company’s provisions for losses under its self-insured components are subject to subsequent adjustment should future actuarial projected results for such periods indicate projected losses greater or less than previously projected.

During the first quarter of 2016, the Company reserved $14.3 million to settle two separate professional liability claims originating from prior years in excess of coverage limits, which was fully funded as of June 30, 2016. See Note 10 for more information regarding these settlements.

The Company’s most recent actuarial valuation was completed in April 2016. Based on the results of the actuarial study completed in April 2016, management determined no additional change was necessary in the consolidated reserves for professional liability losses during the first quarter of 2016 related to prior year loss estimates. The discount rate on professional liability reserves (including IPC as noted below) was 0.9% at June 30, 2016 compared to 1.6% at December 31, 2015.

IPC Professional Liability Reserves

IPC is fully insured on a claims-made basis up to policy limits through a third party malpractice insurance policy, which ends December 31 of each year. The Company has established reserves for this segment for claims incurred and reported and IBNR during the policy period. These reserves of $25.4 million as of June 30, 2016 and the timing of payment of such amounts are estimated based upon actuarial loss projections, which are updated semi-annually, and discounted using the current weighted average Treasury rate over a 10 year period.

XML

Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Contingencies

Contingencies

Litigation

The Company is currently a party to various legal proceedings arising in the ordinary course of business. The legal proceedings the Company is involved in from time to time include lawsuits, claims, audits and investigations, including those arising out of services provided, personal injury claims, professional liability claims, the Company's billing, collection and marketing practices, employment disputes and contractual claims, and seek monetary and other relief, including statutory damages and penalties. While the Company currently believes that the ultimate outcome of such proceedings, individually and in the aggregate, will not have a material adverse effect on the Company's financial position or overall trends in results of operations, litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact on the Company's net earnings in the period in which the ruling occurs. The estimate of the potential impact from such legal proceedings on the Company's financial position or overall results of operations could change in the future.

On August 14, 2015, prior to the closing of the IPC Transaction, a purported shareholder of IPC filed a complaint in the Delaware Court of Chancery captioned Smukler v. IPC Healthcare, Inc., et al. (Case No. 11392-CB), on behalf of a purported class of  IPC shareholders. The lawsuit names as defendants IPC, each of its directors at the time the merger with the Company was announced (the Individual Defendants), the Company, and Intrepid Merger Sub, Inc. (Sub). The August 14, 2015 complaint alleged that the Individual Defendants breached their fiduciary duties by, among other things, failing to take appropriate steps to maximize the value of IPC to its shareholders, failing to value IPC properly, and taking steps to avoid competitive bidding by alternate potential acquirers. The complaint also alleged that IPC, the Company, and Sub aided and abetted those alleged breaches of fiduciary duties by the Individual Defendants. The complaint sought, among other things, certification of the action as a class action; injunctive relief enjoining the merger; an accounting of all damages purportedly suffered by the plaintiff and the class (including rescissory damages in favor of the plaintiff and the class); and the fees and costs associated with the litigation. On August 18, 2015, an additional lawsuit, Crescente v. Singer, et al. (Case No. 11405-CB), was filed in the Delaware Court of Chancery, asserting similar claims and allegations to those in the Smukler lawsuit and seeking similar relief on behalf of the same putative class.

Additionally, on August 19, 2015, prior to the closing of the IPC Transaction, a lawsuit was filed in the Superior Court for the State of California in Los Angeles County, Khemthong v. IPC Healthcare Networks, Inc., et al. (No. BC 591953). The lawsuit asserted similar claims and allegations to those in the Smukler lawsuit and sought similar relief on behalf of the same putative class. On August 27, 2015, the plaintiff filed a request for voluntary dismissal of the suit without prejudice, and on August 28, 2015, the court entered an order granting that request.

 Pursuant to a September 11, 2015 order from the Delaware Court of Chancery (the Consolidation Order), the Smukler and Crescente actions were consolidated, and all further litigation relating to or arising out of the Company’s merger with IPC were directed to be consolidated with such actions under the caption In re IPC Healthcare, Inc. Stockholders Litigation (Case No. 11392-CB) (the Consolidated Action).  On September 17, 2015, an action captioned Spencer v. IPC Healthcare, Inc. (Case. No. 11516-CB) was filed in the Delaware Court of Chancery. Under the Consolidation Order, such action is required to be consolidated with the previously-filed actions. On September 18, 2015, a verified consolidated class action complaint was filed in the Consolidated Action (the Consolidated Complaint).  The Consolidated Complaint alleges substantially the same breaches of fiduciary duty as the August 14, 2015 complaint in the Smukler action, and additionally alleges that the Individual Defendants breached their duty of disclosure by failing to disclose to IPC shareholders all material information necessary for them to evaluate the merger. On October 2, 2015, the defendants in the Consolidated Action moved to dismiss the Consolidated Complaint.

On November 6, 2015, the Company and the other defendants in the Consolidated Action entered into a Memorandum of Understanding with the plaintiffs in the Consolidated Action providing for the settlement and the release of all claims that were or could have been brought against the Company and the other defendants in the Consolidated Action based upon a duty arising under Delaware law to disclose or not omit material information in connection with the IPC Transaction, upon entry of a final order by the Delaware Court of Chancery approving the settlement. The Memorandum of Understanding contemplated that, subject to completion of certain confirmatory discovery by counsel to the plaintiffs, the parties would enter into a stipulation of settlement.

Following a series of rulings by the Court of Chancery in other lawsuits challenging mergers, the Company and the other defendants in the Consolidated Action agreed with the plaintiffs that the Memorandum of Understanding would be superseded and replaced by the voluntary dismissal of the Consolidated Action on the basis that it was mooted by the disclosures contained in the Current Report on the Form 8-K that the Company filed with the SEC on November 6, 2015. On April 12, 2016, the Court entered an order granting plaintiffs’ request to voluntarily dismiss the Consolidated Action as moot and setting a briefing schedule for plaintiffs to make an application to the Court for the payment of their attorneys’ fees and expenses. Plaintiffs filed their application for an award of fees and expenses, in the total amount of $350,000 on May 19, 2016. The Company filed its opposition to such application on June 30, 2016 and on July 14, 2016, plaintiffs filed their reply papers.

On November 13, 2015 the U.S. District Court for the Eastern District of Wisconsin ordered the unsealing and service of a qui tam complaint, filed on March 27, 2014, and captioned United States of America, ex rel. John Mamalakis, M.D., the States of California, Colorado, Delaware, Florida, Georgia, Hawaii, Iowa, Maryland, Michigan, Nevada, New Jersey, North Carolina, Oklahoma, Tennessee, Texas, Wisconsin and the District of Columbia v. Anesthetix Management, LLC, d/b/a Anesthetix of TeamHealth, Team Health Holdings, Inc., Sonya Pease, M.D., John Ippolito, M.D., Edward Lee, M.D., Howard Stroup, M.D., Sammy Dean, M.D., and Jacqueline Peters, M.D. (Defendents) (Case No. 2:14cv00349-CNC). On June 11, 2014, the United States gave notice of its intention, and the intention of all of the other states and the District of Columbia, not to intervene in the lawsuit. On March 10, 2016, Team Health Holdings, Inc. was served with the complaint. The complaint alleges that the defendants submitted false claims to federal and state health insurance programs for “medical direction” of anesthesia services (rather than “medical supervision”) that were provided at Wheaton Franciscan Hospital-All Saints Hospital (All Saints) in Racine, Wisconsin, as well as numerous other non-identified hospitals and clinics from 2010 to the present. Plaintiff also claims retaliatory termination, alleging that he was terminated from his employment for voicing his concerns about the anesthesia services. Plaintiff seeks recovery of all Medicare and Medicaid reimbursement that the defendants received as a result of the allegedly false claims and treble damages under the False Claims Act, as well as a civil penalty for each such false Medicare and Medicaid claim. On April 15, 2016, plaintiff amended his complaint, removing all of the individual defendants as well as the claims filed on behalf of Delaware, Georgia, Hawaii, Iowa, Maryland, Nevada, North Carolina, Oklahoma, Tennessee and Texas. On May 2, 2016, Defendants filed a motion to dismiss the entirety of the complaint pursuant to Federal Rules of Civil Procedure 9(b) and 12(b)(6), or in the alternative, to compel arbitration of the retaliatory discharge claim. On July 1, 2016, Relator filed his opposition to the motion. Defendants filed their reply in support of the motion on July 18, 2016. The Company intends to vigorously defend against the allegations in this matter. The Company does not believe that the final outcome of this matter will be material.

In August 2011, a medical malpractice suit was filed against three of the Company’s affiliates and one of its physicians along with other co-defendants, including a hospital in the Superior Court of New Jersey, Camden County, alleging a failure to diagnose sepsis in 2010. In July 2012, a medical malpractice suit was filed in the Court of Common Pleas, Luzerne, Pennsylvania against one Company affiliate and one of its physicians and a co-defendant hospital, alleging a failure to diagnose a stroke in 2010. In March 2016, both cases resulted in settlements in excess of insurance coverage limits where the Company was required to fund a total of $14.3 million, which represents our contribution to the overall settlements that includes the other defendants. As of June 30, 2016, these settlements have been fully funded.

It is not possible to predict when the above matters may be resolved, the time or resources that the Company will need to devote to the matters, or what impact, if any, the outcome of the matters might have on the Company's business, consolidated financial position, results of operations, or cash flows.

Healthcare Regulatory Matters

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action. From time to time, governmental regulatory agencies will conduct inquiries and audits of the Company’s practices. It is the Company’s current practice and future intent to cooperate fully with such inquiries.

In addition to laws and regulations governing the Medicare and Medicaid programs, there are a number of federal and state laws and regulations governing such matters as the corporate practice of medicine and fee splitting arrangements, anti-kickback statutes, physician self-referral laws, false or fraudulent claims filing and patient privacy requirements. The failure to comply with any of such laws or regulations could have an adverse impact on the Company's operations and financial results. It is management’s belief that the Company is in substantial compliance in all material respects with such laws and regulations.

Government Claim

On June 7, 2010, the Company's subsidiary, IPC, received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that IPC had submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to IPC’s Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. IPC produced responsive documents and was in contact with representatives of the DOJ who informed IPC that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). The case is captioned United States ex rel. Oughatiyan v. IPC The Hospitalist Company, Inc. (Civ. No. 09-C-5418). IPC also was informed that several state attorneys general were examining its Medicaid claims in coordination with the DOJ.

On December 5, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket at that time included the whistleblower’s Complaint which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under common law theories of payment by mistake and unjust enrichment. On August 13, 2014, the Company's subsidiary, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC Healthcare, Inc., which remains the sole defendant in the lawsuit. The parties are engaged in negotiations to attempt to resolve the matter, but if a reasonable settlement cannot be reached, the Company intends to continue vigorously contesting the case.

Florida Medicaid Reimbursement Suspension

The Company's subsidiary, IPC, received notice on August 7, 2015 that the Florida Agency for Health Care Administration (AHCA) temporarily suspended Medicaid fee-for-service and Medicaid managed care payments to IPC’s Florida affiliate, InPatient Consultants of Florida, Inc. d/b/a IPC of Florida, because IPC of Florida is “under investigation by a state or federal agency.” Since receiving this notice, and based on its failure to contain the required specificity under the applicable federal regulation, IPC has sought additional information from AHCA regarding the basis of the payment suspension, including through repeated discussions with the responsible AHCA officials; by submitting a request for documents through the Florida Public Records Law (PRL) on August 27, 2015; and by filing a petition for formal administrative review on September 4, 2015.

Following these actions, IPC received a revised letter on September 9, 2015 in which AHCA clarified that the investigation causing the payment suspension concerns IPC of Florida’s alleged “up-coding” and “billing for the highest level of inpatient hospital care, which may not be medically necessary.” Since receipt of this revised notice, which still failed to contain the required specificity, IPC has continued to engage with AHCA to obtain information that would enable IPC to rebut the basis for the payment suspension. These efforts have included submitting a second PRL request on September 18, 2015 and submitting a letter to AHCA providing information to support a determination by AHCA that it has “good cause” to discontinue the payment suspension, consistent with the applicable federal regulation. On October 23, 2015, IPC received an order dismissing IPC’s petition for formal administrative review on the grounds that there is no final agency action and because the suspension is a contract action not appropriate for an administrative hearing. The Company is continuing its discussions with AHCA officials in an effort to resolve this matter.

It is not possible to predict when any of the above matters may be resolved, the time or resources that the Company will need to devote to the matters, or what impact, if any, the outcome of any of the matters might have on the Company's business, consolidated financial position, results of operations, or cash flows.

XML

Share-based Compensation

6 Months Ended

Jun. 30, 2016

Share-based Compensation [Abstract]

Share-based Compensation

Equity-based Compensation

Equity Incentive Plans

In May 2013, the Company's shareholders approved the Team Health Holdings, Inc. Amended and Restated 2009 Stock Incentive Plan (the Stock Plan) that amended the 2009 Stock Incentive Plan.

In connection with the acquisition of IPC, the IPC replacement awards were issued based on a conversion ratio of the IPC common share value to Team Health weighted average share price immediately prior to the closing. The Company assumed and restated the Amended and Restated Team Health Holdings, Inc. 1997 Equity Participation Plan, the Amended and Restated 2002 Equity Participation Plan of Team Health Holdings, Inc., the Amended and Restated Team Health Holdings, Inc. 2007 Equity Participation Plan, and the Amended and Restated Team Health Holdings, Inc. 2012 Equity Participation Plan (collectively the IPC Plans) for the sole purpose of completing the exchange of equity awards. There will be no further issuances under these plans.

Purpose. The purpose of the Stock Plan is to aid in recruiting and retaining key employees, directors, consultants, and other service providers of outstanding ability and to motivate those employees, directors, consultants, and other service providers to exert their best efforts on behalf of the Company and its affiliates by providing incentives through the granting of options, stock appreciation rights and other stock-based awards.

Shares Subject to the Plan. The Stock Plan provides that the total number of shares of common stock that may be issued is 15,100,000, of which approximately 1,502,000 are available to grant as of June 30, 2016. Shares of the Company’s common stock covered by awards that terminate or lapse without the payment of consideration may be granted again under the Stock Plan.

The following table summarizes the status of options under the Stock Plan as of June 30, 2016:

	Shares (in thousands)		Weighted Average Exercise Price		Aggregate Intrinsic Value (in thousands)		Weighted Average Remaining Life in Years
Outstanding at beginning of year	4,780		$	28.07	$	86,342	5.3
Granted	301		42.70
Exercised	(780	)	19.93		15,547
Expired or forfeited	(69	)	34.80
Outstanding at end of period	4,232		$	30.50	$	57,223	5.2
Exercisable at end of period	3,190		$	24.10	$	56,917	4.7

Intrinsic value is the amount by which the stock price as of June 30, 2016 exceeds the exercise price of the options. The Company granted approximately 301,000 options during the six months ended June 30, 2016. The fair value of the options granted in 2016 was based on the grant date fair value as calculated by the Black-Scholes option pricing formula with the following assumptions: risk-free interest rate of 1.5%, implied volatility of 35.5% and an expected life of the options of 5 years. The expected life is the mid-point between the vesting date and the end of the contractual term. The Company uses this simplified method, as described in ASC 718, due to changes in option grant contractual terms causing insufficient historical exercise data. The Company will continue to evaluate the use of the simplified method as historical exercise data becomes more sufficient. The estimated fair value of options granted during 2016 was $14.26. As of June 30, 2016, the Company had approximately $13.5 million of unrecognized compensation expense, net of estimated forfeitures related to unvested options, which will be recognized over the remaining requisite service period.

Restricted awards are grants of restricted stock, restricted stock units and performance stock units that are not vested (Restricted Awards). The Company granted approximately 547,000 shares of Restricted Awards in 2016. The Company had $36.3 million of expense remaining to be recognized over the requisite service period for Restricted Awards at June 30, 2016. The Restricted Awards generally vest annually over a three to four-year period from the initial grant date for the grants made to the independent board members and management. The performance stock units vest at the end of three years from the initial grant date. The actual number of performance stock units to be awarded will be based on the achievement of certain predetermined financial and operational performance targets during the initial two year period starting in the year of the grant. The related expense will be tracked and adjusted as appropriate to reflect the actual shares issued.

A summary of changes in total outstanding unvested restricted awards for the six months ended June 30, 2016 is as follows (in thousands):

	Restricted Stock		Restricted Units		Performance Units	Total
Outstanding at beginning of year	100		766		—	866
Granted	—		403		144	547
Vested	(52	)	(224	)	—	(276	)
Forfeited and expired	(3	)	(34	)	—	(37	)
Outstanding at June 30, 2016	45		911		144	1,100

Stock Purchase Plans

In May 2010, the Company’s Board of Directors (the Board) adopted the 2010 Employee Stock Purchase Plan (ESPP) and the 2010 Nonqualified Stock Purchase Plan (NQSPP).

The ESPP provides for the issuance of up to 600,000 shares to the Company’s employees. All eligible employees are granted identical rights to purchase common stock in each Board authorized offering under the ESPP. Rights granted pursuant to any offering under the ESPP terminate immediately upon cessation of an employee’s employment for any reason. In general, an employee may reduce his or her contribution or withdraw from participation in an offering at any time during the purchase period for such offering. Employees receive a 5% discount on shares purchased under the ESPP. Rights granted under the plan are not transferable and may be exercised only by the person to whom such rights are granted. Offerings occur every six months in April and October. As of June 30, 2016, contributions under the ESPP totaled $1.4 million. In April 2016, approximately 86,000 shares of the Company’s common stock were issued to plan participants.

The NQSPP provides for the issuance of up to 800,000 shares to our independent contractors. All eligible contractors are granted identical rights to purchase common stock in each Board authorized offering under the NQSPP. Rights granted pursuant to any offering under the NQSPP terminate immediately upon cessation of a contractor’s relationship with the Company for any reason. In general, a contractor may reduce his or her contribution or withdraw from participation in an offering at any time during the purchase period for such offering. Contractors receive a 5% discount on shares purchased under the NQSPP. Rights granted under the NQSPP are not transferable and may be exercised only by the person to whom such rights are granted. Offerings occur every six months in April and October. As of June 30, 2016, contributions under the NQSPP totaled $0.6 million. In April 2016, approximately 39,000 shares of the Company’s common stock were issued to plan participants.

Equity Based Compensation Expense

Equity based compensation expense and the resulting tax benefits were as follows (in thousands):

	Six Months Ended June 30,
	2015		2016
Stock options	$	5,166	$	3,844
Restricted awards	3,985		10,448
Stock purchase plan	62		82
Total equity based compensation expense	$	9,213	$	14,374
Tax benefit of equity based compensation expense	$	3,547	$	5,498

XML

Earnings Per Share

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

The Company computes basic earnings per share using the weighted average number of shares outstanding. The Company computes diluted earnings per share using the weighted average number of shares outstanding plus the dilutive effect of outstanding stock options, restricted awards, and stock purchase plans. The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
Net earnings attributable to Team Health Holdings, Inc. (numerator for basic and diluted earnings per share)	$	28,935	$	18,785	$	56,989	$	19,453
Denominator:
Weighted average shares outstanding	71,956		73,958		71,666		73,650
Effect of dilutive securities:
Stock options	1,374		1,050		1,220		1,058
Restricted awards	270		224		249		419
Stock purchase plans	2		2		2		2
Shares used for diluted earnings per share	73,602		75,234		73,137		75,129
Basic net earnings per share of Team Health Holdings, Inc.	$	0.40	$	0.25	$	0.80	$	0.26
Diluted net earnings per share of Team Health Holdings, Inc.	$	0.39	$	0.25	$	0.78	$	0.26
Securities excluded from diluted earnings per share of Team Health Holdings, Inc. because they were antidilutive:
Stock options	240		1,285		606		1,590
Restricted awards	—		260		—		270

XML

Noncontrolling Interests in Consolidated Entity

6 Months Ended

Jun. 30, 2016

Noncontrolling Interest [Abstract]

Noncontrolling Interest Disclosure

Noncontrolling Interests in Consolidated Entity

The Company is party to two joint venture arrangements. The joint ventures provide administrative management and billing services to certain existing and planned urgent care clinics the Company and joint venture partners operate. The consolidated financial statements include all assets, liabilities, revenues and expenses of the less than 100% owned entity that the Company controls. Accordingly, the Company has recorded noncontrolling interests in the earnings and equity of this entity. In connection with these arrangements, the Company received joint venture contributions of $1.4 million during the six months ended June 30, 2016.

XML

Transaction, Integration and Reorganization Costs

6 Months Ended

Jun. 30, 2016

Transaction, integration, and reorganization costs [Abstract]

Transaction, integration and reorganization costs

Transaction, Integration and Reorganization Costs

For the six months ended June 30, 2016, the Company recognized certain transaction, integration, and reorganization costs in the amount of $27.5 million. These expenses include IPC severance and integration costs of $12.7 million, $9.2 million of professional, advisory, and legal costs associated with the activities of (i) the Board's special advisory committee (which is responsible for reviewing and evaluating possible strategic alternatives available to the Company) and (ii) the JANA agreement, $4.9 million of severance and lease impairment costs associated with a reorganization of the Company's legacy operations, and $0.7 million of legacy transaction costs.

XML

Accumulated Other Comprehensive Income

6 Months Ended

Jun. 30, 2016

Statement of Comprehensive Income [Abstract]

Accumulated Other Comprehensive Earnings (Loss)

Accumulated Other Comprehensive Earnings

The changes in accumulated other comprehensive earnings related to available-for-sale securities were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Balance at beginning of period	$	1,668		$	1,786		$	1,695		$	1,503
Other comprehensive (loss) earnings:
Net unrealized (loss) gain	(896		)	979			(887		)	1,789
Tax benefit (expense)	340			(338		)	337			(492		)
Total other comprehensive (loss) earnings before reclassifications, net of tax	(556		)	641			(550		)	1,297
Net amount reclassified to earnings(1)	(17		)	(13		)	(50		)	(386		)
Tax benefit (expense)(2)	—			—			—			—
Total amount reclassified from accumulated other comprehensive earnings, net of tax(3)	(17		)	(13		)	(50		)	(386		)
Total other comprehensive (loss) earnings	(573		)	628			(600		)	911
Balance at end of period	$	1,095		$	2,414		$	1,095		$	2,414

(1) This amount was included in Other (income) expenses, net on the accompanying Consolidated Statement of Comprehensive Earnings.

(2) These amounts were included in Provision for income taxes on the accompanying Consolidated Statement of Comprehensive Earnings.

(3) A positive amount indicates a corresponding charge to earnings and a negative amount indicates a corresponding benefit to earnings.

XML

Segment Reporting

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

During the fourth quarter of 2015, the Company completed certain changes to its management reporting structure to better align its businesses with the Company objectives and operating strategies. These changes resulted in changes among the Company's previously reported operating and reportable segments. The second quarter 2015 segment results have been reclassified to conform to the current year reporting of these businesses. The Company determined, in accordance with segment reporting guidance, that it provides services through eight operating segments which are aggregated into four reportable segments: Hospital Based Services, IPC Healthcare, Specialty Services, and Other Services. The Hospital Based Services segment, which is an aggregation of emergency medicine, anesthesia, and the Company's legacy acute care services, provides comprehensive healthcare service programs to users of healthcare services on a fee for service as well as a cost plus or contract basis. The IPC Healthcare segment consists of the business acquired in connection with the IPC transaction and provides comprehensive acute hospital medicine and post-acute provider service programs to users of healthcare services. The Specialty Services segment, which is an aggregation of military and government healthcare staffing, clinical services, and nurse call center operations, provides comprehensive healthcare service programs to users of healthcare services in an outpatient setting or in a non-hospital based environment. The Other Services segment is an aggregation of locums staffing, scribes, and billing, collection and consulting services that provides a range of other comprehensive healthcare services. The operating segments included in the Specialty Services or Other Services reportable segments, while similar in the types of services provided by those operating segments included in the Hospital Based Services segment, do not meet the aggregation criteria prescribed by the segment reporting guidance nor do they meet the quantitative thresholds that would require a separate presentation.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies included in our annual report on Form 10-K for fiscal year 2015 filed with the SEC. Segment amounts disclosed are prior to any elimination entries made in consolidation, except in the case of net revenues, where intercompany charges have been eliminated. Certain corporate expenses are not allocated to the segments. These unallocated expenses are corporate expenses, net interest expense, depreciation and amortization, transaction costs and income taxes. The Company evaluates segment performance based on profit and loss before the aforementioned expenses.

The following table presents financial information for each reportable segment. Depreciation, amortization, management fee and other expenses separately identified in the consolidated statements of operations are included as a reduction to the respective segments’ operating earnings for each period below (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Net Revenues:
Hospital Based Services	$	806,584		$	865,564		$	1,575,075		$	1,737,712
IPC Healthcare	—			185,669			—			378,381
Specialty Services	45,857			44,803			101,688			70,910
Other Services	25,493			26,512			41,628			71,159
General Corporate	21			28			48			55
	$	877,955		$	1,122,576		$	1,718,439		$	2,258,217
Operating Earnings:
Hospital Based Services	$	76,585		$	75,170		$	146,612		$	126,923
IPC Healthcare	—			10,454			—			20,268
Specialty Services	6,385			5,653			11,884			10,924
Other Services	5,434			6,398			10,016			17,007
General Corporate	(33,765		)	(33,747		)	(60,689		)	(81,385		)
	$	54,639		$	63,928		$	107,823		$	93,737
Reconciliation of Operating Earnings to Net Earnings:
Operating earnings	$	54,639		$	63,928		$	107,823		$	93,737
Interest expense, net	4,571			30,437			8,560			61,730
Provision for income taxes	21,186			14,577			42,341			12,363
Net earnings	$	28,882		$	18,914		$	56,922		$	19,644

XML

(Policies)

6 Months Ended

Jun. 30, 2016

Accounting Changes and Error Corrections [Abstract]

New Accounting Pronouncements, Policy

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's consolidated financial position or results of operations.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which establishes a comprehensive revenue recognition standard for virtually all industries under U.S. GAAP. The standard is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein, with early adoption permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which will change how companies account for and present lease arrangements. The guidance requires companies to recognize leased assets and liabilities for both capital and operating leases. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods therein, and early adoption is permitted. Companies are required to adopt the guidance on a modified retrospective method. The Company is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting,” which requires companies to recognize the income tax effects of awards in the income statement when the awards vest or are settled (i.e., additional paid-in-capital pools will be eliminated). In addition, the new guidance changes the limit that companies are allowed to withhold for employees without triggering liability classification and allows companies to make a policy election to either recognize forfeitures as they occur or estimate them. The new guidance is  effective for annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods, and early adoption is permitted. The required transition methods for each aspect of the new guidance varies between prospective, retrospective and modified retrospective. The Company has not yet determined which method of adoption it will select and is in the process of evaluating the impact that adoption of this new accounting standard may have on the Company's consolidated financial statements.

The Company has implemented all new accounting pronouncements that are in effect and that could materially impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued, but are not yet effective, that might have a material impact on the consolidated financial statements of the Company unless otherwise noted in prior updates or above.

Business Combinations Policy

In accordance with ASC 805, the Company records its contingent consideration as a component of the opening balance sheet unless there is a continuing employment provision. Contingent consideration with a continuing employment provision is recognized ratably over the defined performance period as compensation expense which is included as a component of general and administrative expense (and parenthetically disclosed with other acquisition-related compensation expense) in the results of the Company’s operations. The payment of contingent purchase obligations is included as a component of financing, unless there is a continuing employment provision, in which case it is included as a component of operating cash flows.

Fair Value of Financial Instruments, Policy

The Company’s insurance subsidiaries' and other investments are valued using market prices on active markets (Level 1) and less active markets (Level 2), in addition to using alternative information when market data is not available (Level 3). Level 1 investment valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets. Level 2 investment valuations are obtained from readily available pricing sources for comparable investments or identical investments in less active markets. The fair values of the Company’s supplemental employee retirement investments are based on quoted prices. Level 3 investment valuations require significant management judgment and are based on transaction price, company performance, and market conditions.

The Company applies the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (ASC Topic 820), in determining the fair value of its financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements.

ASC Topic 820 prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1	Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2	Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;
Level 3	Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Revenue Recognition, Policy

Net revenues consists of fee for service revenue, contract revenue and other revenue. The Company’s net revenues are principally derived from the provision of healthcare staffing services to patients within healthcare facilities and is recorded in the period the services are rendered. Under the fee for service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payors. Fee for service revenue reflects gross fee for service charges less contractual allowances and policy discounts, where applicable. Contractual adjustments represent the Company’s estimate of discounts and other adjustments to be recognized from gross fee for service charges under contractual payment arrangements, primarily with commercial, managed care and governmental payment plans such as Medicare and Medicaid when the Company’s providers participate in such plans. Contractual adjustments are not reflected in self-pay fee for service revenue. Contract revenue represents revenue generated under contracts in which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates, monthly contractual rates, or certain operational or financial metrics. Revenue in such cases is recognized as the hours are worked by the Company’s affiliated staff and contractors or as metrics are realized. Other revenue consists primarily of revenue from management and billing services provided to outside parties. Revenue is recognized for such services pursuant to the terms of the contracts with customers. The Company also records a provision for uncollectible accounts based primarily on historical collection experience to record accounts receivables at the estimated amounts expected to be collected.

Trade and Other Accounts Receivable, Policy

The Company employs several methodologies for determining its allowance for uncollectibles depending on the nature of the net revenues before provision for uncollectibles recognized. The Company initially determines gross revenue for its fee for service patient visits based upon established fee schedule prices. Such gross revenue is reduced for estimated contractual allowances for those patient visits covered by contractual insurance arrangements to result in estimated net revenues before provision for uncollectibles. Net revenues before provision for uncollectibles is then reduced for management’s estimate of uncollectible amounts. Fee for service net revenues represents estimated cash to be collected from such patient visits and is net of management’s estimate of account balances estimated to be uncollectible. The provision for uncollectible fee for service patient visits is based on historical experience resulting from approximately twenty-three million fee for service patient visits and procedures over the last twelve months. The significant volume of patient visits and the terms of thousands of commercial and managed care contracts and the various reimbursement policies relating to governmental healthcare programs do not make it feasible to evaluate fee for service accounts receivable on a specific account basis. Fee for service accounts receivable collection estimates are reviewed on a quarterly basis for each fee for service contract by period of accounts receivable origination. Such reviews include the use of historical cash collection percentages by contract adjusted for the lapse of time since the date of the patient visit. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectibility of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. Contract-related net revenues are billed based on the terms of the contract at amounts expected to be collected. Such billings are typically submitted on a monthly basis and aged trial balances are prepared. Allowances for estimated uncollectible amounts related to such contract billings are made based upon periodic reviews of specific accounts and invoices once it is concluded that such amounts are not likely to be collected. Approximately 98% of the Company’s allowance for doubtful accounts is related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is centered in self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. While the Company does not specifically allocate the allowance for doubtful accounts to individual accounts or specific payor classifications, the portion of the allowance, excluding IPC, associated with fee for service charges as of June 30, 2016 was equal to approximately 93% of outstanding self-pay fee for service patient accounts. The methodologies employed to compute allowances for doubtful accounts were unchanged between 2015 and 2016.

Segment Reporting, Policy

The accounting policies of the segments are the same as those described in the summary of significant accounting policies included in our annual report on Form 10-K for fiscal year 2015 filed with the SEC. Segment amounts disclosed are prior to any elimination entries made in consolidation, except in the case of net revenues, where intercompany charges have been eliminated. Certain corporate expenses are not allocated to the segments. These unallocated expenses are corporate expenses, net interest expense, depreciation and amortization, transaction costs and income taxes. The Company evaluates segment performance based on profit and loss before the aforementioned expenses.

XML

Acquisitions and Contingent Purchase Obligations (Tables)

6 Months Ended

Jun. 30, 2016

Business Combinations [Abstract]

Purchase price allocation

The purchase price for these acquisitions was allocated, based on management’s estimates, in accordance with ASC Topic 805, “Business Combinations” (ASC 805). The Company’s purchase price allocation for business combinations completed during recent periods is preliminary and may be subject to revision as additional information about the fair value of acquired working capital becomes available. Additional information, which existed as of the acquisition date but at that time was unknown to the Company, may become known to the Company during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. The purchase price for these acquisitions completed during the six months ended June 30, 2016 was allocated as shown in the table below (in thousands):

	June 30, 2016
Accounts receivable	$	1,286
Prepaid expenses and other assets	3
Other intangibles (consisting of physician and hospital agreements)	15,600
Goodwill (of which $3.8 million is tax deductible)	16,601
Accounts payable	(41		)
Accrued compensation and physician payable	(291		)
Other accrued liabilities	(241		)
Net deferred income taxes	(2,987		)
Total purchase price	$	29,930

IPC Healthcare, Inc. (IPC) Acquisition

On November 23, 2015, the Company completed the acquisition of IPC in a cash transaction. At closing, the Company paid approximately $1.60 billion in cash to the former owners of IPC in exchange for all of the outstanding equity interests of IPC.

The accounting for the acquisition of IPC will be completed within the timeframe prescribed by the provisions of ASC 805. The Company continues to obtain information relative to the fair values of assets acquired and liabilities assumed. Acquired assets and assumed liabilities include, but are not limited to, accounts receivable, other intangible assets, current and noncurrent taxes payable, deferred taxes, contingent purchase liabilities, and other accrued liabilities. The valuations are based on appraisal reports or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed.

During 2016, factors became known that resulted in changes to the purchase price allocation of assets and liabilities, existing at the date of the IPC transaction. The estimated fair values of assets acquired and liabilities assumed, specifically accounts receivable, current and noncurrent taxes payable, deferred taxes, contingent purchase liability and other intangible assets, may be subject to change as additional information is received. The purchase price allocation adjustments for this acquisition are summarized as follows (in thousands):

	As of			Adjustments to			As of
	December 31, 2015			Purchase Price Allocation			June 30, 2016
Short term investments	$	1,985		$	—		$	1,985
Accounts receivable	127,265			(6,955		)	120,310
Prepaid expenses and other assets	6,347			(316		)	6,031
Receivables under insured programs	36,255			—			36,255
Property and equipment	10,541			216			10,757
Income tax receivable	12,528			—			12,528
Net deferred income taxes	64,301			(3,608		)	60,693
Other intangibles (consisting of marketing-related and technology-based intangibles and physician and hospital agreements)	4,975			21,700			26,675
Goodwill (of which the tax deductible amount was $368,283)	1,574,757			3,212			1,577,969
Accounts payable	(15,627		)	(33		)	(15,660		)
Accrued compensation and physician payable	(43,856		)	—			(43,856		)
Other accrued liabilities	(63,809		)	(13,260		)	(77,069		)
Contingent purchase liability	(30,639		)	(2,768		)	(33,407		)
Assumed notes payable	(148,249		)	—			(148,249		)
Other non-current liabilities	(61,894		)	1,812			(60,082		)
Total consideration paid, net of acquired cash and cash equivalents of $28,059	$	1,474,880		$	—		$	1,474,880

Accumulated contingent purchase expense liability

The changes to the Company’s accumulated contingent purchase liability for the six months ended June 30, 2016 are as follows (in thousands):

Contingent purchase liability at December 31, 2015	$	57,080
Payments	(9,501		)
Contingent purchase and other acquisition compensation expense recognized	18,851
Adjustments to contingent purchase liability recognized at acquisition date	2,781
Contingent purchase liability at June 30, 2016	$	69,211

Estimated unrecognized contingent purchase compensation expense

Estimated unrecognized contingent purchase compensation expense as of June 30, 2016 is as follows (in thousands):

For the remainder of the year ended December 31, 2016	$	16,409
For the year ended December 31, 2017	9,681
For the year ended December 31, 2018	3,635
For the year ended December 31, 2019	1,515
For the year ended December 31, 2020	625
	$	31,865

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

Summary of assets and liabilities measured at fair value on a recurring basis

The following table provides information on those assets and liabilities the Company currently measures at fair value on a recurring basis as of December 31, 2015 and June 30, 2016 (in thousands):

	Carrying Amount in Consolidated Balance Sheet December 31, 2015		Fair Value December 31, 2015		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	18,238	$	18,238	$	18,238	$	—	$	—
Municipal bonds	87,121		87,121		—		87,121		—
Mutual funds	64		64		—		64		—
Private investments	2,818		2,818		—		—		2,818
Corporate bonds	3,699		3,699		—		3,699		—
Total investments of insurance subsidiaries	$	111,940	$	111,940	$	18,238	$	90,884	$	2,818
Supplemental employee retirement plan investments:
Mutual funds	$	45,868	$	45,868	$	—	$	45,868	$	—

	Carrying Amount in Consolidated Balance Sheet June 30, 2016		Fair Value June 30, 2016		Fair Value Level 1		Fair Value Level 2		Fair Value Level 3
Insurance subsidiaries' and other investments:
Money market funds	$	14,654	$	14,654	$	14,654	$	—	$	—
Municipal bonds	86,389		86,389		—		86,389		—
Mutual funds	54		54		—		54		—
Private investments	2,185		2,185		—		—		2,185
Corporate bonds	8,108		8,108		—		8,108		—
Total investments of insurance subsidiaries	$	111,390	$	111,390	$	14,654	$	94,551	$	2,185
Supplemental employee retirement plan investments:
Mutual funds	$	52,237	$	52,237	$	—	$	52,237	$	—

XML

Investments (Tables)

6 Months Ended

Jun. 30, 2016

Investments [Abstract]

Summary of amortized cost basis and aggregate fair value of available-for-sale securities by investment type

At December 31, 2015 and June 30, 2016, amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by investment type were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Money market funds	$	18,238	$	—	$	—		$	18,238
Municipal bonds	84,983		2,411		(273		)	87,121
Mutual funds	64		—		—			64
Private investments	2,712		106		—			2,818
Corporate bonds	3,718		6		(25		)	3,699
	$	109,715	$	2,523	$	(298	)	$	111,940
June 30, 2016
Money market funds	$	14,654	$	—	$	—		$	14,654
Municipal bonds	83,100		3,432		(143		)	86,389
Mutual funds	54		—		—			54
Private Investments	1,982		203		—			2,185
Corporate bonds	7,974		134		—			8,108
	$	107,764	$	3,769	$	(143	)	$	111,390

Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities

At December 31, 2015 and June 30, 2016, the amortized cost basis and aggregate fair value of the Company’s available-for-sale securities by contractual maturities were as follows (in thousands):

	Cost Basis		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2015
Due in less than one year	$	24,099	$	35	$	(54	)	$	24,080
Due after one year through five years	57,537		1,647		(79		)	59,105
Due after five years through ten years	23,389		674		(56		)	24,007
Due after ten years	1,914		61		(109		)	1,866
Total	$	106,939	$	2,417	$	(298	)	$	109,058
June 30, 2016
Due in less than one year	$	24,816	$	122	$	(17	)	$	24,921
Due after one year through five years	58,911		2,235		(25		)	61,121
Due after five years through ten years	20,001		1,204		—			21,205
Due after ten years	2,000		5		(101		)	1,904
Total	$	105,728	$	3,566	$	(143	)	$	109,151

Summary of temporarily impaired available-for-sale investment securities

A summary of the Company’s temporarily impaired available-for-sale investment securities as of December 31, 2015 and June 30, 2016 follows (in thousands):

	Impaired Less Than 12 Months						Impaired Over 12 Months					Total
	Fair Value		Unrealized Losses				Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
December 31, 2015
Municipal bonds	$	13,189	$	(103	)		$	2,575	$	(170	)	$	15,764	$	(273	)
Corporate bonds	3,120		(25		)		—		—			3,120		(25		)
Total investment	$	16,309	$	(128	)		$	2,575	$	(170	)	$	18,884	$	(298	)
June 30, 2016
Municipal bonds	$	2,405	$	(30	)		$	2,782	$	(113	)	$	5,187	$	(143	)
Corporate bonds	1,048		—			(a)	—		—			1,048		—
Total investment	$	3,453	$	(30	)		$	2,782	$	(113	)	$	6,235	$	(143	)

(a) Unrealized loss is less than $1,000.

Summary of trading gains and losses on investments related to participant directed supplemental employee retirement plan

As of December 31, 2015 and June 30, 2016, the investments related to the participant directed supplemental employee retirement plan totaled $45.9 million and $52.2 million, respectively, and are included in other assets in the accompanying consolidated balance sheets. The net trading gains on those investments for the six months ended June 30, 2015 and June 30, 2016 that were still held by the Company as of June 30, 2015 and June 30, 2016 are as follows (in thousands):

	2015		2016
Net gains (losses) recognized during the six months ended June 30, 2015 and 2016, respectively on trading securities	$	1,066	$	(530	)
Less: Net gains (losses) recognized during the period on trading securities sold during the six months ended June 30, 2015 and 2016, respectively	20		(207		)
Unrealized gains (losses) recognized on trading securities still held at June 30, 2015 and 2016, respectively	$	1,046	$	(323	)

XML

Net Revenue (Tables)

6 Months Ended

Jun. 30, 2016

Revenue, Net [Abstract]

Schedule of net revenue

Net revenues consisted of the following (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2015					2016					2015					2016
Medicare	$	178,168		20.3	%	$	339,092		30.2	%	$	346,927		20.2	%	$	687,863		30.5	%
Medicaid	157,601			18.0		202,918			18.1		310,136			18.0		399,810			17.7
Commercial and managed care	448,043			51.0		526,954			46.9		860,000			50.0		1,060,089			46.9
Self-pay	464,089			52.9		505,687			45.0		908,342			52.9		1,014,549			44.9
Other	19,921			2.3		23,147			2.1		40,202			2.3		46,961			2.1
Unbilled	5,523			0.6		(6,695		)	(0.6	)	13,609			0.8		2,583			0.1
Net fee for service revenue before provision for uncollectibles	1,273,345			145.0		1,591,103			141.7		2,479,216			144.3		3,211,855			142.3
Contract revenue before provision for uncollectibles	183,727			20.9		206,117			18.4		367,367			21.4		406,945			18.0
Other	9,912			1.2		18,684			1.7		18,690			1.0		36,635			1.6
Net revenues before provision for uncollectibles	1,466,984			167.1		1,815,904			161.8		2,865,273			166.7		3,655,435			161.9
Provision for uncollectibles	(589,029		)	(67.1	)	(693,328		)	(61.8	)	(1,146,834		)	(66.7	)	(1,397,218		)	(61.9	)
Net revenues	$	877,955		100.0	%	$	1,122,576		100.0	%	$	1,718,439		100.0	%	$	2,258,217		100.0	%

XML

Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Changes In Goodwill

The changes in the carrying amount of goodwill during the year ended December 31, 2015 and the six months ended June 30, 2016 were as follows (in thousands):

Goodwill	$	869,038
Accumulated impairment loss	(144,579		)
Additions through acquisitions	1,703,343
Balance, December 31, 2015	$	2,427,802
Goodwill	$	2,572,381
Accumulated impairment loss	(144,579		)
Increases from prior year acquisition purchase price allocation adjustments	3,453
Additions through current year acquisitions	16,601
Balance, June 30, 2016	$	2,447,856

Summary of intangible assets and related amortization

The following is a summary of intangible assets and related amortization as of December 31, 2015 and June 30, 2016 (in thousands):

	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2015:
Contracts	$	494,569	$	(170,873	)
Other	21,716		(9,775		)
Total	$	516,285	$	(180,648	)
As of June 30, 2016:
Contracts	$	519,151	$	(211,829	)
Other	33,636		(15,674		)
Total	$	552,787	$	(227,503	)
Aggregate amortization expense:
For the six months ended June 30, 2016			$	47,653
Estimated amortization expense:
For the remainder of the year ended December 31, 2016			$	46,379
For the year ended December 31, 2017			88,051
For the year ended December 31, 2018			72,357
For the year ended December 31, 2019			63,326
For the year ended December 31, 2020			43,495
For the years ended December 31, 2021 and thereafter			11,676
Total			$	325,284

XML

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Schedule of long-term debt

Long-term debt as of June 30, 2016 consisted of the following (in thousands):

Tranche A Term Loan Facility	$	562,500
Tranche B Term Loan Facility	1,308,720
7.25% Senior Notes due 2023	545,000
Revolving Credit Facility	7,500
Total outstanding debt	2,423,720
Debt issuance costs	(50,252		)
	2,373,468
Less current portion	(61,870		)
	$	2,311,598

Schedule of aggregate annual maturities of long-term debt

Aggregate annual maturities of long-term debt as of June 30, 2016 are as follows (in thousands):

2016	$	61,870
2017	69,370
2018	73,120
2019	418,120
2020 and thereafter	1,801,240

XML

Professional Liability Insurance (Tables)

6 Months Ended

Jun. 30, 2016

Malpractice Insurance [Abstract]

Summary of professional liability loss reserves

The Company’s professional liability loss reserves included in other accrued liabilities and other non-current liabilities in the accompanying consolidated balance sheets consisted of the following (in thousands):

	December 31, 2015		June 30, 2016
Estimated losses under self-insured programs	$	245,070	$	257,751
Estimated losses under commercial insurance programs	126,751		139,713
	371,821		397,464
Less estimated payable within one year	105,028		104,578
	$	266,793	$	292,886

Summary of estimated losses under self-insured programs

The changes to the Company’s estimated losses under self-insured programs as of June 30, 2016 were as follows (in thousands):

Balance, December 31, 2015	$	245,070
Reserves related to current period	37,049
Changes related to prior year reserves	14,284
Assumed liabilities	(1,812		)
Payments for current period reserves	(262		)
Payments for prior period reserves	(36,578		)
Balance, June 30, 2016	$	257,751

XML

Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Share-based Compensation [Abstract]

Stock options status under Stock Plan

The following table summarizes the status of options under the Stock Plan as of June 30, 2016:

	Shares (in thousands)		Weighted Average Exercise Price		Aggregate Intrinsic Value (in thousands)		Weighted Average Remaining Life in Years
Outstanding at beginning of year	4,780		$	28.07	$	86,342	5.3
Granted	301		42.70
Exercised	(780	)	19.93		15,547
Expired or forfeited	(69	)	34.80
Outstanding at end of period	4,232		$	30.50	$	57,223	5.2
Exercisable at end of period	3,190		$	24.10	$	56,917	4.7

Summary of changes in unvested shares of restricted awards

A summary of changes in total outstanding unvested restricted awards for the six months ended June 30, 2016 is as follows (in thousands):

	Restricted Stock		Restricted Units		Performance Units	Total
Outstanding at beginning of year	100		766		—	866
Granted	—		403		144	547
Vested	(52	)	(224	)	—	(276	)
Forfeited and expired	(3	)	(34	)	—	(37	)
Outstanding at June 30, 2016	45		911		144	1,100

Share-based compensation

Equity based compensation expense and the resulting tax benefits were as follows (in thousands):

	Six Months Ended June 30,
	2015		2016
Stock options	$	5,166	$	3,844
Restricted awards	3,985		10,448
Stock purchase plan	62		82
Total equity based compensation expense	$	9,213	$	14,374
Tax benefit of equity based compensation expense	$	3,547	$	5,498

XML

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
Net earnings attributable to Team Health Holdings, Inc. (numerator for basic and diluted earnings per share)	$	28,935	$	18,785	$	56,989	$	19,453
Denominator:
Weighted average shares outstanding	71,956		73,958		71,666		73,650
Effect of dilutive securities:
Stock options	1,374		1,050		1,220		1,058
Restricted awards	270		224		249		419
Stock purchase plans	2		2		2		2
Shares used for diluted earnings per share	73,602		75,234		73,137		75,129
Basic net earnings per share of Team Health Holdings, Inc.	$	0.40	$	0.25	$	0.80	$	0.26
Diluted net earnings per share of Team Health Holdings, Inc.	$	0.39	$	0.25	$	0.78	$	0.26
Securities excluded from diluted earnings per share of Team Health Holdings, Inc. because they were antidilutive:
Stock options	240		1,285		606		1,590
Restricted awards	—		260		—		270

XML

Accumulated Other Comprehensive Income (Tables)

6 Months Ended

Jun. 30, 2016

Statement of Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive earnings related to available-for-sale securities were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Balance at beginning of period	$	1,668		$	1,786		$	1,695		$	1,503
Other comprehensive (loss) earnings:
Net unrealized (loss) gain	(896		)	979			(887		)	1,789
Tax benefit (expense)	340			(338		)	337			(492		)
Total other comprehensive (loss) earnings before reclassifications, net of tax	(556		)	641			(550		)	1,297
Net amount reclassified to earnings(1)	(17		)	(13		)	(50		)	(386		)
Tax benefit (expense)(2)	—			—			—			—
Total amount reclassified from accumulated other comprehensive earnings, net of tax(3)	(17		)	(13		)	(50		)	(386		)
Total other comprehensive (loss) earnings	(573		)	628			(600		)	911
Balance at end of period	$	1,095		$	2,414		$	1,095		$	2,414

(1) This amount was included in Other (income) expenses, net on the accompanying Consolidated Statement of Comprehensive Earnings.

(2) These amounts were included in Provision for income taxes on the accompanying Consolidated Statement of Comprehensive Earnings.

(3) A positive amount indicates a corresponding charge to earnings and a negative amount indicates a corresponding benefit to earnings.

XML

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Summary of financial information of reportable segment

The following table presents financial information for each reportable segment. Depreciation, amortization, management fee and other expenses separately identified in the consolidated statements of operations are included as a reduction to the respective segments’ operating earnings for each period below (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2016			2015			2016
Net Revenues:
Hospital Based Services	$	806,584		$	865,564		$	1,575,075		$	1,737,712
IPC Healthcare	—			185,669			—			378,381
Specialty Services	45,857			44,803			101,688			70,910
Other Services	25,493			26,512			41,628			71,159
General Corporate	21			28			48			55
	$	877,955		$	1,122,576		$	1,718,439		$	2,258,217
Operating Earnings:
Hospital Based Services	$	76,585		$	75,170		$	146,612		$	126,923
IPC Healthcare	—			10,454			—			20,268
Specialty Services	6,385			5,653			11,884			10,924
Other Services	5,434			6,398			10,016			17,007
General Corporate	(33,765		)	(33,747		)	(60,689		)	(81,385		)
	$	54,639		$	63,928		$	107,823		$	93,737
Reconciliation of Operating Earnings to Net Earnings:
Operating earnings	$	54,639		$	63,928		$	107,823		$	93,737
Interest expense, net	4,571			30,437			8,560			61,730
Provision for income taxes	21,186			14,577			42,341			12,363
Net earnings	$	28,882		$	18,914		$	56,922		$	19,644

XML

Acquisitions and Contingent Purchase Obligations - Purchase Price Allocation (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,447,856	$ 2,427,802
Current Year Acquisitions
Business Acquisition [Line Items]
Accounts receivable	1,286
Prepaid expenses and other assets	3
Net deferred income taxes	(2,987)
Other intangibles	15,600
Goodwill	16,601
Accounts payable	(41)
Accrued compensation and physician payable	(291)
Other accrued liabilities	(241)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	29,930
Tax deductible goodwill	3,800
IPC Acquisition [Member]
Business Acquisition [Line Items]
Short term investments	1,985	1,985
Accounts receivable	120,310	127,265
Adjustments to the purchase price allocation, Accounts Receivable	(6,955)
Prepaid expenses and other assets	6,031	6,347
Adjustments to the purchase price allocation, Prepaids and Other Assets	(316)
Receivables under insured programs	36,255	36,255
Property and equipment	10,757	10,541
Adjustments to the purchase price allocation, Property, Plant, and Equipment	216
Income tax receivable	12,528	12,528
Net deferred income taxes	60,693	64,301
Adjustments to the purchase price allocation - deferred tax	(3,608)
Other intangibles	26,675	4,975
Adjustments to the purchase price allocation, Other Intangibles	21,700
Goodwill	1,577,969	1,574,757
Adjustments to the purchase price allocation, Goodwill	3,212
Accounts payable	(15,660)	(15,627)
Adjustments to the purchase price allocation, Accounts Payable	(33)
Accrued compensation and physician payable	(43,856)	(43,856)
Other accrued liabilities	(77,069)	(63,809)
Adjustments to the purchase price allocation, Other Accrued Liabilities	(13,260)
Contingent purchase liability	(33,407)	(30,639)
Adjustments to the purchase price allocation, Contingent Purchase Liability	(2,768)
Assumed notes payable	(148,249)	(148,249)
Other non-current liabilities	(60,082)	(61,894)
Adjustments to the purchase price allocation, Other Non-Current Liabilities	1,812
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	1,474,880	$ 1,474,880
Tax deductible goodwill	368,300
Acquired Cash and Equivalents	$ 28,059

XML

Acquisitions and Contingent Purchase Obligations - Contingent Purchase Liability (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Contingent purchase liability at December 31, 2015			$ 57,080
Payments			(9,501)
Contingent purchase and other acquisition compensation expense recognized	$ 9,762	$ 7,856	18,851	$ 15,760
Adjustments to contingent purchase liability recognized at acquisition date	2,781		2,781
Contingent purchase liability at June 30, 2016	$ 69,211		$ 69,211

XML

Acquisitions and Contingent Purchase Obligations - Estimated Contingent Purchase Expense (Details) $ in Thousands	Jun. 30, 2016 USD ($)
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	$ 31,865
For the remainder of the year ended December 31, 2016
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	16,409
For the year ended December 31, 2017
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	9,681
For the year ended December 31, 2018
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	3,635
For the year ended December 31, 2019
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	1,515
For the year ended December 31, 2020
Business Combination, Separately Recognized Transactions [Line Items]
Estimated unrecognized contingent purchase compensation expense	$ 625

XML

Acquisitions and Contingent Purchase Obligations (Details Textual) visit in Thousands, $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 23, 2015 USD ($)	Jul. 31, 2016 visit	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Business	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) visit	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Number of businesses acquired | Business					3
Total cash paid for acquisitions					$ 29,930	$ 84,792
Fee for service patient visits | visit							23,000
Estimated contingent consideration accounted for as compensation expense			$ 101,100		101,100		$ 101,100
Accrued contingent purchase liability			69,211		69,211		69,211	$ 57,080
Remaining estimated liability to be recorded as contingent purchase compensation expense			31,865		31,865		$ 31,865
Contingent purchase and other acquisition compensation expense recognized			$ 9,762	$ 7,856	18,851	15,760
Current Year Acquisitions
Business Acquisition [Line Items]
Total cash paid for acquisitions					29,930
IPC Acquisition [Member]
Business Acquisition [Line Items]
Payments to acquire businesses, gross	$ 1,600,000
Subsequent Event [Member]
Business Acquisition [Line Items]
Fee for service patient visits | visit		18
General and Administrative Expense
Business Acquisition [Line Items]
Contingent purchase and other acquisition compensation expense recognized					$ 18,851	$ 15,760

XML

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	$ 52,237	$ 45,868
Fair Value Level 2 [Member] | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	52,237	45,868
Reported Value Measurement [Member] | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	52,237	45,868
Insurance subsidiaries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	111,390	111,940
Insurance subsidiaries [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	14,654	18,238
Insurance subsidiaries [Member] | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	86,389	87,121
Insurance subsidiaries [Member] | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	54	64
Insurance subsidiaries [Member] | Private investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	2,185	2,818
Insurance subsidiaries [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	8,108	3,699
Insurance subsidiaries [Member] | Fair Value Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	14,654	18,238
Insurance subsidiaries [Member] | Fair Value Level 1 [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	14,654	18,238
Insurance subsidiaries [Member] | Fair Value Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	94,551	90,884
Insurance subsidiaries [Member] | Fair Value Level 2 [Member] | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	86,389	87,121
Insurance subsidiaries [Member] | Fair Value Level 2 [Member] | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	54	64
Insurance subsidiaries [Member] | Fair Value Level 2 [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	8,108	3,699
Insurance subsidiaries [Member] | Fair Value Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	2,185	2,818
Insurance subsidiaries [Member] | Fair Value Level 3 [Member] | Private investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	2,185	2,818
Insurance subsidiaries [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	111,390	111,940
Insurance subsidiaries [Member] | Reported Value Measurement [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	14,654	18,238
Insurance subsidiaries [Member] | Reported Value Measurement [Member] | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	86,389	87,121
Insurance subsidiaries [Member] | Reported Value Measurement [Member] | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	54	64
Insurance subsidiaries [Member] | Reported Value Measurement [Member] | Private investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	2,185	2,818
Insurance subsidiaries [Member] | Reported Value Measurement [Member] | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments the Company currently measures at fair value on a recurring basis	$ 8,108	$ 3,699

XML

Fair Value Measurements (Details Textual) $ in Thousands	Jun. 30, 2016 USD ($)
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by investment type
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	$ 0
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	0
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount	0
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount	0
Fair value of outstanding debt	2,470,000
Carrying value of debt	$ 2,423,720

XML

Investments - Amortized Cost Basis and Aggregate Fair Value by Investment Type (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	$ 107,764	$ 109,715
Gross Unrealized Gains	3,769	2,523
Gross Unrealized Losses	(143)	(298)
Fair Value	111,390	111,940
Money market funds
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	14,654	18,238
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	14,654	18,238
Municipal bonds
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	83,100	84,983
Gross Unrealized Gains	3,432	2,411
Gross Unrealized Losses	(143)	(273)
Fair Value	86,389	87,121
Mutual funds
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	54	64
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	54	64
Private investments
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	1,982	2,712
Gross Unrealized Gains	203	106
Gross Unrealized Losses	0	0
Fair Value	2,185	2,818
Corporate bonds
Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]
Cost Basis	7,974	3,718
Gross Unrealized Gains	134	6
Gross Unrealized Losses	0	(25)
Fair Value	$ 8,108	$ 3,699

XML

Investments - Amortized Cost Basis and Aggregate Fair Value by Contractual Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities
Due in less than one year, Cost Basis	$ 24,816	$ 24,099
Due after one year through five years, Cost Basis	58,911	57,537
Due after five years through ten years, Cost Basis	20,001	23,389
Due after ten years, Cost Basis	2,000	1,914
Total Cost Basis	105,728	106,939
Due in less than one year, Fair Value	24,921	24,080
Due after one year through five years, Fair Value	61,121	59,105
Due after five years through ten years, Fair Value	21,205	24,007
Due after ten years, Fair Value	1,904	1,866
Total Fair Value	109,151	109,058
Gross Unrealized Gain	3,566	2,417
Gross Unrealized Loss	(143)	(298)
Due in less than one year
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities
Gross Unrealized Gain	122	35
Gross Unrealized Loss	(17)	(54)
Due after one year through five years
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities
Gross Unrealized Gain	2,235	1,647
Gross Unrealized Loss	(25)	(79)
Due after five years through ten years
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities
Gross Unrealized Gain	1,204	674
Gross Unrealized Loss	0	(56)
Due after ten years
Summary of amortized cost basis and aggregate fair value of available-for-sale securities by contractual maturities
Gross Unrealized Gain	5	61
Gross Unrealized Loss	$ (101)	$ (109)

XML

Investments - Temporarily Impaired Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Summary of temporarily impaired available-for-sale investment securities
Impaired Less Than 12 Months, Fair Value	$ 3,453	$ 16,309
Impaired Less Than 12 Months, Unrealized Losses	(30)	(128)
Impaired Over 12 Months, Fair Value	2,782	2,575
Impaired Over 12 Months, Unrealized Losses	(113)	(170)
Total, Fair Value	6,235	18,884
Total, Unrealized Losses	(143)	(298)
Municipal bonds
Summary of temporarily impaired available-for-sale investment securities
Impaired Less Than 12 Months, Fair Value	2,405	13,189
Impaired Less Than 12 Months, Unrealized Losses	(30)	(103)
Impaired Over 12 Months, Fair Value	2,782	2,575
Impaired Over 12 Months, Unrealized Losses	(113)	(170)
Total, Fair Value	5,187	15,764
Total, Unrealized Losses	(143)	(273)
Corporate bonds
Summary of temporarily impaired available-for-sale investment securities
Impaired Less Than 12 Months, Fair Value	1,048	3,120
Impaired Less Than 12 Months, Unrealized Losses	0	(25)
Impaired Over 12 Months, Fair Value	0	0
Impaired Over 12 Months, Unrealized Losses	0	0
Total, Fair Value	1,048	3,120
Total, Unrealized Losses	$ 0	$ (25)

XML

Investments - Trading Gains and Losses on Participant Directed Investments (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Investments [Abstract]
Net gains (losses) recognized during the six months ended June 30, 2015 and 2016, respectively on trading securities	$ (530)	$ 1,066
Less: Net gains (losses) recognized during the period on trading securities sold during the six months ended June 30, 2015 and 2016, respectively	(207)	20
Unrealized gains (losses) recognized on trading securities still held at June 30, 2015 and 2016, respectively	$ (323)	$ 1,046

XML

Investments (Details Textual) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Recorded gain on the sale of investments	$ 386
Supplemental employee retirement plan	$ 52,237	$ 45,868

XML

Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 1,591,103	$ 1,273,345	$ 3,211,855	$ 2,479,216
Percentage of net fee-for-service revenue before provision for uncollectibles	141.70%	145.00%	142.30%	144.30%
Contract revenue before provision for uncollectibles	$ 206,117	$ 183,727	$ 406,945	$ 367,367
Percentage of contract before provision for uncollectibles	18.40%	20.90%	18.00%	21.40%
Other	$ 18,684	$ 9,912	$ 36,635	$ 18,690
Percentage, other	1.70%	1.20%	1.60%	1.00%
Net revenues before provision for uncollectibles	$ 1,815,904	$ 1,466,984	$ 3,655,435	$ 2,865,273
Percentage of net revenue before provision for uncollectibles	161.80%	167.10%	161.90%	166.70%
Provision for uncollectibles	$ (693,328)	$ (589,029)	$ (1,397,218)	$ (1,146,834)
Percentage of provision for uncollectibles	(61.80%)	(67.10%)	(61.90%)	(66.70%)
Net revenue	$ 1,122,576	$ 877,955	$ 2,258,217	$ 1,718,439
Percentage of net revenue	100.00%	100.00%	100.00%	100.00%
Medicare [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 339,092	$ 178,168	$ 687,863	$ 346,927
Percentage of net fee-for-service revenue before provision for uncollectibles	30.20%	20.30%	30.50%	20.20%
Medicaid [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 202,918	$ 157,601	$ 399,810	$ 310,136
Percentage of net fee-for-service revenue before provision for uncollectibles	18.10%	18.00%	17.70%	18.00%
Commercial and managed care [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 526,954	$ 448,043	$ 1,060,089	$ 860,000
Percentage of net fee-for-service revenue before provision for uncollectibles	46.90%	51.00%	46.90%	50.00%
Self-pay [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 505,687	$ 464,089	$ 1,014,549	$ 908,342
Percentage of net fee-for-service revenue before provision for uncollectibles	45.00%	52.90%	44.90%	52.90%
Other [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ 23,147	$ 19,921	$ 46,961	$ 40,202
Percentage of net fee-for-service revenue before provision for uncollectibles	2.10%	2.30%	2.10%	2.30%
Unbilled Revenue [Member]
Schedule of net revenue
Net fee for service revenue before provision for uncollectibles	$ (6,695)	$ 5,523	$ 2,583	$ 13,609
Percentage of net fee-for-service revenue before provision for uncollectibles	(0.60%)	0.60%	0.10%	0.80%

XML

Net Revenue (Details Textual) visit in Millions	12 Months Ended
	Jun. 30, 2016 visit
Revenue, Net [Abstract]
Fee for service patient visits	23
Doubtful accounts related to gross fees for fee-for-service patient visits	98.00%
Outstanding self-pay fee-for-service patient accounts	93.00%

XML

Goodwill and Other Intangible Assets - Changes in Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill, gross	$ 2,572,381	$ 869,038
Accumulated impairment loss	(144,579)	(144,579)
Additions through acquisitions		1,703,343
Beginning Balance	2,427,802
Ending Balance	2,447,856	$ 2,427,802
Prior Year Acquisitions [Member]
Goodwill [Line Items]
Increases from prior year acquisition purchase price allocation adjustments	3,453
Current Year Acquisitions
Goodwill [Line Items]
Additions through acquisitions	16,601
Ending Balance	$ 16,601

XML

Goodwill and Other Intangible Assets - Intangible Assets and Related Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Summary of intangible assets and related amortization
Gross Carrying Amount	$ 552,787		$ 552,787		$ 516,285
Accumulated Amortization	(227,503)		(227,503)		(180,648)
Aggregate amortization expense:
For the six months ended June 30, 2016	24,142	$ 21,175	47,653	$ 41,452
Estimated amortization expense:
For the remainder of the year ended December 31, 2016	46,379		46,379
For the year ended December 31, 2017	88,051		88,051
For the year ended December 31, 2018	72,357		72,357
For the year ended December 31, 2019	63,326		63,326
For the year ended December 31, 2020	43,495		43,495
For the years ended December 31, 2021 and thereafter	11,676		11,676
Intangible Assets, Net (Excluding Goodwill)	325,284		325,284		335,637
Contracts
Summary of intangible assets and related amortization
Gross Carrying Amount	519,151		519,151		494,569
Accumulated Amortization	(211,829)		(211,829)		(170,873)
Other
Summary of intangible assets and related amortization
Gross Carrying Amount	33,636		33,636		21,716
Accumulated Amortization	$ (15,674)		$ (15,674)		$ (9,775)

XML

Goodwill and Other Intangible Assets (Details Textual)	6 Months Ended
	Jun. 30, 2016
Finite Lived Intangible Assets [Line Items]
Remaining amortization period	3 years 5 months 12 days
Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful life of contract intangibles	8 years
Minimum [Member]
Finite Lived Intangible Assets [Line Items]
Estimated useful life of contract intangibles	1 year

XML

Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule of long-term debt
Long-term debt	$ 2,373,468
Total outstanding debt	2,423,720
Debt Issuance Costs, Net	(50,252)
Current maturities of long-term debt	(61,870)	$ (68,900)
Long term debt, less current maturities	2,311,598	$ 2,337,363
7.25% Senior Notes [Member] | Senior Notes [Member]
Schedule of long-term debt
Long-term debt	545,000
Term A Loan Facility [Member] | Notes Payable to Banks [Member]
Schedule of long-term debt
Long-term debt	562,500
Term B Loan Facility [Member] | Notes Payable to Banks [Member]
Schedule of long-term debt
Long-term debt	1,308,720
Revolving Credit Facility [Member] | Line of Credit [Member]
Schedule of long-term debt
Long-term debt	$ 7,500

XML

Long-Term Debt - Aggregate Annual Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Maturities of Long-term Debt [Abstract]
Rolling year one	$ 61,870	$ 68,900
Rolling year two	69,370
Rolling year three	73,120
Rolling year four	418,120
Rolling year five	$ 1,801,240

XML

Long-Term Debt (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Long-term debt	$ 2,373,468		$ 2,373,468
Standby letters of credit [Member]
Debt Instrument [Line Items]
Letters of credit outstanding	6,800		6,800
Line of Credit [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Borrowing capacity	650,000		$ 650,000
Revolver maturity date			Oct. 02, 2019
Percentage points added to LIBOR			2.00%
Unused capacity interest rate			0.35%
Long-term debt	7,500		$ 7,500
Notes Payable to Banks [Member] | Term A Loan Facility [Member]
Debt Instrument [Line Items]
Face amount of debt instrument	600,000		$ 600,000
Maturity date			Oct. 02, 2019
Percentage points added to LIBOR			2.00%
Weighted average interest rate			2.81%
Long-term debt	562,500		$ 562,500
Notes Payable to Banks [Member] | Term B Loan Facility [Member]
Debt Instrument [Line Items]
Face amount of debt instrument	$ 1,310,000		$ 1,310,000
Maturity date			Nov. 23, 2022
Percentage points added to LIBOR	3.00%	3.75%
Prepayment Fee Percentage	1.00%		1.00%
Long-term debt	$ 1,308,720		$ 1,308,720
Senior Notes [Member] | 7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Face amount of debt instrument	545,000		$ 545,000
Maturity date			Dec. 15, 2023
Long-term debt	$ 545,000		$ 545,000
Stated interest rate	7.25%		7.25%
Redemption price			100.00%
Percentage of principal amount redeemed			40.00%
Partial redemption price			107.25%
Minimum [Member] | Notes Payable to Banks [Member] | Term B Loan Facility [Member]
Debt Instrument [Line Items]
Percentage points added to LIBOR			0.75%

XML

Professional Liability Insurance - Professional Liability Loss Reserve (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Malpractice Insurance [Abstract]
Estimated losses under self-insured programs	$ 257,751	$ 245,070
Estimated losses under commercial insurance programs	139,713	126,751
Professional liability loss reserves	397,464	371,821
Less estimated payable within one year	104,578	105,028
Professional liability loss reserves, Noncurrent	$ 292,886	$ 266,793

XML

Professional Liability Insurance - Estimated Losses Under Self-Insured Programs (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Malpractice Insurance [Abstract]
Balance, December 31, 2015	$ 245,070
Reserves related to current period	37,049
Changes related to prior year reserves	14,284
Assumed liabilities	(1,812)
Payments for current period reserves	(262)
Payments for prior period reserves	(36,578)
Balance, June 30, 2016	$ 257,751

XML

Professional Liability Insurance (Details Textual) $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) Claim	Dec. 31, 2015 USD ($)
Malpractice Insurance [Line Items]
Estimated losses under self-insured programs		$ 257,751	$ 245,070
Reserve for settlement of prior year claims		$ 14,284
Number of claims settled | Claim		2
Prior year claims and claims adjustment expense	$ 0
Professional liability reserves, discount rate		0.90%	1.60%
IPC malpractice insurance reserves		$ 397,464	$ 371,821
Estimated IBNR
Malpractice Insurance [Line Items]
Estimated losses under self-insured programs		154,200	157,400
Specific Case Reserves
Malpractice Insurance [Line Items]
Estimated losses under self-insured programs		103,600	87,700
Settled But Not Yet Funded Specific Case Reserves
Malpractice Insurance [Line Items]
Estimated losses under self-insured programs		2,500	3,000
Unsettled Specific Case Reserves
Malpractice Insurance [Line Items]
Estimated losses under self-insured programs		101,100	$ 84,700
IPC Acquisition [Member]
Malpractice Insurance [Line Items]
IPC malpractice insurance reserves		$ 25,400
Discount Factor Period		10 years

XML

Contingencies (Details Textual) - 6 months ended Jun. 30, 2016	healthcare_professionals	USD ($)	Business	state
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value		$ 350,000
Reserve for settlement of prior year claims		$ 14,284,000
August 2011 [Member]
Loss Contingencies [Line Items]
Number of defendants	1		3
July 2012 [Member]
Loss Contingencies [Line Items]
Number of defendants	1		1
Civ. No. 09-C-5418 [Member]
Loss Contingencies [Line Items]
Number of defendants | Business			29
Number of plaintiffs | state				12

XML

Share-based Compensation - Stock Option Status Under Stock Plan (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2016
Shares (in thousands)
Outstanding at beginning of year			4,780
Granted			301
Exercised			(780)
Expired or forfeited			(69)
Outstanding at end of period	4,232	4,780	4,232
Exercisable at end of period	3,190		3,190
Weighted Average Exercise Price
Outstanding at beginning of year			$ 28.07
Granted			42.70
Exercised			19.93
Expired or forfeited			34.80
Outstanding at end of period	$ 30.50	$ 28.07	30.50
Exercisable at end of period	$ 24.10		$ 24.10
Aggregate Intrinsic Value (in thousands) and Weighted Average Remaining Life in Years
Aggregate intrinsic value outstanding at beginning of year			$ 86,342
Aggregate intrinsic value exercised			15,547
Aggregate intrinsic value outstanding at end of period	$ 57,223	$ 86,342	57,223
Aggregate intrinsic value exercisable at end of period	$ 56,917		$ 56,917
Weighted average remaining life at balance sheet date	5 years 2 months 12 days	5 years 3 months 18 days
Weighted average remaining life exercisable at end of period	4 years 8 months 12 days

XML

Share-based Compensation - Changes in Unvested Shares of Restricted Awards (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2016 shares
Restricted Stock
Summary of changes in unvested restricted stock awards
Outstanding at beginning of year	100
Granted	0
Vested	(52)
Forfeited and expired	(3)
Outstanding at June 30, 2016	45
Restricted Units
Summary of changes in unvested restricted stock awards
Outstanding at beginning of year	766
Granted	403
Vested	(224)
Forfeited and expired	(34)
Outstanding at June 30, 2016	911
Performance Units
Summary of changes in unvested restricted stock awards
Outstanding at beginning of year	0
Granted	144
Vested	0
Forfeited and expired	0
Outstanding at June 30, 2016	144
Restricted Awards
Summary of changes in unvested restricted stock awards
Outstanding at beginning of year	866
Granted	547
Vested	(276)
Forfeited and expired	(37)
Outstanding at June 30, 2016	1,100

XML

Share-based Compensation - Equity Based Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity based compensation expense	$ 14,374	$ 9,213
Tax benefit of equity based compensation expense	5,498	3,547
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity based compensation expense	3,844	5,166
Restricted Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity based compensation expense	10,448	3,985
Stock Purchase Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity based compensation expense	$ 82	$ 62

XML

Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	6 Months Ended
	Apr. 30, 2016	Jun. 30, 2016
Stock options
Share-Based Compensation (Textual) [Abstract]
Options granted in period		301,000
Unrecognized compensation expense, options		$ 13.5
Restricted awards
Share-Based Compensation (Textual) [Abstract]
Restricted stock awards granted		547,000
Unrecognized compensation expense, restricted stock		$ 36.3
Performance Units
Share-Based Compensation (Textual) [Abstract]
Restricted stock awards granted		144,000
Award vesting period		2 years
Award requisite service period		3 years
2009 Stock Plan [Member]
Share-Based Compensation (Textual) [Abstract]
Total number of shares of common stock that may be issued		15,100,000
Number of shares available for grant		1,502,000
2009 Stock Plan [Member] | Stock options
Share-Based Compensation (Textual) [Abstract]
Risk free interest rate		1.50%
Expected volatility rate		35.50%
Expected term		5 years
Weighted average grant date fair value		$ 14.26
2010 Employee Stock Purchase Plan [Member] | Employee Stock [Member]
Share-Based Compensation (Textual) [Abstract]
Total number of shares of common stock that may be issued		600,000
Discount on shares purchased		5.00%
Contributions to the stock purchase plan		$ 1.4
Shares issued during period under Employee Stock Purchase Plan	86,000
2010 Nonqualified Stock Purchase Plan [Member] | Nonqualified Stock Purchase Plan [Member]
Share-Based Compensation (Textual) [Abstract]
Total number of shares of common stock that may be issued		800,000
Discount on shares purchased		5.00%
Contributions to the stock purchase plan		$ 0.6
Shares issued during period under Non-qualified Stock Purchase Plans	39,000
Minimum [Member] | Restricted awards
Share-Based Compensation (Textual) [Abstract]
Award vesting period		3 years
Maximum [Member] | Restricted awards
Share-Based Compensation (Textual) [Abstract]
Award vesting period		4 years

XML

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Basic and diluted earnings per share
Net earnings attributable to Team Health Holdings, Inc. (numerator for basic and diluted earnings per share)	$ 18,785	$ 28,935	$ 19,453	$ 56,989
Denominator:
Weighted average shares outstanding	73,958	71,956	73,650	71,666
Stock options	1,050	1,374	1,058	1,220
Restricted awards	224	270	419	249
Stock purchase plans	2	2	2	2
Shares used for diluted earnings per share	75,234	73,602	75,129	73,137
Basic net earnings per share of Team Health Holdings, Inc.	$ 0.25	$ 0.40	$ 0.26	$ 0.80
Diluted net earnings per share of Team Health Holdings, Inc.	$ 0.25	$ 0.39	$ 0.26	$ 0.78
Stock options
Denominator:
Securities excluded from diluted earnings per share of Team Health Holdings, Inc. because they were antidilutive:	1,285	240	1,590	606
Restricted awards
Denominator:
Securities excluded from diluted earnings per share of Team Health Holdings, Inc. because they were antidilutive:	260	0	270	0

XML

Noncontrolling Interests in Consolidated Entity (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($) Business	Jun. 30, 2015 USD ($)
Noncontrolling Interest [Abstract]
Number of Joint Venture Arrangements | Business	2
Contributions from noncontrolling interests | $	$ 1,377	$ 1,377

XML

Transaction, Integration and Reorganization Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Acquisition [Line Items]
Transaction, integration, and reorganization costs	$ 6,106	$ 2,215	$ 27,501	$ 3,301
Professional, advisory and legal costs			9,200
Severance and lease impairment costs			4,900
IPC Acquisition [Member]
Business Acquisition [Line Items]
Recognized transaction costs			12,700
Non-IPC [Member]
Business Acquisition [Line Items]
Recognized transaction costs			$ 700

XML

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Accumulated other comprehensive earnings, beginning balance		$ 1,786	$ 1,668	$ 1,503	$ 1,695
Net unrealized (loss) gain		979	(896)	1,789	(887)
Tax benefit (expense)		(338)	340	(492)	337
Total other comprehensive (loss) earnings before reclassifications, net of tax		641	(556)	1,297	(550)
Net amount reclassified to earnings(1)	[1]	(13)	(17)	(386)	(50)
Tax benefit (expense)(2)	[2]	0	0	0	0
Total amount reclassified from accumulated other comprehensive earnings, net of tax(3)	[3]	(13)	(17)	(386)	(50)
Total other comprehensive (loss) earnings		628	(573)	911	(600)
Accumulated other comprehensive earnings, ending balance		$ 2,414	$ 1,095	$ 2,414	$ 1,095

[1] This amount was included in Other (income) expenses, net on the accompanying Consolidated Statement of Comprehensive Earnings.

[2] These amounts were included in Provision for income taxes on the accompanying Consolidated Statement of Comprehensive Earnings.

[3] A positive amount indicates a corresponding charge to earnings and a negative amount indicates a corresponding benefit to earnings.

XML

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary of financial information of reportable segment
Net Revenues:	$ 1,122,576	$ 877,955	$ 2,258,217	$ 1,718,439
Operating Earnings:	63,928	54,639	93,737	107,823
Interest expense, net	30,437	4,571	61,730	8,560
Provision for income taxes	14,577	21,186	12,363	42,341
Net earnings	18,914	28,882	19,644	56,922
Hospital Based Services [Member]
Summary of financial information of reportable segment
Net Revenues:	865,564	806,584	1,737,712	1,575,075
Operating Earnings:	75,170	76,585	126,923	146,612
IPC Healthcare
Summary of financial information of reportable segment
Net Revenues:	185,669	0	378,381	0
Operating Earnings:	10,454	0	20,268	0
Specialty Services
Summary of financial information of reportable segment
Net Revenues:	44,803	45,857	70,910	101,688
Operating Earnings:	5,653	6,385	10,924	11,884
Other Services
Summary of financial information of reportable segment
Net Revenues:	26,512	25,493	71,159	41,628
Operating Earnings:	6,398	5,434	17,007	10,016
Corporate Segment [Member]
Summary of financial information of reportable segment
Net Revenues:	28	21	55	48
Operating Earnings:	$ (33,747)	$ (33,765)	$ (81,385)	$ (60,689)

XML

Segment Reporting (Details Textual)	6 Months Ended
	Jun. 30, 2016 Segments
Segment Reporting Information, Additional Information [Abstract]
Number of Operating Segments	8
Number of Reportable Segments	4